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Rheumatoid arthritis (RA) is a common disorder characterized by chronic inflammation pre­
dominantly in the joints, bursae and tendon sheats, which can cause severe destruction of the 
cartilage and underlying bone, leading to deformations and loss of function. Extra-articular tis­
sues can also be involved in the inflammatory process accounting for the extra-articular mani­
festations of RA. A prevalence of 0.5-1% of the population worldwide is reported, with a peak 
incidence between 40 and 60 years, women being affected 2 to 3 times more than men.
The pathogenesis of RA remains to be elucidated and is believed to be multifactorial. The initial 
phase of RA is probably a T-cell mediated, antigen specific process that results in acute inflam­
mation in genetically susceptible persons. Antigens that have been considered are either autoantigens 
or foreign antigens, but as yet no clear candidate antigen has been identified. Possible candidate 
autoantigens include type II collagen, proteoglycans, chondrocyte antigens, heat shock proteins 
and immunoglobulins. Foreign antigens introduced by infections have often been considered, but 
so far no microorganisms, either bacterial or viral, have been implicated in the pathogenesis of 
RA definitely [1]. Genetic susceptibility is related partly to polymorphisms in the human leuco­
cyte antigen (HLA) system. In caucasian populations HLA DR4, and especially Dw4 and Dw14 
are associated with increased risks of RA [2].
The perpetuation of synovitis in RA likely results from the interaction between T-cells, fibroblast­
like cells and macrophage-like cells. Synovial cells from the macrophage lineage (type A synovial 
cell) produce interleukin-1 (IL-1), tum or necrosis factor-a (TNFa) and other cytokines. 
Interleukin-6 (IL-6) is one of the cytokines produced by synovial fibroblasts (type B synovial 
cells). The autocrine and paracrine production of these and other cytokines can account for much 
of the characteristics of chronic inflammation in the joint [3].
Proinflammatory cytokines like IL-1, IL-6 and TN Fa are released in the systemic circulation and 
can stimulate the hypothalamic-pituitary-adrenal (HPA) axis. This may result in increased 
production of cortisol, which has anti-inflammatory properties. Activation of the HPA-axis 
therefore provides an anti-inflammatory feedback pathway [4].
The HPA-axis is a neuroendocrine pathway that plays an im portant role in maintaining and 
restoring homeostasis and allows an organism to respond adequately to different forms of stress. 
The pathway consists of the hypothalamus, located at the basis of the brain, the pituitary gland, 
which is connected to the hypothalamic region by the pituitary stalk, and the adrenal glands, 
located above the kidneys. Corticotrophin releasing hormone (CRH) and arginine vasopressin 
(AVP) are produced in the hypothalamus, and they reach the anterior pituitary through the portal 
vessels. CRH stimulates the synthesis and secretion of adrenocorticotrophic hormone (ACTH) by 
the pituitary gland. ACTH induces the production and secretion of the glucocorticoid cortisol, in 
the zona fasciculata of the adrenal gland. This glucocorticoid has strong anti-inflammatory prop­
erties and is vital in the organism’s response to inflammatory challenge and to stress. ACTH also
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stimulates the secretion of androgens by the adrenal gland, including dehydroepiandrosterone 
(DHEA), which has also been shown to have anti-inflammatory properties, and has been implicated 
to play a role in the pathogenesis of RA [5].
The interaction between the immune and the neuroendocrine system is not restricted to the HPA- 
axis. The hypothalamic-pituitary-gonadal axis for example, is suppressed by pro-inflammatory 
cytokines. However, this does not constitute another anti-inflammatory feed back loop since 
testosterone and estradiol have a suppressing effect on immune function. Another systemic anti­
inflammatory system is the hypothalamic-autonomic nervous system (HANS) which is stimulated 
by the same pro-inflammatory cytokines as the HPA-axis. Stimulation of the HANS results in 
increased production of anti-inflammatory neurotransmitters like norepinephrine [6].
The female predominance of RA, especially in premenopausal women, the remittance during 
pregnancy and the exacerbation after pregnancy, especially in women who breastfeed [7,8], are 
observations which also have drawn attention to a possible role of hormones, in particular pro­
lactin, in the pathogenesis of the disease. A num ber of other hormones were found to have stim­
ulatory effects on the immune response. These include growth hormone, thyroxin and insulin [9-11]. 
In patients with RA, altered neuroendocrine responses may contribute to the perpetuation of syn­
ovitis. This hypothesis was first put forward after it was shown that the susceptibility of Lewis rats 
to arthritis induced by streptococcal cell wall is related to a defective HPA-axis at the hypothala­
mic level [12,13]. Subsequently, Chikanza et al. found defective cortisol responses to major sur­
gery-associated stress in patients with RA [14]. They also found evidence for an upregulated pro­
lactin response in this disease [15]. Im portant limitations in the studies by Chikanza et al. are the 
limited number of patients that have been studied and the lack of control for the possible effects 
of antirheumatic medication in the patients with longstanding disease that they included.
If horm onal abnormalities play a role in the development of RA, this could have therapeutic 
consequences. Systemic treatm ent with low dose corticosteroids early in disease, to balance the 
insufficient cortisol response, could be beneficial and prevent progression to a chronic phase. 
Treatment aimed at inhibition of prolactin secretion might reduce disease activity. The main aim 
of the research described in this thesis is therefore to further evaluate the activity of the HPA-axis 
and the secretion of prolactin in patients with RA.
In chapter 2, the results of a study with a similar design as the studies by Chikanza et al. are 
described. Cortisol and prolactin responses after total hip or knee replacement are compared 
between patients with RA and prim ary osteoarthritis.
The next 5 chapters are dedicated to detailed investigations of the activity of the HPA-axis in 
patients with RA.
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In chapter 3, the literature on the role of the HPA-axis in RA is reviewed, but also the possible role 
of peripheral (intra-articular) CRH as a pro-inflammatory mediator.
In chapter 4, the activity of the HPA-axis is measured in 50 patients with RA in 3 groups: recent 
onset active RA (n=20), longstanding active RA (n=20) and longstanding RA in remission 
(n=10), and compared with 20 healthy controls. ACTH and cortisol levels are assessed under basal 
conditions and after insulin-induced hypoglycaemia, a standardized form of stress. In addition, 
patients with recent onset RA underwent a CRH test and a dexamethasone suppression test. 
Plasma levels of IL-1P, TN Fa and IL-6 were also measured.
In chapter 5, the changes in basal and stimulated HPA-axis activity in 20 patients with recent onset 
RA are reported after 2 weeks treatm ent with naproxen and after 6 months of additional treat­
m ent with sulphasalazine or methotrexate.
In chapter 6, a double blind, placebo-controlled study of the influence of naproxen on the activity 
of the HPA-axis in 40 healthy volunteers is described. The activity of the HPA-axis was measured 
before and after the use of naproxen or placebo during a period of two weeks. Plasma ACTH and 
cortisol were measured under basal circumstances and during a bicycle ergometry test with sub­
maximal physical exercise.
In chapter 7, the results of a study of the effects of TN Fa blocking agents on ACTH and cortisol 
levels are described. Plasma, salivary and urinary cortisol levels and plasma levels of ACTH were 
measured in 13 RA patients treated with a TN Fa neutralizing agent and in 5 patients with RA 
treated with placebo.
The next part of this thesis concentrates on prolactin levels in patients with RA.
In chapter 8, the literature on the role of prolactin in RA is reviewed.
In chapter 9, prolactin levels are compared between 20 patients with untreated, recent onset RA 
and 20 age- and sex-matched healthy controls. In addition, prolactin levels in 6 postmenopausal 
patients with longstanding active RA are compared with those in 6 healthy postmenopausal 
women. The 20 patients with active RA were studied both before and after 2 weeks and 6 months 
of antirheumatic treatment. Prolactin levels were assessed under basal conditions and after 
insulin-induced hypoglycaemia.
In chapter 1 0 , the results of an open study of the effects of the dopamine-agonist quinagolide on 
disease activity and prolactin levels in patients with active RA are reported.
This thesis ends with a summary and general discussion in chapter 1 1 .
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Hypothalam ic-pituitary-adrenal Axis A c tiv ity  and Prolactin  Secretion in Patients w ith  Rheumatoid A r th r itr is
Similar response of ACTH, cortisol and 
prolactin to surgery in rheumatoid 
arthritis and osteoarthritis
Parts of this chapter have been published as a letter to the editor:
Eijsbouts A, van den Hoogen F, Laan R, de Waal Malefijt M, Hermus A, Sweep C, de 
Rooij DJ, van de Putte L. Similar response of adrenocorticotrophic hormone, cortisol 
and prolactin to surgery in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 
1998; 37: 1138-1139.
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In order to examine the existence of a defective cortisol and excessive prolactin response to surgery 
in patients with rheumatoid arthritis (RA) as suggested by a previous report we studied 9 patients 
w ith RA and 10 patients with osteoarthritis (OA) before and after knee or hip replacement. 
Plasma ACTH, plasma cortisol and serum prolactin levels were determined immediately before 
surgery and on the following 4 days. Cortisol before surgery was in the norm al range and did not 
differ significantly between the groups. After surgery no significant changes in cortisol levels 
occurred. ACTH before surgery was normal and showed a comparable decrease the day after surgery 
in both groups and returned to baseline values in the following days. Prolactin before surgery was 
norm al in both groups. After surgery no change in prolactin levels was observed. In contrast to a 
previous study we found no differences between RA and OA patients in cortisol, ACTH and pro­
lactin levels before and after major surgery.
t In troduct ion
In recent years evidence has accumulated that there is a bilateral communication between the 
endocrine system and the immune system [1]. The concept has emerged that during an immune 
response cytokines like tum or necrosis factor alpha (TNFa), interleukin-ip (IL-iP) and inter­
leukin-6 (IL-6) are released and stimulate the hypothalamus to produce corticotrophin releasing 
hormone (CRH), which stimulates the pituitary gland to release adrenocorticotrophic hormone 
(ACTH). ACTH in its turn stimulates the adrenal glands to produce and release cortisol. 
Glucocorticosteroids have a strong anti-inflammatory effect which is illustrated by the fact that 
patients with adrenal failure can not cope with inflammatory events and may die if corticos­
teroids are not substituted. Further proof of the importance of the hypothalamic-pituitary-adre- 
nal-axis (HPA-axis) for the immune response comes from experiments in animals: in rats with a 
norm al HPA-axis an injection with streptococcal cell wall peptidoglycan (SCW) induces a mild 
transient acute arthritis. They develop a stronger reaction followed by an acute arthritis if they are 
treated with the corticosterone-receptor antagonist RU 486. In the Lewis rat, which releases insuf­
ficient amounts of corticosteroids as a result of a deficient CRH release by the hypothalamus, the 
same injection induces acute arthritis followed by a chronic proliferative erosive phase, which 
resembles that of rheumatoid arthritis (RA) in humans. This reaction does not occur if the rats 
are concurrently treated with glucocorticosteroids [2,3].
Several studies have shown the influence of prolactin on the immune system. It has been shown that 
administration of prolactin leads to an increased weight of spleen and thymus due to enhanced 
DNA-synthesis in splenic lymphocytes and thymocytes [4], and receptors for prolactin have been
t S u m m ary
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found on lymphocytes [5]. Adjuvant arthritis in rats did not occur after hypophysectomy, but treatment 
with prolactin restored their immunocompetence and made them susceptible to this disease [6]. 
Studies in humans have confirmed the importance of the HPA-axis in patients with RA. The 
num ber of glucocorticoid receptors in RA patients was found to be significantly lower than in 
control subjects [7] and treatm ent with corticosteroids suppresses inflammation in RA. Studies 
by Chikanza et al. [8,9] suggest a defective HPA response in patients w ith RA, illustrated by a 
diurnal cortisol rhythm which was at the lower limit of normal, and a failure to increase cortisol 
levels following surgery, despite high levels of circulating cytokines. They also found increased 
levels of prolactin in patients with RA and an abnormal increase of prolactin levels after surgery
[10]. Based on these findings they conclude that in RA a defective HPA response and excessive 
prolactin reaction lead to a pro-inflammatory horm onal status which might play a role in the 
pathogenesis of RA.
These horm onal abnormalities might have clinical consequences: for instance glucocorticoid 
treatm ent at the beginning of RA might prevent its progression to a chronic phase [11] and the 
inhibition of prolactin might reduce disease activity. The latter has been tested in clinical trials 
and indeed, some studies report on the beneficial effect of bromocriptine treatment, which 
suppresses prolactin secretion, in rheumatic diseases such as RA [12], psoriatic arthritis [13,14] 
and Reiter's syndrome [15]. The aim of this study was to examine the existence of a defective HPA 
response and excessive prolactin secretion after surgery in patients with RA.
w P a t ien ts  and M e th o d s  
Patients
Nine patients with RA and 10 patients with osteoarthritis (OA) were studied. They were all 
recruited from patients attending the departments of Rheumatology or Orthopedics at the 
University Hospital Nijmegen or the St. Maartenskliniek Nijmegen. Patients with RA fulfilled the 
revised criteria for RA of the American College of Rheumatology [16].
Patients were included if they had rheumatoid factor positive RA, or OA, were 18 years or older 
and needed total knee or hip replacement. Seven RA patients were using disease-modifying 
antirheumatic drugs (DMARDs), including aurothioglucose, sulphasalazine, methotrexate, 
azathioprine and hydrochloroquine. All OA patients and all but one RA patients were treated with 
NSAIDs, including naproxen, diclophenac, indomethacin, and ibuprophen. Exclusion criteria 
were: use of corticosteroids in the previous year, use of oral contraceptives or drugs interfering 
with cortisol secretion and/or metabolism, oophorectomy, endocrine disorders, excessive alcohol 
intake and malignancy.
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Methods
On the day of admission screening was performed and informed consent was obtained. In 
patients with RA disease activity was assessed by means of the Disease Activity Score [17], 
consisting of the Ritchie articular index [18], total number of swollen joints (TSW44), erythrocyte 
sedimentation rate (ESR) and a visual analogue scale (VAS) for general health.
At 7:30 AM before surgery and at the same time on the following 4 days after surgery blood was 
collected for determination of plasma ACTH, plasma cortisol and serum prolactin levels. Blood 
for the determination of ACTH was immediately placed in ice and transported to the laboratory.
Hormone assays
Blood was collected in pre-chilled K-EDTA tubes and centrifuged for 10 minutes at 1500xg (4 °C) 
within one hour. The plasma obtained was aliquoted in polystyrene tubes containing 250 KlU/ml 
plasma Trasylol® (aprotonine, Bayer, Leverkusen, Germany), frozen and stored at - 20 °C. 
A C T H : ACTH in plasma was measured by an imm unoradiometric assay (IRMA) based on two 
polyclonal antibodies (EuroDiagnostics, Arnhem, The Netherlands). The catching antibody is 
directed against the C-terminal part of the ACTH molecule and coupled via a sheep anti-rabbit 
antibody to a polystyrene tube. The detecting antibody is directed against the N-terminal part of 
ACTH and radioiodinated. Standard curves were prepared by spiking ACTH-free plasma with 
ACTH-(1-39) (MRC 74/555). The assay was performed as follows. Two hundred microliters of 
sample or standard (0-220 pmol/l) were added to the coated tubes and subsequently iodinated 
ACTH antiserum (250,000 dpm/200|il) was added. The mixture was incubated for 24 hours at 
room temperature. The supernatant was decanted and the tubes washed two times with 0.9% 
NaCl. Radioactivity in the tubes was counted using an automatic gamma-counter (1470 TM 
Wallac, Turku, Finland). The sensitivity of the assay was 0.5 pmol/l and the within- and between- 
assay coefficients of variation of the IRMA procedure were 4.4% and 7.2% respectively. All samples 
were measured in duplo. The IRMA specifically detects ACTH-(1-39). Crossreactivity with 
ACTH-(1-24), CLIP and P-endorphin was < 0.1%. Normal range at 8:00 AM: 1.3-9.2 pmol/l. 
Cortisol: Plasma cortisol levels were measured by radioimmunoassay using an antiserum raised in 
rabbit against a cortisol-21-hemisuccinate-bovine serum albumin conjugate. The following 
crossreactivities (expressed as % on mass basis) were obtained: desoxy-cortisol, 3.1%; cortison, 
0.5%; dexamethason, 0.2%; prednisolone, 7.1%. Standard and samples (50 |il) are diluted 1:100 
with ethanol/water (5/95, v/v) and corticosteroid binding globulin was denatured by incubation 
at 70°C for one hour. Subsequently tracer ([1,2,6,7- 3H]cortisol) and antibody were added and 
bound and free hormone were seperated by dextran-coated charcoal after incubation for 18 hours 
at 4 °C. After centrifugation the supernatants were decanted and radioactivity was measured. The 
sensitivity of the assay was 0.02 |imol/l. The within- and between-assay coefficients of variation
19
were 4.5% and 6.6% at 0.21 |im ol/l and 4.0% and 3.8% at 1.04 |im ol/l respectively. Normal range 
at 8:00 AM: 0.19-0.55 |imol/l.
Prolactin: Serum prolactin levels were measured using the Spectria competitive solid-phase RIA 
from Farmos Diagnostica (Turku, Finland) as described earlier [19]. The sensitivity of the assay 
was 30 mIU/l. The within- and between-assay coefficients of variation were 5.8% and 10% at 430 
mIU/l and 4.9% and 8.5% at 1200 mIU/l respectively. Normal range: 100-700 mIU/l.
Stat istical analysis
Results are expressed as the mean ± standard error of the mean (SEM). Statistical comparisons 
were made w ith paired t-test within groups and w ith unpaired t-test between groups, using a sig­
nificance level of p  < 0.05.
w Results
Demographic details of the patients are shown in Table 1. There was no significant difference in 
age between the two groups (RA: mean [SEM] 63.3 [3.5] years, OA: 66.4 [2.1]). In patients with 
RA mean Disease Activity Score was 3.50 [0.3] and range 1.60 to 4.71. Mean ESR was 25.6 [3.4].
a c t hA C I H  Before surgery, serum ACTH levels were in the norm al range, both in the RA patients (6.7 
[1.3]) and the OA patients (5.32 [1.2]) (Fig. 1A). The first day after surgery a comparable decrease 
was seen in both  groups (RA: mean -3.86, p = 0.02, OA: -2.55, p = 0.07). Values returned to nor­
mal on the third day after surgery.
C o rtiso 1  Before surgery, plasma cortisol levels were at the upper part of the normal range, both 
in patients with RA (0.48 [0.04]) and in patients with OA (0.58 [0.04]) (Fig. 1B). Following surgery 
a trend towards a decrease in plasma cortisol levels in patients with OA on the first day after surgery 
followed by a rise with a maximum on the fourth day was observed. In RA patients after surgery 
a trend towards a rise of plasma cortisol levels was seen with a maximum on the third day. 
However, the changes found were not significant neither within nor between groups.
P r o la c t in  There were no significant differences in prolactin levels before surgery between both 
groups (RA: mean 339, SEM 36, OA: mean 278, SEM 34), nor were there any significant changes 
in prolactin levels after surgery (Fig. 1C).
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In this study we were unable to find any significant differences between RA and OA patients in 
plasma cortisol, plasma ACTH and serum prolactin levels at any measuring point, both before 
or after surgery. These observations are in disagreement with the study of Chikanza et al. [8,10]. 
There are three important differences between their and our studies: Firstly, we found higher 
levels of cortisol in both RA and OA patients before and after surgery. Secondly, we did not see 
a rise in cortisol after surgery in either group. Thirdly, we did not find an excessive secretion of 
prolactin before or after surgery. Possible explanations for the different findings between our 
study and the study by Chikanza et al. are discussed below.
The levels of cortisol that we found before the operation were at the upper limit of normal in both 
RA and OA patients and we attribute this to the stress in anticipation of the operation. After the 
operation levels stayed at these high levels possibly due to pain and an activated imm une system 
during wound healing. In contrast, Chikanza et al. found lower levels of cortisol before and also 
after the operation especially in the RA patients but also in the OA patients. This might be partly 
related to the fact that in our patients blood was drawn at 7:30 AM and in Chikanza's study at 
9:00 AM. Looking at the study of Chikanza et al. who studied the diurnal rhytm and the reactions 
to surgery in different groups of patients there is a striking difference between the levels of cortisol 
at 9:00 AM when the diurnal rhythm was studied and at 9:00 AM before the operation; the levels 
before surgery are lower in all three groups, also on day three and four after surgery. A possible 
explanation for this might be that the patients had received more pre-medication and were more 
sedated than the patients in our study. Another explanation might be the use of antirheumatic 
therapy: In the study by Chikanza et al. the diurnal rhythm of cortisol was studied in 10 patients 
w ith active RA, 10 patients with noninflammatory arthritis (NIA) and in 10 patients with 
osteomyelitis (OM). Whereas all patients with RA were treated with NSAIDs, only 5 of the NIA 
and none of the OM patients were. Nine RA patients were also treated with a DMARD. The RA 
patients showed the lowest cortisol values with a normal diurnal pattern, the NIA patients had 
somewhat higher values, and the OM patients, who did not use NSAIDs, had the highest values. 
The high cortisol values of the OM patients are to be expected because of their active inflamma­
tion, but one would expect the same high values in the RA patients with a comparable degree of 
inflammation. The fact that this was not found might suggest a hypothalamic defect but might 
also be the result of concomittant pharmacotherapy of these patients, i.e. NSAIDs and/or 
DMARDs.
We did not observe a rise in cortisol levels on the day after the operation in RA or OA patients, 
allthough there has possibly been a rise in cortisol shortly after the operation in both groups indi­
cated by a significant decline in ACTH on the m orning after surgery. This reaction however was
w Discussion
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similar in RA and OA patients. Maybe drawing blood sooner after the operation would have 
shown this presumed cortisol response. A study in patients undergoing neck surgery showed 
profound elevations of ACTH and cortisol directly after the operation with return to baseline the 
next morning [20].
In the study of Chikanza et al. [8,10] the reactions to surgery were studied in 10 patients with RA 
(7 using NSAIDs, 9 using DMARDs), 9 with OA (7 using NSAIDs) and 10 with OM. Before surgery 
cortisol levels were similar in RA and OA patients, of which the same number of patients used 
NSAIDs, but higher in OM (not using NSAIDs). On the first two days after operation however 
RA patients showed no increased cortisol levels whereas OM and OA patients did have increased 
cortisol levels reaching a peak at 48 hours and returning to norm al on day 3. On day 3 and 4 no 
differences were seen between the 3 groups. This difference in reaction after surgery cannot be 
explained by the use of NSAIDs as this was comparable in RA and OA. A possible influence of 
DMARDs on the HPA-axis cannot be excluded.
From the above data it appears that NSAIDs may be involved in influencing the HPA-axis. Data 
currently available, indeed, suggest that this is a real possibility. Several studies have shown that 
cytokines, especially IL-ip and IL-6, activate the HPA-axis by stimulating CRH release from the 
hypothalamus [21,22,23]. One of the possible mechanisms by which cytokines may induce CRH 
release is through the synthesis of prostaglandins, which act within the hypothalamus to stimulate 
the secretion of CRH [24,25]. An in vitro study in rats [26] showed that the effects of both IL-1 
and IL-6 on CRH release were antagonised by specifically inhibiting the synthesis of 
prostaglandins via the cyclooxygenase pathway by NSAIDs (indomethacin and naproxen). In vivo 
studies in animals have shown that the effect of cytokines on CRH release could be antagonised 
by blocking the cyclooxygenase pathway and thereby prostaglandin synthesis by NSAIDs 
[27,28,29]. In addition in a study in humans, aspirin was shown to inhibit vasopressin-induced 
HPA activity [30]. On account of these findings, NSAIDs might be responsible for a decreased 
cortisol response.
The fact that we did not observe higher levels of prolactin before the operation in patients with 
RA nor an excessive secretion of prolactin after surgery might be explained by a difference in disease 
activity as illustrated by the ESR; 25.6 ± 10.3 versus 56.9 ± 18 m m /hour in the study by Chikanza 
et al. However, our patients did have active disease as demonstrated by the DAS-score (3.50 ± 0.3). 
Although not significantly different, mean prolactin levels before surgery were somewhat higher 
in RA patients than in OA patients (339 ± 107 versus 278 ± 107) and maybe the difference would 
have been greater if the RA patients in our group had had more active disease. On the other hand, 
in a recent study in patients with newly diagnosed RA [31], who had not been treated with 
glucocorticoids, disease-modifying drugs or NSAIDs (some of them had only been taking 
NSAIDs occasionally), both basal and stimulated prolactin levels showed no difference when
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compared to healthy controls. Also in two other studies no significant difference was found in 
prolactin levels between patients with RA and controls [32,33]. Whether NSAIDs can also influence 
prolactin secretion has not been studied extensively, but one study in humans [34] showed a 
decrease in plasma prolactin levels during PGE2 infusion and an increase after use of NSAIDs: 
more clearly after the use of indomethacin than after naproxen.
In conclusion we found neither a defective response of the pituitary-adrenal axis nor an excessive 
prolactin secretion in patients with RA. In contrast we found relatively high levels of cortisol 
before and after surgery and indications of a possible cortisol response on the day of the operation 
w ith no difference between RA and OA patients. We therefore suggest that it is doubtful whether 
a defective hypothalamic response and excessive prolactin secretion exist in patients with RA. 
Further studies are necessary to elucidate the reactions of the HPA-axis and prolactin in RA, the 
possible influence of NSAIDs and their mode of action on the HPA-axis in RA patients.
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Table 1 . Demographic features of study subjects
RA patients (n=9) OA patients (n=10)
Age (years) 63 .3  ±  3 .5 66 .4  ±  2.1
male:female
O
J 64
Disease duration (years) 17 .8  ± 4 .3 2.±.27.
ESR (mm/hour) 25 .6  ±  3 .4 -
DAS 3 .5 0  ±  0 .3 -
DMARDs 7 -
NSAIDs 8 10
Values are Mean ± SEM, number o f patients or number o f drugs. RA = rheumatoid arthritis. OA = osteo­
arthritis. ESR = erythrocyte sedimentation rate. DAS = disease activity score. DMARDs = disease modifying 
antirheumatic drugs. NSAIDs = nonsteroidal antiinflammatory drugs.
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0 1 2  3 4
Figure 1 Adrenocorticotrophic hormone (ACTH) (A), Cortisol (B) and prolactin (C) levels in patients with
RA (------) and OA (------ ). Values on day 0 are taken a t 7:30 A M  on the day o f surgery. Day 1-4 are days after
surgery. Values are the mean ± SEM.
Eijsbouts AMM, Murphy EP. The role of the hypothalamic-pituitary-adrenal axis in 
rheumatoid arthritis. Bailliere’s Clinical Rheumatology 1999;13:599-613.
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w A b s t r a c t
It has become clear that there is a bidirectional communication between the neuroendocrine and 
the immune system and that both systems influence each other and interact under physiologic 
conditions and in response to inflammatory stimuli. The hypothalamic-pituitary-adrenal axis 
plays an im portant role in regulating and controlling immune responses and dysfunction of the 
axis has been implicated in the pathogenesis of rheumatoid arthritis. Corticotrophin-releasing 
hormone (CRH), one of the main hormones of the axis, is also released extra-hypothalamic, 
peripherally at the site of inflammation and may modulate inflammatory responses locally.
In this chapter we will discuss the role of the HPA-axis and peripheral CRH, its influences on 
imm une function and what is known about the possible pathogenetic role of the HPA-axis and 
peripheral CRH in RA.
w Centra l  role of the  Hypotha lam ic-P i tu i tary -Adrenal  
(HPA) axis
Regulat ion,  ho rmones  and funct ion
The HPA-axis is a neuroendocrine pathway that plays an im portant role in maintaining and 
restoring homeostasis and allows an organism to respond adequately to stress. In the hypothala­
mus, especially in the paraventricular nucleus, corticotrophin releasing hormone (CRH) is secreted 
and through the portal vessels reaches the anterior pituitary. By binding to pituitary cell surface 
receptors CRH stimulates transcription of pro-opiomelanocorticotrophin (POMC) through the 
secondary messenger cyclic AMP (cAMP). POMC is a precursor of several neuropeptides inclu­
ding adrenocorticotrophic hormone (ACTH). CRH is the most specific and potent ACTH secre- 
tagogue and it controls the synthesis and secretion of ACTH into the circulation, in synergy with 
arginine vasopressine (AVP), a neurohormone which also originates from the hypothalamus and 
reaches the anterior pituitary by the portal vessels.
ACTH induces the secretion of the glucocorticoid cortisol, which is produced in the zona fascicu- 
lata of the adrenal gland. Cortisol through a negative feed-back mechanism inhibits the secretion 
of CRH, AVP and ACTH, thereby inhibiting its own action, and ACTH probably inhibits the pro­
duction of CRH.
Cortisol is produced under basal conditions in a circadian rhythm with a peak at about 8:00 AM 
around waking, gradually decreasing during the rest of the day to a nadir around midnight. 
Furthermore a pulsatile production of cortisol occurs in response to many different forms of
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stress, such as physical exercise, pain, fear and inflammatory stimuli. Cortisol is bound to plasma 
proteins, mostly cortisol-binding globulin (CBG), except for 3-10% which circulates free and 
after diffusing through cell membranes can bind to the cytoplasmic glucocorticoid receptor. The 
glucocorticoid-receptor-hormone complex translocates to the nucleus and, after a num ber of 
events, binds to DNA at specific sites of glucocorticoid responsive genes. This modulates the tran­
scription of specific messenger RNAs, which affect the levels of encoded protein products. These 
glucocorticoid-regulated proteins exert many different effects of glucocorticoids. Glucocorticoid 
receptors are present in virtually every nucleated cell of the body.
Bi lateral  commun icat ion between the neuroendocr ine  
and immune systems
In recent years convincing evidence has accumulated to suggest that a bilateral communication 
exists between the endocrine and the immune system. Influences of the endocrine system on the 
imm une response will be discussed, followed by influences of the imm une system on the 
endocrine system, with emphasis on the role of the HPA-axis in these interactions.
The first evidence of the importance of the neuroendocrine system for immune function dates 
from 1930, when it was discovered that hypophysectomy in rats caused an involution of the thy­
mus. It was also discovered that Addison's disease, which renders patients unable to cope with 
infectious and other inflammatory events, is caused by adrenal insufficiency resulting in lack of 
glucocorticoids. A num ber of hormones were found to have an effect on immune reactions. For 
example androgens, estrogens, progesterone, glucocorticoids and endorphins were shown to have 
a suppressing effect on the immune response, whereas growth hormone, prolactin (PRL), thy­
roxine and insuline increase the response. Receptors for growth hormone and PRL have been 
found on T and B lymphocytes [1].
Glucocorticoids are im portant im m unomodulators and this knowledge has led to their wides­
pread clinical use. They have various effects on the imm une system. They influence the circulat­
ing population of white blood cells and cause accumulation of leucocytes at the inflammatory 
site. Endogenous levels of glucocorticoids occurring under physiologic conditions influence the 
basal operation of lymphocytes which indicates that the HPA-axis affects the activity of the immune 
system under basal conditions. Glucocorticoids have also been shown to inhibit the production of 
cytokines such as interleukin 1 and 2 (IL-1, IL-2), tum or necrosis factor (TNF), colony stimulating 
factor and gamma-interferon production and affect the production of interleukin 4 (IL-4). Finally 
they also affect cytokine-mediated expression of class l and ll MHC antigens on macrophages.
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The first real evidence of the influence of the immune system on neuroendocrine functions was 
the observation of an increase in serum corticosterone during an imm une response [2]. Since the 
discovery of cytokines insight into the communication between both systems has grown and it 
has been discovered that the HPA-axis can be activated by cytokines, in particular IL-ip, IL-6 and 
TN Fa [3,4]. It is still not clear how cytokines activate the HPA-axis. Various possible explanati­
ons have been suggested. Activated imm unocompetent cells such as monocytes, lymphocytes and 
macrophages can permeate the blood-brain barrier and secrete cytokines and other inflammatory 
mediators within the brain. Cytokines may act at the level of the median eminence, which is out­
side the blood-brain barrier, or they may be produced within the neuroendocrine system. It has 
already been shown that glial cells, neuronal cells, endothelial and smooth-muscle cells of blood 
vessels in the brain are able to produce and secrete cytokines such as IL-1, 2, 4 and 6 and TNFa 
[5]. IL-1 receptor antagonist (IL-ira) and receptors for several cytokines have been found in var­
ious areas of the rat brain [6].
In addition to communication between the immune system and the neuroendocrine system at 
the level of the hypothalamus, communication also takes place at the pituitary [6] and at more 
peripheral levels. The adrenal gland, the main effector organ of the HPA-axis, is also a site where 
synthesis and action of cytokines occurs [7]. Immunocompetent cells, such as macrophages, 
monocytes and lymphocytes, are located within the adrenal cortex where they produce cytokines. 
Adrenocortical cells themselves have been shown to produce TNFa, IL-1 and IL-6 mRNA. These 
cytokines probably induce adrenal hyperplasia, influence the production of cortisol and the 
release of other cytokines in an autocrine fashion. Furthermore, in in vitro studies with rat and 
human adrenocortical cells, cytokines, like IL-2, IL-3, interferons and TGF-S, have been shown to 
influence adrenocortical cell function.
Cells of the immune system have been shown to possess the mRNA for POMC, the precursor of 
ACTH, and have been reported to produce various hormone-like substances like CRH, ACTH, 
growth hormone and PRL [8,9].
In conclusion the neuroendocrine and imm une systems share common peptides and ligands and 
can influence each other in a bidirectional way, at several different levels [10].
Animal  models  with HPA-axis dysfunct ion
The understanding of neuroendocrine-imm une interaction has led to the concept of neuro- 
im m unomodulation, the possibility that neuroendocrine actions can influence and modulate the 
imm une response. This has given rise to the idea that neuroendocrine dysfunction may play a role
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in the development of autoimmune diseases. Several animal models show the influence of neu­
roendocrine disorders on inflammatory disease.
Obese strain (OS) chickens for example, that develop a spontaneous autoimmune thyroiditis, a 
model resembling Hashimoto thyroiditis in humans, show decreased or even absent reaction of 
glucocorticoid levels in response to IL-1 compared to healthy controls. The defect of this immuno- 
endocrine feedback loop appeared to be localized in the hypothalamus or pituitary gland or in 
both. A comparable defect of imm uno-endocrine communication was found in certain mouse 
strains that spontaneously develop disease resembling human autoimmune disease. In young 
lupus-prone (NZB/W)F1 and MRL/MP-lpr mice a lower increase in plasma corticosterone levels 
was observed after injection of recombinant IL-1 when compared to normal mice [11].
Hypophysectomized rats showed impaired imm une reactions to various antigenic stimuli. They 
did not develop adjuvant arthritis, but treatm ent with PRL restored their immunocompetence 
and made them succeptible to this disease. Decreased antibody formation in rats after hypophy- 
sectomy could be restored by PRL. Moreover, when normal rats were treated with bromocriptine, 
a dopamin-agonist decreasing prolactin secretion, the development of adjuvant arthritis was 
inhibited [12,13].
In normal Fisher (F344/N) rats, an injection with streptococcal cell wall peptidoglycan polysac­
charide (SCW) induces a mild transient acute arthritis. They develop a much stronger reaction with 
a more severe arthritis during treatment with a glucocorticoid antagonist (RU 486), demonstrating 
that an intact response of the HPA-axis is required for their relative resistance to arthritis. Lewis rats 
(LEW/N) are much more vulnerable to this induced arthritis and, in response to an injection with 
SCW, develop an acute arthritis, followed by a chronic phase, resembling rheumatoid arthritis (RA) 
in humans. This succeptibility of Lewis rats to SCW arthritis has been shown to be related to a defec­
tive HPA-axis response with depressed corticosterone levels, probably in part due to a defect at the 
level of the hypothalamus. If the corticosterone deficient Lewis rats are concurrently treated with 
glucocorticosteroids they show only a mild arthrits similar to normal rats [14,15].
These findings have given support to the hypothesis that the HPA-axis plays an im portant role in 
inhibiting and modulating inflammatory responses thereby protecting the organism against 
damage caused by an overshoot of immune reactions. A defect in the function of this axis may 
result in insufficient inhibition of an inflammatory response and thus fascilitate the development 
of chronic inflammatory disease, such as RA.
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► Periphera l role of CRH as a pro- in flammatory mediator
P a r a c r i n e /a u to c r i n e  act ions of CRH
A relationship between altered CRH levels and inflammation has previously been demonstrated. 
HPA-axis responses to inflammatory stimuli in arthritis-susceptible Lewis (LEW/N) and arthritis- 
resistant Fisher (F344/N) rat strains have been described above. While the LEW/N rats have a defi­
cient hypothalamic CRH response to virtually all stimuli, the F344/N rats display robust increases in 
hypothalamic CRH with resultant differences in levels of plasma ACTH and glucocorticoids [14]. 
These results suggest that altered HPA-axis responses may play an important role in the contrasting 
susceptibility of the LEW/N and F344/N rats to the process of inflammatory arthritis. Interestingly, 
the impaired hypothalamic CRH responses of the LEW/N strain contrasts with the high levels of 
CRH expression at the site of inflammation [16]. Thus while CRH exerts an indirect systemic imm u­
nosuppressive effect, in this rat model peripheral hyper-secretion of CRH is associated with increased 
susceptibility to induced arthritis. CRH probably also plays an important role in human inflamma­
tory joint diseases since CRH mRNA and protein are markedly increased in synovia and surrounding 
tissue from arthritic joints and in synovial fluid taken from patients suffering from RA [17,18].
CRH and the immune response
A growing body of data now supports direct involvement of extra-hypothalamic or peripheral 
CRH in the modulation of inflammatory responses. First, CRH mRNA is expressed in immune 
cells of the rat spleen and thymus and in human peripheral blood leukocytes. In addition to RA, 
inflamed tissue from patients with ulcerative colitis and Hashimoto thyroiditis both contain ele­
vated CRH mRNA and protein [19,20]. Second, CRH receptors are present on resident 
macrophages of mouse spleen [21] and human peripheral blood lymphocytes and monocytes 
[22]. Third, direct interaction of CRH with imm une cells in vitro results in stimulation of lym­
phocyte proliferation, expression of interleukin-2 receptor and stimulation of leukocyte secretion 
of ACTH, P-endorphin, Il-1 and IL-2 [23]. Other studies have revealed CRH regulation of the 
acute phase response in hepatocytes and enhancement of natural killer cell mediated lysis. Finally, 
an essential role for imm une CRH in the mediation of localized inflammatory response is sup­
ported in an in vivo rat model of acute inflammation where CRH is produced in peripheral 
inflammatory sites and is active locally. Most importantly, immunoneutralisation of this localized 
CRH synthesis, using anti-CRH antibodies, causes a specific suppression of the inflammatory 
response comparable to inhibitory levels seen with TN Fa -antibodies [24].
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The recent construction of mice lacking CRH provides additional evidence for the role of periph­
eral CRH in inflammation and confirms that CRH is required for the induction of the inflam­
m atory response [25]. Initial analysis of these mice revealed that immune activation of the HPA- 
axis does not require direct stimulation by CRH and may be occurring at the level of the pituitary 
and/or the adrenal gland. The CRH deficient mice provide an essential model to further dissect 
the regulation of peripheral CRH expression, its effects on immune cells and the actual position 
of this peptide in the inflammatory cascade [25]. Taken together, these findings further support 
the evidence that peripheral CRH acts as an autocrine or paracrine inflammatory mediator and 
highlights its importance in integrating the responses of the central nervous, endocrine and 
imm une systems to physiological and immunological stimuli.
► A possible role of the  HPA-axis in the  
pathogenesis  of RA
From clinical experience and from research we know that stress and major life events influence 
disease activity in patients with RA [26]. Experimental studies also show the possible importance 
of the HPA-axis in RA. Chikanza et al [27-29] showed that patients with RA had low diurnal cor­
tisol levels compared to patients with osteoarthritis and osteomyelits, despite high levels of 
cytokines IL-1 and IL-6. In response to surgical stress caused by a total hip or knee replacement 
they had a lower cortisol response when compared to the other two groups. They also found that 
patients with RA had higher levels of PRL under norm al circumstances and an excessive PRL 
response after surgery than the other two groups. They found normal pituitary and adrenal func­
tion in RA as illustrated by a norm al CRH test and concluded that the site of the defective inter­
actions between the imm une and neuroendocrine system is the hypothalamus. They formed the 
hypothesis that in RA a defective HPA response and excessive PRL reaction lead to a pro-inflam­
matory horm onal status which might play a role in the pathogenesis of RA.
A num ber of studies support this theory, but also a num ber of studies do not confirm these find­
ings or even contradict them. In favour are the following observations: The inflammatory activi­
ty of RA was found to correlate with adrenal cortisol secretion [30,31] and the circadian rhythm 
of disease activity in RA may be related to cortisol and PRL levels with maximal disease activity 
between 02:00 and 04:00 AM, when cortisol, with antiinflammatory effects, is low and PRL, with 
proinflammatory influence, reaches its highest levels. Moreover patients with active RA were 
shown to have a lower num ber of corticosteroid receptors than healthy controls, while their
C R H -d e fic ie n t mice
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serum cortisol levels did not significantly differ from the controls [32]. This diminished number 
of receptors however does not result in glucocorticoid resistence [33] and the relevance of the 
diminished num ber of receptors is not clear. High levels of PRL have also been reported in other 
forms of autoimmune arthritis like SLE [34] and treatment with bromocriptine has been reported 
to be beneficial in RA, Reiter's disease and psoriatic arthritis [35-37].
In contrast to these findings a study comparing patients with RA and osteoarthritis detected no 
differences in cortisol and PRL levels before and after surgical stress caused by a total hip or knee 
replacement [38]. However, one can still argue that norm al cortisol levels in active RA are insuf­
ficiently low for the degree of inflammation. A recent study showed lower levels of cortisol in spite 
of higher levels of ACTH, at baseline and in response to a multiple releasing hormone (MRH) test 
w ith a lower cortisol/ACTH ratio in patients with RA compared to healthy controls, suggesting 
impaired adrenal responsiveness in RA. PRL levels at baseline were normal, but a reduced PRL 
response was seen after stimulation [39]. Another study showed reduced adrenal steroid and 
insulin-like growth factor-1 (IGF-I) levels in patients with RA, but norm al baseline and dynamic 
cortisol levels, which can still be considered abnormal in the setting of sustained inflammation 
[40].Normal levels ofPRL [41,42] and even low PRL levels with decreased bioactivity ofPRL [43] 
were found in patients with RA compared to healthy controls, and some studies did not find a 
beneficial effect of treatment w ith bromocriptine in RA [44,45].
In conclusion, indications of an insufficient HPA response in patients with RA have been found, 
but its role in the pathogenesis of RA is still under debate.
»The possible role of per iphera l  CRH in the  
pathogenesis  of RA
CRH express ion in inf lamed synovium
Demonstration of local CRH secretion in arthritic joints of patients with RA and in several animal 
models of inflammatory joint disease represents important evidence suggesting a role of peripher­
al CRH in the pathogenesis of RA. Levels of immunoreactive CRH (140 ± 33 pg/ml), comparable to 
those observed in the hypophyseal portal system (100-1000 pg/l), are found in RA synovial fluid. 
CRH expression in synovium and synovial fluid from RA patients is significantly higher than in OA 
patients [17,18]. Research in rats showed elevated immunoreactive CRH levels in the synovial lin­
ing layer, subsynovial stromal cells, blood vessels, endothelial cells and infiltrating mononuclear cells 
of the inflamed synovium. However, it remains to be demonstrated if CRH is synthesised by all these 
cell types [16]. Nevertheless, the concentration of immunoreactive CRH in synovium displays a sig­
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nificant correlation with the extent and intensity of mononuclear cell infiltration. Another source 
of peripheral CRH, which may contribute to local CRH within the joint, is the peripheral nervous 
system (PNS). In animal models, CRH is found in the dorsal sensory afferent and sympathetic 
interomediolateral columns of the spinal cord as well as the dorsal root and sympathetic ganglia 
[46]. Sensory afferent unmyelinated c-fibres release of neuropeptides, such as Substance P and neu- 
rokinen A, contributes to neurogenic inflammation and have been implicated in joint inflammation 
and destruction [47]. Indeed such findings have suggested an attractive explanation for the docu­
mented symmetry of joint involvement and distal joint involvement associated with RA. Local CRH 
expression in inflamed tissue is the predominant factor required for peripheral opioid analgesia 
[48]. Immune cell peptides such as P-endorphins mediate the effects of CRH and can activate opioid 
receptors on peripheral sensory nerves to inhibit inflammatory pain. The interaction between CRH 
and P-endorphin release may be direct, as in the anterior pituitary, or mediated through cytokines 
[48]. P-Endorphin can have a pro-inflammatory or anti-inflammatory function depending on its 
concentration at the site of inflammation. Immunohistochemical analysis has identified the pres­
ence of P-endorphin in synovial tissue from patients with RA, but not in OA patients. The level of 
P-endorhpin expression correlates with the degree of inflammation in RA [48].
Role of CRH at  si tes of in f lammat ion
One hypothesis proposis that the majority of immune CRH seen in the early stages of inflamma­
tion is of neuronal rather than imm une cell origin. The recent demonstration that the mast cell 
is the major target for immune CRH at inflammatory sites in a dose dependent and receptor 
mediated response may represent the early action on neuronal derived CRH in the pathogenesis 
of inflammation [50]. The mast cell is an imm uno-competent cell that contributes to inflamma­
tory responses and provides a source of pro-inflammatory cytokines, histamine and prostanoids 
leading to vasodilation and increased vascular permeability at inflammatory sites. These 
pro-inflammatory mediators induce and activate immune cells, thus, potentiating the inflammatory 
response giving rise to further inflammatory release from nerve endings. RA synovial tissue is rich in 
blood vessels with inflammatory angiogenesis being an important component of chronic synovitis. 
Initial in vitro reports propose that CRH is a potent stimulator of angiogenesis in a role analogous 
to that of Substance P in inflammatory conditions [25]. While CRH receptor subtypes in human 
synovium remain to be elucidated the identification of specific CRH binding sites in rat synovium 
further supports a local physiological role for CRH in the pathogenesis of inflammatory joint 
disease [16]. Despite increased CRH at sites of inflammation plasma CRH levels remain normal 
suggesting that the high affinity binding sites in synovium may function to maintain CRH levels 
within the joint and prevent locally produced CRH from functioning distally.
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Several lines of evidence indicate that members of the nuclear receptor family of transcription 
factors play an im portant co-ordinate neuroendocrine regulatory role at all levels of the HPA-axis 
[51]. The family includes receptors for lipophilic hormones and vitamins as well as a majority of 
orphan receptors whose physiological function is poorly understood. NURR1 (also called RNR-1 
and NOT) is an orphan member of this superfamily that is expressed predominantly in the central 
nervous system. The protein exhibits a close structural relationship to the orphan receptors 
NUR77 (also called NGFI-B/N10/NAK) and NOR-1 (also called MINOR/TEC). All three proteins 
are members of the NURR subfamily that bind to a cis-acting consensus sequence to regulate 
gene expression. Murphy et al. previously demonstrated that this NURR subfamily can regulate 
the expression of the CRH and POMC genes by interacting with specific cis-acting sequences in 
their proximal promoter regions [51]. NURR1 and NUR77 are rapidly induced by CRH in 
prim ary pituitary cells, resulting in increased synthesis of POMC. Synovium explants incubated 
w ith physiologically relevant concentrations of CRH rapidly induce expression of the NURR 
transcription factors [52]. Furthermore the authors have shown that this induction can be 
mimicked by activating cAMP pathways in isolated synoviocytes. The cAMP/protein kinase A 
pathway is an important signaling pathway in RA synoviocytes. These data suggest that at least one 
function of immune CRH in synovium may be to increase expression of the NURR subfamily of 
transcription factors through cAMP pathways. Preliminary studies have focused on understanding 
the regulation of the CRH gene in physiological and pathological states. Using cell culture and 
transient transfection assays the molecular mechanisms of CRH gene expression in human RA 
synoviocytes have been studied. The cytokines IL-1, IL-6, TN Fa and the prostaglandin PGE2, 
enhanced the transcriptional activity of the CRH promoter in primary synoviocyte cell lines 
providing evidence that pro-inflammatory cytokines associated with RA can modulate peripheral 
CRH gene expression [53]. The same pro-inflammatory mediators rapidly and robustly increase 
NURR1 and NUR77 mRNA and protein in these cells, while pretreatment with glucocorticoids 
can block this induction, indicating a significant role for this family of nuclear transcription in 
joint inflammation [52] (figure 1).
Hormona l  regulat ion of per iphera l  CRH
Glucocorticoids are the most potent natural anti-inflammatory agents used to date. Inflamma­
tory arthritis is extremely sensitive to glucocorticoids, which are commonly used in the treatment 
and control of the disease. In animal models administration of glucocorticoids (dexamethasone) 
leads to dose dependent inhibition of acute cell mediated inflammation in the arthritis-suscepti­
ble Lewis (LEW/N), while administration of the glucocorticoid antagonist RU486, caused a dose 
dependent increase in the inflammatory response of the arthritis-resistant Fisher (F344/N) rat 
strain [14]. These results suggest that manipulation of glucocorticoid levels may reverse the
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effects of HPA deficiency on the inflammatory response. Dexamethasone significantly reduced 
immunoreactive levels of increased peripheral CRH in the joints of animals with induced arthri­
tis. However, while this treatm ent was sufficient to remove infiltrating cells, some CRH expres­
sion remained, further supporting a non-im m une cell source of CRH in synovium [16].
Females produce more vigorous cellular and hum oral imm une reactions, are more resistant to 
infection and suffer a higher incidence of autoimmune diseases than males. Horm onal status may 
influence RA since RA has a higher prevalence in the female than the male (3:1). There also exists 
a menopausal peak of RA, dramatic improvements of the disease seen during pregnancy and sub­
sequent RA flares in the postpartum  period suggesting estrogen and/or progesterone deficiency 
may play a role in the pathogenesis of RA [54]. However, while oral contraceptives may lessen or 
defer the onset of RA slightly, estrogens are not able to alleviate the symptoms of RA [55]. Indeed 
the use of estrogen based contraception in female RA patients has been associated with worsening 
of disease activity and the severity of RA is also aggravated during the increased estradiol phases 
of the menstrual cycle. The role of sex steroids has been investigated in experimental arthritic 
models. The female arthritis susceptible Lewis rat shows an even greater susceptibility to inflam­
m atory responses and has elevated synovial CRH levels compared to the male [56]. Castrated 
Lewis males or P -estradiol treated males were found to develop arthritis as severe as that observed 
in Lewis females. Estrogens can stimulate adhesion molecules and their receptors in immune 
cells. Estrogen binding sites are expressed on macrophage-like synoviocytes and T-lymphocyte 
cells of normal and rheumatoid human synovium and there is in vitro evidence for direct estrogenic 
regulation of human CRH gene transcription. Therefore, the possibility exists that estrogen medi­
ated enhancement of synovial CRH and immune cells may be contributing factors in the gender 
related differences seen in inflamatory arthritis.
► RA, pregnancy and the  pos t -par tum  period
Pregnancy is known to influence the course of RA in women. A characteristic feature of RA is 
remission of the disease during gestation and exacerbation in the post partum  period. The third 
trimester of human pregnancy is characterised by a hyperactive HPA-axis possibly driven, in part, 
by increasing circulating levels of placental CRH and gradual decreasing levels of CRH binding 
protein (CRH-bp). CRH-bp circulates in human plasma and has been shown to reduce the 
bio-activity of placental CRH by sequestering CRH and preventing CRH recognition at its receptor. 
Normally, CRH levels in the peripheral circulation are low. However, during pregnancy maternal 
plasma CRH concentrations can rise to as much as 9 ng/ml. CRH concentrations rise exponen-
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tially as pregnancy advances peaking during labour and rapidly falling to low levels after parturition. 
The physiological roles of high CRH levels during gestation remain unknown. Studies have exam­
ined the relationship between CRH production and increased cortisol levels seen during pregnancy. 
Placental CRH may stimulate maternal pituitary ACTH secretion and contribute to gestational 
hypercortisolism. However, due to the fact that results indicate only a weak positive role of 
placental CRH on glucocorticoid secretion in vivo it is clearly not the exclusive regulator of maternal 
ACTH and cortisol increase during human pregnancy. Nevertheless, the possibility that high levels 
of CRH produced by the placenta contribute to the suppression of the maternal immune system 
cannot be ruled out. Recent evidence indicates that placental CRH directly stimulates dehy- 
droepiandrosterone (DHEA) secretion by human fetal adrenal cells [59]. DHEA is the major 
androgen in women. Androgens fulfill a considerable immunosuppressive role on both cellular 
and hum oral immune responses. Serum DHEAS (the inactive sulfate of DHEA or prohormone) 
has been shown to be significanltly decreased among women with pre-menopausal onset of RA. 
Androgen replacement therapy has been undertaken in the treatm ent of male patients with RA, 
and evidence indicating that low androgen concentrations may be a causal factor of RA contin­
ues to accumulate [60]. DHEA supplied by the fetal adrenals is the principal substrate for 
placental estrogen synthesis [59]. Estrogen has been implicated in the positive regulation of hypo­
thalamic and peripheral CRH, however, there is no evidence of a direct correlation between pla­
cental CRH and estrogen levels in vivo [58]. Estrogen can increase HPA activity by down-regulating 
glucocorticoid receptor binding in the hypothalamus and the anterior pituitary. During preg­
nancy increased levels of estrogen and progesterone are thought to contribute to the amelioration 
of RA, generally considered a cellular-Th1 classified disease. Estrogen has been shown to stimu­
late humoral (Th2) and inhibit cellular (Th1) imm une responses. Progesterone is generally 
immunosuppressive and plays a role in stimulating a switch from Th1 to Th2 imm une responses 
[60]. This shift to an enhancement of hum oral im m unity appears to prohibit cell mediated 
imm une effects by the mother, prevents rejection of the developing fetus and may induce a 
protective effect against the development of RA. Evidence from animal models of collagen 
induced arthritis indicates that maintained pregnancy levels of estrogen but not progesterone or 
glucocorticoids afford protection from post-partum exacerbation of arthritis [61]. The amelioration 
of RA during human pregnancy is an intricate process and to date the specific factor(s) involved 
remain elusive. The postpartum period is associated with a suppression of hypothalamic CRH and 
a rapid decline of maternal glucocorticoids, estrogen and progesterone levels and an increase in 
PRL. Recent data show a higher incidence of RA development particularly when the mother 
breast feeds [54], which is associated with a hypo-responsive HPA-axis and enhanced prolactin 
secretion, and both responses have been implicated in contributing to the development and
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persistence of RA. Horm onal changes may explain an increased incidence of RA development or 
aggravation of RA symptoms following parturition, possibly through restored cell mediated 
imm une responses.
w Influences of drugs on the  HPA-axis
A num ber of drugs are known to influence the actions of the HPA-axis. The most im portant are 
of course synthetic glucocorticoids, which strongly suppress the secretion of endogenous corti­
costeroids and induce adrenal atrophy. It has been shown that this effect can last up to a year after 
administration. Other drugs known to influence the HPA-axis are oestrogens, phenytoin, sedative 
hypnotics, imidazole derivates like ketoconazole and alcohol [62]. It is not known whether drugs 
that are frequently used by patients with RA, namely NSAIDs and DMARDs, also influence HPA- 
axis activity, but this can not be excluded. One of the possible mechanisms by which cytokines 
may induce CRH release is through the synthesis of prostaglandins, which act within the hypo­
thalamus to stimulate the secretion of CRH [63]. An in vitro study in rats showed that the effects 
of both IL-1 and IL-6 on CRH release were antagonized by specific inhibition of the synthesis of 
prostaglandins via the cyclooxygenase pathway by NSAIDs (indomethacin and naproxen) [64]. In 
vivo studies in animals have shown that the effect of cytokines on CRH release could be anta­
gonized by blocking the cyclooxygenase pathway, and thereby prostaglandin synthesis, by NSAIDs 
[65,66], and in humans, aspirin was shown to inhibit vasopressin-induced HPA activity [67]. On 
account of these findings, NSAIDs might be responsible for a decreased cortisol response. It has 
also been found that DMARDs have some influence on cytokine profiles [68], and as cytokines 
influence HPA-axis activity, it is possible that DMARDs in this way change HPA responsiveness. 
In most studies about the function of the HPA-axis in patients with RA, NSAIDs and/or 
DMARDs were being used, and while corticosteroids were often not used in the 3 or 6 months 
previously their effect can last much longer. Generally nothing is mentioned with regard to the 
use of oral contraceptives, containing estrogens. When abnormalities of the HPA-axis are found 
in patients with RA the question arises whether these abnormalities are a cause or a result of the 
disease and whether they may be caused by medication.
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If hormonal abnormalities play a role in the pathogenesis of RA, they form a rationale for a ther­
apeutic approach in the form of neuroendocrine-immunomodulation. In this respect one could 
consider systemic treatment with low dose corticosteroids early in disease, to balance the insuf­
ficient cortisol response and to prevent progression to a chronic phase. Treatment with 
dopamine-agonists could inhibit excessive prolactin secretion and thereby antagonize its pro- 
inflammatory effects and reduce disease activity.
Immuno-neutralisation of CRH at peripheral inflammatory sites in rats significantly inhibits 
inflammation similar to the anti-inflammatory effects of TN Fa antibodies [24]. Thus CRH 
antagonists may have therapeutic promise in controlling local inflammation in diseases such as 
RA where the pathophysiology involves hypersecretion. The recent in vivo evaluation of a CRH 
receptor type 1 antagonist, antalarmin, has yielded exciting results in rats and suggests antalarmin 
may provide a clinically effective CRH antagonist. Chronic administration of antalarmin has no 
effect on metabolic regulation, minimal effects on pituitary-adrenal function yet can significantly 
inhibit carageen-induced inflammation in the rat [68].
However at this point in time the role of a defective HPA-axis in the pathogenesis of RA is a pos­
sibility but not yet certain, and the results concerning the role of PRL are contradictary. Most 
studies involving the role of the HPA-axis in RA concern small numbers of patients, while hor­
monal variations can be large, and in many studies patients used medication such as NSAIDs or 
DMARDs. In addition corticosteroids have sometimes not been stopped for long enough. Further 
studies on the role of the HPA-axis in RA and the possible influence by medication are neccesary. 
In order to evaluate the beneficial effects of drugs restoring possible horm onal dysfunction, con­
trolled randomized clinical trials w ith long term follow up are required. In conclusion neuroen- 
docrine-immunomodulation is an exciting and promising concept, but still in an experimental 
status, and recommendations about clinical management at this time cannot be made.
w S u m m ary
The HPA-axis plays an important regulatory and modulatory role in normal immune function, 
permitting adequate responses to invading organisms and other inflammatory stimuli, but pro­
tecting the organism against damage caused by an overshoot of immune reactions. In animal 
models dysfunction of the HPA-axis is associated with the development of auto-immune dis­
ease. In humans normal or low cortisol levels have been found in patients with RA under nor-
w M a n a g e m e n t
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mal circumstances or in response to stress, whereas higher levels would be expected during 
active inflammation. This indicates an insufficient HPA response in patients with RA.
Extra-hypothalamic or peripheral CRH acts as an autocrine/paracrine pro-inflammatory media­
tor and has been shown, in animal studies, to play an im portant role in local inflammatory 
responses. In humans elevated levels of CRH mRNA and protein were found in synovium and 
synovial fluid of patients with RA, suggesting a role of CRH as a pro-inflammatory mediator in 
this disease.
Findings concerning prolactin (PRL), a pituitary hormone with pro-inflammatory properties, are 
contradictory. Abnormally high PRL levels, norm al and even abnormally low levels have been 
found in patients with RA and treatm ent with bromocriptine has yielded contrasting results. 
Possible influences of medication on the results of studies in patients with RA need to be consid­
ered and further studies will be neccesary to establish whether HPA-axis dysfunction or other 
hormonal abnormalities play a role in the pathogenesis of RA and whether therapeutic approaches 
to manipulate these abnormalities can ameliorate disease outcome in RA.
R e s e a r c h  A g e n d a
Examine responses of the HPA-axis in large groups of RA patients in comparison with 
healthy subjects and patients with other chronic inflammatory disease.
Perform further research on the role of peripheral CRH in humans with RA
Study prolactin levels in large groups of RA patients
Perform clinical trials with agents that can influence hormonal status thereby modulating 
the imm une response, aimed at reducing disease activity in patients with RA
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F igure legend
Figure 1. Central and proposed peripheral roles o f corticotropin releasing hormone (CRH) in the neuro-immune 
regulation o f inflammation. As a key regulator o f the hypothalamic-pituitary-adrenal (HPA) axis CRH modu­
lates the inflammatory response through glucocorticoids (GS) [2]. CRH also functions as a pro-inflammatory 
mediator a t peripheral sites o f inflammation [24]. Pro-inflammatory cytokines regulate both central and periph­
eral CRH expression and activate the HPA-axis at the level o f  the hypothalamus, pituitary and adrenal gland 
[3,4,7,8]. The mast cell is a major target for peripheral CRH action [50] a t inflammatory sites. The nuclear tran­
scription factors NURR1 and NUR77 are regulated centrally and peripherally by CRH and inflammatory 
cytokines [51-53]. The NURR subfamily plays an important neuroendocrine-regulatory role a t all levels o f  the 
HPA-axis including negative feedback inhibition by GS. Expression o f CRH, POMC and steroid-21-hydroxylase 
(21-OH) are under the transcriptional control o f  the NURR subfamily and GS [51].
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w A b s t r a c t
Objective
To study the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatoid arthritis (RA). 
Methods
Fifty patients with RA participated in 3 groups: recent onset active RA (n=20), longstanding 
active RA (n=20) and longstanding RA in remission (n=10), and were compared with 20 healthy 
controls. The activity of the HPA-axis was assessed under basal conditions and in response to 
stress (insulin tolerance test, ITT). In addition, patients with recent onset RA underwent a corti­
cotropin releasing hormone (CRH) test and a dexamethasone suppression test. Plasma levels of 
interleukin (IL)-ip, tum or necrosis factor-a (TNFa) and IL-6 were also measured.
Resul ts
Basal plasma, salivary and urinary cortisol levels and plasma adrenocorticotropic hormone 
(ACTH) levels were not different between patients with RA and healthy controls. During the ITT, 
cortisol levels were consistently lower in RA patients than in healthy controls. ACTH levels during 
the ITT were not different between patients with RA and healthy controls. ACTH and cortisol 
responses to CRH were assessed only in patients with recent onset RA and were found to be with­
in norm al limits. Basal circulating plasma IL-6 levels were significantly higher in patients with 
active RA than in the other groups.
Conclusion
Under the standardized conditions of the ITT, patients with RA have decreased plasma cortisol 
levels compared to healthy controls, despite elevated levels of IL-6. The defect is probably located 
at the adrenal level and may be of pathogenetic significance for the development of chronic 
arthritis.
w Introduct ion
During inflammatory processes the release of proinflammatory cytokines like interleukin (IL)- 
ip , tum or necrosis factor-a (TNFa) and IL-6 stimulates the hypothalamic-pituitary-adrenal axis 
(HPA-axis) to produce larger am ounts o f glucocorticoids. The increased adrenal 
glucocorticoid production suppresses inflammatory responses. Defects in glucocorticoid produc­
tion might cause an acute arthritis to develop into chronic arthritis and such defects have been
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suggested to contribute to the pathogenesis of rheumatoid arthritis (RA). The possible existence 
of a defective HPA-axis in RA has been studied extensively. Three recent reviews agree that previous, 
mostly small, studies have failed to show significantly decreased basal cortisol levels in patients 
with untreated RA, but that there may be an inability to m ount adequate cortisol responses in 
relation to the level of inflammation [1,2,3].
To further explore the possible role of abnormal HPA-axis responses in the pathogenesis of RA, 
we studied HPA-axis activity in a group of 50 patients with RA. Antirheumatic drug therapy was 
discontinued prior to the study in all patients. Results were compared with those obtained in 
healthy controls. The activity of the HPA-axis was assessed by measuring plasma ACTH and cor­
tisol levels under basal conditions and during the insulin tolerance test (ITT), a standardized form 
of hypoglycaemia associated stress. In addition, we performed a corticotropin-releasing hormone 
(CRH) test and a dexamethasone suppression test in patients with recent-onset RA. In order to 
assess whether abnormal reactions of the HPA-axis might be related to abnormal cytokine levels, 
we also measured the plasma concentrations of the cytokines IL-ip, IL-6 and TNFa.
w P a t ien ts  and M e th o d s  
Patients
Four different groups of subjects were included: healthy controls (n = 20), patients with recent onset 
(<1 year) active RA (n = 20), patients with longstanding (>5 years) active RA (n = 20) and patients 
with longstanding (>5 years) RA in remission (n = 10).
All patients with RA fulfilled the revised criteria for RA of the American College of Rheumatology 
[4] and were IgM rheumatoid factor positive. Disease activity was defined according to well accepted 
criteria [5]. RA patients with active disease had a Disease Activity Score (DAS) > 3.5, and patients 
with RA in remission a DAS < 1.5. None of the patients had ever been treated with oral or intra­
venous glucocorticoids, and none of them had been treated with intramuscular or intra-articular 
corticosteroids in the year previous to the study. The patients with recent onset RA had not been 
treated with a disease modifying antirheumatic drug (DMARD), and treatment with nonsteroidal 
antiinflammatory drugs (NSAID) was stopped in all patients one week prior to the study. In patients 
with longstanding RA the use of a DMARD was discontinued two weeks before the study.
The healthy controls were age and sex matched to the patients with active, recent-onset RA.
All participants were aged between 18 and 65 years and were excluded if they had any condition 
or medication that is known to influence the activity of the HPA-axis. This also excluded patients 
using oral contraceptives [7]. Other exclusion criteria employed were anemia (Hb < 6.5 mmol/l),
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renal or hepatic disorders, and contra-indications for undergoing the stress of an ITT, such as 
cardiovascular disorders, hypertension and epilepsy.
All participants voluntarily signed an informed consent form. The study protocol was approved 
by the hospital's review board for experiments on human subjects.
Methods
Disease act ivi ty
In patients with RA disease activity was assessed with a composite disease activity score, which 
includes the erythrocyte sedimentation rate (ESR), the Ritchie articular index, the num ber of 
swollen joints and a visual analogue scale for general well-being [5].
HPA-axis act ivi ty 
Basal values
Blood was drawn at 0900 h (fasting) and at 1600 h for determination of plasma total cortisol, free 
cortisol, cortisol binding globulin (CBG; only in healthy controls and patients with recent onset 
RA) and ACTH concentrations. Urine was collected for determination of total cortisol excretion 
in 24 hours, and on the same day salivary samples were taken every 4 hours for a period of 24 
hours starting at 0800 h, for determination of the circadian cortisol rhythm. Salivary samples 
were collected by means of an absorbent swab, taken in the m outh for 5 minutes. It was then 
placed in a tube and kept in the refrigerator, and the next day all samples of 24 hours were brought 
to the laboratory, where they were centrifuged and the saliva samples frozen, until they were 
analysed.
Cor t i co t rop in  re leas ing hormone  (CRH) te s t
CRH tests were performed only in patients with recent-onset RA, with the subjects fasting and in 
a supine position. At 0830 h a catheter was inserted in an antecubital vein and kept patent by 
saline solution. After a 30 minute rest 100 |ig human CRH (CRH®, 100 |ig/m l corticorelinetri- 
fluoracetaat, Ferring BV, Hoofddorp, the Netherlands) was administered at 0900 h as a bolus 
injection. Blood samples for ACTH and cortisol assays were collected at 0, 20, 30, 60, 120 and 180 
minutes. The results were compared to the reference values used in our laboratory.
Dexamethasone suppress ion te s t
The dexamethasone suppression test was done only in patients with recent-onset RA. Two tablets 
of 0.5 mg dexamethasone (Centrafarm services BV, Etten-Leur, the Netherlands) were taken orally
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at 2300 h, and the next morning, after an overnight fast, blood was drawn at 0900 h for determi­
nation of ACTH and cortisol.
Insul ine to le rance te s t  (ITT)
An ITT was performed in all subjects. All subjects were fasting and in a supine position. At 0830 
h a catheter was inserted in an antecubital vein and kept patent by saline solution. After a 30 
minutes rest insulin (Actrapid®, Novo-Nordisk, Bagsvaerd, Denmark) was administered at 0900 
h as a bolus injection at a dose of 0.1 units/kg body weight. Blood samples were collected at 0, 20, 
30, 45, 60, 90, 120 and 180 minutes.
Cytokines
The plasma levels of IL-1P, IL-6 and TN Fa were measured in all participants at 0900 h (fasting) 
and at 1600 h.
Labora to ry  methods 
Blood col lec t ion and handl ing
Blood for measurement of ACTH and cortisol was collected in pre-chilled K3-EDTA tubes 
(Vacutainer Systems, Becton and Dickinson, Rutherford, HJ, USA) and centrifuged for 10 m in­
utes at 1500 g (4 °C). The plasma obtained was aliquoted in polystyrene tubes, and to the tubes 
for the ACTH assay 25 |il Trasylol® (aprotinin, 10,000 KIU/ml; Bayer, Leverkusen, Germany) was 
added. Blood for measurement of circulating cytokines was drawn in 4 ml EDTA-K3 tubes 
containing 250 |il Trasylol®. The tubes were centrifugated immediately at 2,000 g for 10 minutes. 
Aliquots of plasma were stored at -20 °C until assay. The ex-vivo production of cytokines was 
measured in whole blood using two 4 ml EDTA-K3 tubes containing 250 |il Trasylol®. After 24 h 
incubation at 37 °C the tubes were centrifuged and the plasma stored at -20 °C.
Labora to ry  assays
A C T H : ACTH in plasma was measured by an im m unoradiometric assay (IRMA) based on two 
polyclonal antibodies (EuroDiagnostics, Arnhem, The Netherlands). The catching antibody is 
directed against the C-terminal part of the ACTH molecule and coupled via a sheep anti-rabbit 
antibody to a polystyrene tube. The detecting antibody is directed against the N-terminal part of 
ACTH and radioiodinated. Standard curves were prepared by spiking ACTH-free plasma with 
ACTH-(1-39) (MRC 74/555). The assay was performed as follows. Two hundred microliters of 
sample or standard (0-220 pmol/l) were added to the coated tubes and subsequently iodinated 
ACTH antiserum (250,000 dpm/200|il) was added. The mixture was incubated for 24 hours at
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room temperature. The supernatant was decanted and the tubes washed two times with 0.9% NaCl. 
Radioactivity in the tubes was counted using an automatic gamma-counter (1470 Wizard TM Wallac, 
Turku, Finland). The sensitivity of the assay was 0.5 pmol/l and the within- and between-assay coef­
ficients of variation were 4.4% and 7.2% respectively. All samples were measured in duplo. The 
IRMA specifically detects ACTH-(1-39). Crossreactivity w ith ACTH-(1-24), CLIP and 
P-endorphin was < 0.1%. Normal range at 8:00 a.m.: 1.3-9.2 pmol/l.
P lasm a Cortisol: Plasma cortisol levels were measured by RIA using an antiserum raised in rabbit 
against a cortisol-21-hemisuccinate-bovine serum albumin conjugate. Standard and samples (50 |il) 
were diluted 1:100 with ethanol/water (5/95, v/v) and corticosteroid binding globulin was dena­
tured by incubation at 70 °C for 1 hour. Subsequently, tracer ([1,2,6,7-3H]cortisol) and antibody 
were added, and bound and free hormone were separated by dextran-coated charcoal after incu­
bation for 18 hours at 4 °C. After centrifugation the supernatants were decanted and radioactivity 
measured. The sensitivity of the assay was 0.02 |imol/l. The within- and between-assay coeffi­
cients of variation were 4.5% and 6.6% at 0.21 |imol/l. Normal range at 0800 h 0.19 - 0.55 |imol/l 
and at 1600 h 0.06 - 0.38 |imol/l.
P lasm a CBG: CBG was measured by means of a radioimmunoassay kit manufactured by RADIM 
(Angleur-Liege, Belgium). Within- and between-assay precision were 3.7% and 7.0% at a level of 
0.50 |im ol/l .
Plasm a free cortisol: The plasma free cortisol fraction was measured by indirect equilibrium dialysis 
by a method described earlier for androstenedione [7]. Briefly, 3H-cortisol that has been 
previously purified by paperchromatography is added to the plasma sample. An aliquot of 180 |il 
of this mixture is dialysed against an equal volume of phosphate-buffered saline (PBS) for 4 hours 
in specially designed equipment (Diachema AG, Muenchen, Germany). After dialysis, 50 |il 
aliquots were taken from the dialysates and counted for radioactivity. The original concentration 
of radioactivity was assessed by counting the same volume of the plasma and tracer. The fraction 
or percent free cortisol was calculated while taking into account the dilution inherent in equilib­
rium  dialysis. Multiplication of the free fraction by the total concentration yields the free cortisol 
concentration. The within-assay coefficient of variation (cv) was 8.5% and the between-assay cv 
of duplicate means was 5.5% at an average free cortisol fraction of 5.0%.
Salivary a n d  urine  cortisol: Salivary cortisol as well as 24-hour urinary free cortisol (i.e. extractable 
by organic solvents) were measured by radioimmunoassay after previous extraction and paper 
chromatography [7]
R IA  fo r  cytokines: Interleukin-1P, IL-6 and TN Fa were measured in duplicate by RIA after incu­
bation for 24 hrs as described previously by Drenth et al. [8].
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Stat is t ica l  analysis
The first analysis considered all groups separately. All 3 patient groups were compared with the 
healthy controls. Subsequently, the 2 groups of patients with longstanding RA were also 
compared with the group of patients with recent onset RA and w ith each other. In the absence of 
differences between the 3 RA groups (p>0.20 for all comparisons), all 50 patients with RA were 
finally considered as one group and compared with the healthy controls.
Responses of ACTH and cortisol to hypoglycemia were integrated over time as area under the 
response curve (AUC) from 0 to 180 minutes. The AUCs were calculated with the trapezoid 
method from the individual hormone levels at the various time points and expressed as square 
millimeters (mm2). In these calculations 1 minute equals 1 mm (both curves), 1 pmol/l equals 1 
m m  (ACTH) and 1 |im ol/l equals 1 mm (cortisol). The maximal rise in ACTH and cortisol after 
insulin administration was calculated as the maximal difference in hormone levels compared to 
the value at 0 minutes. An AUC was also calculated with the trapezoid method from the cortisol 
levels in salivary samples over 24 hours. Again the AUC was expressed as square millimeters 
(mm2): 1 hour equals 1 mm and 1 nmol/l equals 1 mm.
Comparisons between groups were made with the unpaired t-test or with the Mann-W hitney test 
if data were not normally distributed. P-values are based on 2 tailed tests and considered significant 
at the 0.05 level. Due to the exploratory nature of the study, no adjustments to probability values 
were made for multiple comparisons.
w Results
The characteristics of the patients in each of the 4 groups are shown in table 1. The 20 patients with 
recent onset RA and the 20 healthy controls were matched for age and sex, and included 3 men and 
17 women. The groups of patients with RA in remission included more men than women. There 
were no significant differences in age between the groups. The high DAS in patients with recent 
onset RA and longstanding active RA reflects active disease, in contrast to the low DAS in long­
standing RA in remission. This was also shown by the ESR, which was significantly higher in 
patients with recent onset active RA and longstanding active RA than in the other groups.
Basal values
Basal plasma levels of ACTH and cortisol in the 4 groups are shown in table 2. No significant 
differences were present between the healthy controls on the one hand and any of the RA groups on 
the other. The 3 RA groups also did not differ from each other (p>0.20 for all comparisons). When 
all RA patients were analysed in one group, again no significant differences in plasma ACTH, total
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and free cortisol levels were found between the combined RA group and the healthy controls.
CBG was measured in healthy controls and patients with recent onset RA. No significant differ­
ences were present between the 2 groups. At 9:00 a.m. the mean (SD) CBG was 0.83 (0.10) |imol/l 
and 0.83 (0.11) |imol/l respectively (p>0.20). At 4:00 p.m. these values were 0.83 (0.15) and 0.84 
(0.17) |imol/l respectively (p>0.20).
The urinary cortisol excretion in the 3 patient groups and in the combined RA group, did not 
significantly differ from the healthy controls (table 2).
Salivary cortisol levels (figure 1) showed a norm al circadian cortisol rhythm in all groups with a 
somewhat higher peak at 0800 h in patients with recent onset RA than in healthy controls, but 
this difference was not statistically different: 10.9 (7.4) versus 8.9 (4.0) nmol/l (p>0.20). The 
analysis of the AUC’s for salivary cortisol also showed no significant differences between the 
healthy controls and the other groups (p>0.15; data not shown).
The mean (SD) plasma levels of IL-6 in healthy controls were 8 (2) pg/ml at 0900 h and 8 (3) 
pg/ml at 1600 h. In patients with recent active RA these values were 28 (8) pg/ml (p=0.004 versus 
healthy controls) and 17 (16) pg/ml (p=0.04) respectively. In patients with active longstanding RA 
these values were 37 (35) pg/ml (p=0.002 versus healthy controls) and 15 (13) pg/ml (p=0.05) 
respectively. In patients w ith RA in remission, the values were not significantly different from 
those in healthy controls. Basal values of TN Fa and IL-1P were similar in RA patients and healthy 
controls and no significant differences were present between the groups (data not shown).
CRH-tests and dexamethasone suppression tests
After stimulation with CRH all 20 patients with recent onset active RA showed an increase of 
ACTH levels followed by an increase in cortisol levels in the norm al range of our laboratory (data 
not shown). After suppression with dexamethasone all patients had adequately low levels of cortisol 
(< 0.06 |imol/l).
Insulin tolerance tests
In response to insulin injection, plasma glucose levels decreased in all groups with a nadir at 30 
minutes. The test was considered adequate if a glucose level < 2.0 mmol/l was reached. If not, the 
test was repeated with a 50% higher dose of insulin. This occurred in two patients, but both of 
them reached a glucose level < 2.0 mmol/l when the test was repeated. There were no significant 
differences between the groups in the hypoglycemia nadir that was reached during the ITT. 
During the ITT no significant differences were found in plasma ACTH levels between the group 
of healthy controls and any of the 3 patient groups, and the AUC’s for ACTH during the ITT were 
not different between the groups (p>0.20, data not shown). The 3 groups with RA patients also 
did not significantly differ from each other (p>0.20 for all comparisons). Figure 2a shows the
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ACTH curves for the healthy controls and the combined RA group. No significant differences 
were found between the 2 groups at any point in time.
In the 3 RA groups, plasma cortisol levels during the ITT were not different from each other 
(p>0.20 for all comparisons) and consistently lower than in healthy controls. Figure 2b shows the 
cortisol curves for the combined RA group and the healthy controls only. Plasma cortisol levels 
were significantly lower in the RA patients at all points in time (p-values varying between 0.002 
and 0.05). Figure 3 shows the AUC for cortisol during the ITT for all groups. The patients with 
active, recent onset RA showed a trend towards a lower AUC (p=0.07 versus healthy controls). For 
both groups with longstanding RA the difference with the healthy controls was statistically 
significant (p=0.01 for both comparisons). When all patients with RA were considered as one 
group, the AUC for cortisol was also significantly lower than in the healthy controls: 103 (18) 
m m 2 versus 89 (17) m m 2 (p=0.005).
The maximal rise of cortisol during the test was not different between healthy controls, recent onset 
RA, longstanding active RA and longstanding RA in remission. The mean (SD) values were 0.31 
(0.14), 0.31 (0.15), 0.29 (0.15) and 0.30 (0.18) mmol/l respectively (p>0.20 for all comparisons).
w Discussion
For some time it has been hypothesized that patients with RA may have a defective activity of 
the HPA-axis. Three recent reviews discuss this topic extensively. Abnormalities, if  any, could 
reside in the hypothalamus, the pituitary or the adrenal gland [1,2,3]. We have studied a large 
group of RA patients and tested the activity of the HPA-axis by several methods. Basal ACTH 
and cortisol levels were measured and the response of the HPA-axis to insulin induced hypogly- 
caemia, a standardized form of stress, was also assessed.
The results of our study are compatible with the hypothesis of alterations in adrenal activity in 
RA. During the ITT, lower plasma cortisol levels were consistently found in all 3 groups of RA 
patients when compared to healthy controls, both before and after hypoglycaemia. In the group 
of recent-onset RA a trend towards a lower AUC for cortisol was observed (p=0.07). In both 
groups of patients with longstanding RA the difference in AUC for cortisol was statistically 
significant (p=0.01). Between the 3 RA groups no differences were found and when the combined 
group of all RA patients (n=50) was compared with the healthy controls, the AUC for cortisol was 
also significantly lower than in healthy controls (p=0.005). The longstanding RA groups had a 
male overrepresentation and one might argue that this influenced our results. We therefore 
performed an additional analysis that was limited to the female participants. Again, the AUC for 
cortisol was significantly lower (p=0.01) in female RA patients (n= 28) than in female healthy
H
ypothalam
ic-pituitary-adrenal axis 
activity 
in 
patients 
with 
rheum
atoid 
a
rth
ritis
C
ha
pt
er
 
4 58
controls (n=17). The differences in total plasma cortisol levels between RA patients and healthy 
controls are not due to differences in CBG levels because the mean CBG levels were identical 
between RA patients and controls.
The initial cortisol levels before hypoglycaemia may reflect basal horm onal activity better than the 
other basal assessments. During the ITT the first blood samplings were done 30 minutes after 
insertion of an intravenous catheter during which period all subjects were at rest in a supine posi­
tion. In contrast, the other blood samplings were done under conditions that were not standardized 
and which probably varied between patients. This may explain why no significant differences 
were found in basal cortisol levels outside the context of the ITT.
The maximal rise in cortisol after insulin administration was not different between the groups and 
the cortisol response curves of RA patients were similar in shape compared with the healthy controls. 
Therefore, patients with RA reacted to hypoglycaemia with a normal increase in cortisol levels. 
However, due to lower basal levels they attained lower peak levels.
Patients with RA showed norm al ACTH responses to hypoglycaemia. The hypothesis in the liter­
ature of a defective hypothalamic function in RA is supported by 1 study. In that study, a defective 
cortisol response to major surgery in combination with norm al ACTH and cortisol responses in 
the CRH test, was found in 10 RA patients [9]. In a similar study, these results were not repro­
duced [10]. Dekkers et al. used daily life stressors to study the activity of the HPA-axis in 29 
patients with RA and found a trend towards a smaller ACTH response than in healthy controls
[11]. Most patients in their study however, used NSAIDs which have been associated with lower 
ACTH levels [12]. The ITT has sofar not been used to compare ACTH responses between patients 
w ith RA and healthy controls. CRH tests have been done more widely. In most studies, ACTH 
responses to CRH have been norm al suggesting no pituitary defects [9,13-17]. In one study by 
Cutolo et al. the peak ACTH value but not the AUC for the ACTH response curve after CRH was 
lower in RA patients than in controls [18]. In another study, Hall et al. did find significantly 
elevated unstimulated ACTH levels in non-treated RA patients [12]. In our study both basal 
ACTH levels and ACTH levels during the ITT were not significantly different compared to 
healthy controls. We conclude that the deceased adrenal activity in RA is probably not due to 
decreased pituitary ACTH secretion.
Three other studies have found subtle changes in stimulated cortisol levels. First, Gudbjornsson et 
al. showed that patients with untreated RA (n=18) had a decreased cortisol response especially in 
the later phases after CRH administration [13]. Other authors have found no significant 
differences in cortisol responses after CRH in RA patients when compared to healthy controls [9,14­
18]. In our study, the CRH test was performed only in the patients with recent-onset RA. Although 
the plasma ACTH and cortisol levels were within the normal range of our laboratory, this does not
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exclude the possibility of alterations in HPA-axis activity. Second, Gutiérrez et al. studied 10 patients 
with active RA with an ITT. Although the integrated cortisol response to hypoglycaemia was not dif­
ferent from the control group, the early rise in cortisol was significantly lower in the RA patients 
than in the normal controls [19]. Finally, Dekkers et al. found a significantly decreased cortisol 
response after daily life stressors in RA patients treated with NSAIDs [11].
The changes in the adrenal responsivity that we observed are subtle and not associated with 
decreased basal cortisol levels assessed under less standardized conditions, neither in our nor in 
previous studies [1,2,3]. Nevertheless, it may be argued that normal cortisol levels are inappro­
priately low for the degree of inflammation in active RA. Proinflammatory cytokines can stimu­
late the HPA-axis. In our study we observed high levels of IL-6 in patients with active RA and nor­
mal levels in patients with longstanding RA in remission. Decreased plasma cortisol levels were 
found during the ITT both in RA in remission and in active RA. Apparently, elevated plasma IL-6 
levels failed to stimulate the HPA-axis in patients with active RA. This may have contributed to 
the development of chronic arthritis since glucocorticoids inhibit inflammatory responses [3]. In 
other chronic inflammatory diseases, such as Crohn’s disease, decreased activity of the HPA-axis 
has also been suggested to exist [3].
In a small study, treatm ent with an NSAID has been suggested to influence the HPA-axis 
response, especially at the hypothalamic or pituitary level [12]. In our study all patients with RA 
had discontinued their antirheumatic drugs. NSAIDs were stopped one week and DMARDs two 
weeks before the tests. Our results therefore apply to untreated patients with RA.
We conclude that HPA-axis responsiveness is reduced in untreated patients with RA when com­
pared to healthy controls and that the defect is most likely located at the adrenal level. This 
phenom enon may contribute to the pathogenesis of the disease. Further research is needed to elu­
cidate the underlying mechanisms and the influence of antirheumatic drug therapy on HPA-axis 
responsivity.
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Characteristics of the study subjects
Healthy controls Rheumatoid a rth ritis
active disease remission
recent onset longstanding longstanding
N 20 20 20 10
Age (yr) 47.5 [9.8] 49 .0  [12.0] 52.1 [7.4] 53.0 [7.4]
Male:female 3:17 3:17 10:10 9:1
Disease duration (yr) - 0.4 [0.3] 9.8 [6.8] 12.5 [9.1]
DAS (units) - 4 .26 [0.67] 4.38 [0.76] 1.36 [0.54]
ESR (mm/hr) 4.2 [3.2] 21.6 [24.7] 19.8 [17.9] 10.5 [8.4]
Values are mean [SD]
DAS = disease activity score
ESR = erythrocyte sedimentation rate.
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Basal plasma levels of adrenocorticotropic hormone (ACTH), total 
cortisol, free cortisol and total urinary cortisol excretion.
Healthy controls Rheumatoid a rth ritis
active disease remission
recent onset longstanding longstanding
N 20 20 20 10
09 0 0  h
ACTH (pmol/l) 3.7 [2.2] 5.5 [3.5] 4 .2 [2.3] 4.8 [3.1]
to ta l cortisol (mmol/l) 0.44 [0.11] 0.45 [0.12] 0.43 [0.08] 0.41 [0.12]
free cortisol (nmol/l) 20.1 [4.7] 20.5 [4.6] 21.6 [4.0] 22.7 [6.2]
16 00  h
ACTH (pmol/l) 3.3 [1.6] 4 .3 [2.4] 4 .0 [2.6] 3.9 [2.0]
to ta l cortisol (mmol/l) 0.27 [0.10] 0.26 [0.09] 0.26 [0.09] 0.25 [0.10]
free cortisol (nmol/l) 12.3 [4.3] 12.3 [4.4] 13.0 [5.2] 13.8 [5.9]
urinary cortisol
(nmol/24 hr) 69.6 [26.5] 67.5 [36.0] 71.8 [37.7] 70.2 [18.2]
Values are mean [SD]. No significant differences were found between the healthy controls and any o f the 
other groups.
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Figuur 1
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Figure 1
Circadian levels ofcortisol in salivary samples during 24 hours. No significant differences were found between the 
different groups compared to healthy volunteers at any time point.
Figuur 2A
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Figure 2
Plasma levels (mean and SEM) o f ACTH (A ) and cortisol (B) during insulin tolerance tests ofhealthy controls 
(n=20) and all RA patients (n=50). Insulin bolus injections were administered a t 0900 h. Plasma levels o f cortisol 
showed a significant difference between the two groups at all time points (p<0.05)
Figuur 3
Figure 3
Area under the curve (mean and SD) for plasma cortisol during insulin tolerance tests for 4 study groups: 1 = healthy 
controls (n=20), 2 = recent onset RA (n=20), 3 = longstanding active RA (n=20), 4 = longstanding RA in remission 
(n=10). P-values refer to the comparison with the healthy controls.
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Objective
To study the effects of antirheumatic drugs on hypothalamic-pituitary-adrenal (HPA) axis activity 
in patients with rheumatoid arthritis (RA).
Methods
Twenty patients with recent-onset active RA were studied before antirheumatic treatment, after 2 
weeks of naproxen, and after 6 months of additional treatment with sulphasalazine or methotrex­
ate. The results before treatment were compared with those obtained in twenty age and sex matched 
healthy controls (HC). Activity of the HPA-axis was assessed under basal conditions and during 
insulin tolerance tests (ITT). The ex vivo production of interleukin (IL)-ip, tum or necrosis factor-a 
(TNFa) and IL-6 in whole blood samples was measured with and without stimulation by LPS.
Resul ts
At baseline, plasma ACTH and cortisol levels were not different between patients with RA and HC. 
The unstimulated ex-vivo production of IL-6 was significantly higher in RA patients than in HC. 
After 2 weeks of treatment with naproxen, urinary cortisol excretion decreased significantly (p=0.03), 
and the area under the curve for plasma cortisol during the ITT was significantly lower (p=0.015). 
After 6 months, basal plasma, salivary and urinary cortisol levels, and plasma cortisol and ACTH 
levels during the ITT, were all unchanged in comparison to the pre-treatm ent period. The 
unstimulated ex-vivo production of IL-ip was significantly lower than before treatment.
Conclusion
Our results suggest that non-steroidal anti-inflammatory drugs suppress the HPA-axis in the first 
weeks of treatment. After 6 months this suppressive effect is no longer present, suggesting the 
existence of adaptive mechanisms.
w Introduct ion
One of the factors that may contribute to the chronicity of joint inflammation in patients with 
rheumatoid arthritis (RA) is a deficient activity of the hypothalamic-pituitary-adrenal (HPA) axis 
[1]. Non-steroidal anti-inflammatory drugs (NSAID) have been shown to influence the interac­
tions between the imm une system and the HPA-axis in many animal studies [2,3]. However, the 
effects of NSAIDs on the activity of the HPA-axis have not been studied extensively in patients 
w ith RA. In one small study, the use of NSAIDs was shown to be associated with decreased
w S u m m ary
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adrenocorticotropic hormone (ACTH) levels [4]. There is evidence that pro-inflammatory 
cytokines stimulate the HPA-axis at either the hypothalamic, pituitary or adrenal level in patients 
with RA [1]. Prostaglandins may be involved in these stimulatory effects as in rats it was shown, 
that the responses of ACTH to IL-ip and IL-6 are blunted by pretreatment with indomethacin 
[5-7], ketoprofen [8] and a selective cyclooxygenase-2 inhibitor [8]. Pro-inflammatory cytokines 
like IL-1 and IL-6 can also stimulate the adrenal cortex to produce cortisol independently from 
ACTH [9]. Prostaglandins are involved in the transmission of these effects, which can be inhibited 
by blocking the cyclooxygenase pathway with NSAIDs [9].
The aim of our study was to examine the effects of antirheumatic treatment on HPA-axis activity 
in patients with RA. The activity of the HPA-axis was assessed both under basal conditions and 
after stimulation by insulin-induced hypoglycemia during the insulin tolerance test (ITT), a 
standardized form of stress. Because of the possible role of pro-inflammatory cytokines in 
stimulating the HPA-axis in RA, the ex-vivo production of interleukin (IL)-1P, tum or necrosis 
factor-a (TNFa) and IL-6 was also assessed.
w Subjects and Methods  
Subjects
Twenty patients with active, recent-onset (< 1 year) RA were included in the study. All patients 
fulfilled the revised criteria for RA of the American College of Rheumatology [10] and were IgM 
rheumatoid factor positive. Active disease was defined as a disease activity score (DAS) > 3.5 [11]. 
None of the patients had ever been treated with oral, intramuscular or intra-articular gluco­
corticoids. Patients had not been treated with a disease modifying antirheumatic drug (DMARD). 
Treatment with NSAIDs was discontinued in all patients one week prior to the study. Twenty age 
and sex matched healthy controls were also studied.
All patients with RA were studied at baseline, after 2 weeks and after 6 months. At baseline all 
patients were without treatment, as described above. Thereafter, all patients were started on 
naproxen 500 mg twice a day and studied again after 2 weeks. A DMARD was then added to the 
therapeutic regimen by the rheumatologist in charge of the patient, if indicated. The initial 
DMARD was sulphasalazine which could be switched to methotrexate if necessary. After 6 
months of therapy patients were assessed again.
All subjects were aged between 18 and 65 years and were excluded if they had any condition or 
medication that is known to influence the activity of the HPA-axis [12]. This also excluded 
patients using oral contraceptives. Other exclusion criteria employed were anemia (Hb < 6.5 
mmol/l), renal or hepatic disorders, and contra-indications for undergoing the stress of an insulin
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tolerance test (ITT), such as cardiovascular disorders, hypertension and epilepsy.
All subjects voluntarily signed an informed consent form. The study protocol was approved by 
the hospital's ethical committee.
Methods
Disease activ ity
In patients with RA, disease activity was assessed at baseline, after 2 weeks and after 6 months with 
a composite disease activity score, which includes the erythrocyte sedimentation rate (ESR), the 
Ritchie articular index, the num ber of swollen joints and a visual analogue scale for general well­
being [11].
HPA-axis activ ity
The activity of the HPA-axis was assessed under basal conditions and during an insulin tolerance 
test (ITT) in all subjects at baseline and after 2 weeks and 6 months in patients with RA.
For the assessments under basal conditions, blood was drawn at 9:00 AM while patients were 
fasting, and at 4:00 PM for determination of plasma total cortisol, free cortisol, cortisol binding 
globulin (CBG) and ACTH concentrations. Urine was collected for determination of cortisol 
excretion in 24 hours. On the same day salivary samples were collected every 4 hours for a period 
of 24 hours starting at 8:00 AM, for determination of the circadian cortisol rhythm. Salivary samples 
were collected by means of an absorbent swab, taken in the m outh for 5 minutes. It was then 
placed in a tube and kept in the refrigerator, and the next day all samples were brought to the lab­
oratory, where they were centrifuged and frozen, until analysis.
ITTs were performed on separate days with the subjects fasting and in a supine position. At 8:30 
AM a catheter was inserted in an antecubital vein and kept patent by saline solution. After a 30 
minute rest, insulin (Actrapid® 100 IU/ml, Novo-Nordisk, Bagsvaerd, Denmark) was adminis­
tered as a bolus injection at a dose of 0.1 units/kg body weight. Blood samples were collected at 
0, 20, 30, 45, 60, 90, 120 and 180 minutes for determination of glucose, cortisol and ACTH con­
centrations. The test was considered adequate if a glucose level < 2.0 mmol/l was reached. If not, 
the test was repeated with a 50% higher dose of insulin. This occurred in one patient, but this 
patient reached a glucose level < 2.0 mmol/l when the test was repeated.
Blood for measurement of ACTH and cortisol was collected in pre-chilled K3-EDTA tubes 
(Vacutainer Systems, Becton and Dickinson, Rutherford, HJ, USA) and centrifuged for 10 m in­
utes at 1500 g (4 °C). The plasma obtained was aliquoted in polystyrene tubes, and 25 |il 
Trasylol® (aprotinin, 10,000 KIU/ml; Bayer, Leverkusen, Germany) was added to the tubes for
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the ACTH assay.
ACTH in plasma was measured by an imm unoradiometric assay (IRMA) based on two polyclonal 
antibodies (EuroDiagnostics, Arnhem, The Netherlands). Standard curves were prepared by spiking 
ACTH-free plasma with ACTH1-39 (MRC 74/555). The sensitivity of the assay was 0.5 pmol/l and 
the within- and between-assay coefficients of variation (cv) were 4.4% and 7.2% respectively. 
Normal range at 8:00 AM: 1.3-9.2 pmol/l.
Plasma cortisol levels were measured by a radioimmunoassay which has been described before
[12]. The sensitivity of the assay was 0.02 |imol/l. The within- and between-assay coefficients of 
variation were 4.5% and 6.6% at 0.21 |imol/l. Normal range at 8:00 AM 0.19 -  0.55 |imol/-
l and at 4.00 p.m. 0.06 - 0.38 |imol/l.
Plasma CBG was measured by means of a radioimmunoassay kit manufactured by RADIM 
(Angleur-Liege, Belgium). W ithin- and between-assay precision were 3.7% and 7.0% at a level of 
0.50 |im ol/l .
The plasma free cortisol fraction was measured by indirect equilibrium dialysis by a method 
described earlier for androstenedione [13]. Briefly, 3H-cortisol that had been previously purified 
by paperchromatography is added to the plasma sample. An aliquot of 180 |il of this mixture is 
dialysed against an equal volume of phosphate-buffered saline (PBS) for 4 hours in specially 
designed equipment (Diachema AG, München, Germany). After dialysis, 50 |il aliquots were 
taken from the dialysates and counted for radioactivity. The original concentration of radioactivity 
was assessed by counting the same volume of the plasma and tracer. The fraction or percent free 
cortisol was calculated while taking into account the dilution inherent in equilibrium dialysis. 
Multiplication of the free fraction by the total concentration yields the free cortisol concentration. 
The within-assay cv was 8.5% and the between-assay cv of duplicate means was 5.5% at an aver­
age free cortisol fraction of 5.0%.
Salivary cortisol as well as 24-hour urinary free cortisol (i.e. extractable by organic solvents) were 
measured by radioimmunoassay after previous extraction and paper chromatography [14].
Cytokines
The ex-vivo production of IL-1ß, TN Fa and IL-6 was measured in whole blood samples collected 
at 9:00 AM (fasting) and at 4:00 PM. Blood was collected in two 4 ml EDTA-K3 tubes 
containing 250 |il Trasylol ®. Fifty microliters LPS (final concentration 10 |ig/ml; E. coli serotype 
055:b5; Sigma St. Louis, USA) was added under sterile conditions to one tube; the other tube was 
incubated without LPS. The tubes were incubated for 24 hours at 37 °C and centrifuged there­
after. Aliquots were stored at -20 °C until assay. IL-1ß, IL-6 and TN Fa were measured in duplicate 
by radioimmunoassay as described previously by D renth et al. [15].
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Statistical analysis
Responses of ACTH and cortisol to hypoglycemia were integrated over time as area under the 
response curve (AUC) from 0 to 180 minutes. The calculated AUCs were divided by 180 minutes to 
obtain a mean integrated level of ACTH and cortisol during the ITT. The maximal rise in ACTH and 
cortisol after insulin administration was calculated as the difference in concentration between the 
levels of these hormones at 0 minutes and at the time point with the highest concentration during 
the ITT. An AUC was also calculated for the cortisol measurements in salivary samples over 24 hours. 
The prim ary outcome measure was the integrated mean plasma cortisol level during the ITT. 
Secondary outcomes included basal plasma, salivary and urinary cortisol and plasma ACTH 
levels, plasma levels of ACTH and cortisol at individual time points during the ITT, the maximal 
rise of plasma ACTH and cortisol in response to hypoglycaemia and the mean integrated plasma 
ACTH level during the ITT.
Comparisons between healthy controls and patients with RA were made with the unpaired i-test 
or with the M ann-W hitney test if data were not normally distributed. In patients with RA, 
changes from baseline after 2 weeks and after 6 months were analysed with paired i-test or with 
the Wilcoxon signed rank test if data were not normally distributed. All P-values are based on 2 
tailed tests and considered significant at the 0.05 level.
w Results
The 20 patients with RA and the 20 healthy controls were matched for age and sex, and both 
groups included 3 men and 17 women. The healthy controls and patients with RA had a mean 
(SD) age of 47.5 (9.8) years and 49.0 (12.0) years respectively. All 20 patients with RA were studied 
again after 2 weeks treatment with naproxen. Subsequently, 1 patient was treated with systemic 
corticosteroids and 2 patients received no DMARD therapy. These 3 patients did not participate 
in the assessments after 6 months.
Disease activity
Table 1 shows the baseline disease activity and the changes from baseline after 2 weeks and after 
6 months. After 2 weeks use of naproxen the DAS decreased significantly with a mean value of 0.7 
(p=0.0003). The individual components of the DAS also showed significant decreases with the 
exception of the ESR. After 6 months of additional treatment with either sulphasalazine or 
methotrexate, the DAS showed further improvement of disease activity (1.6 units, p=0.0002 versus 
baseline). The ESR however still showed no significant change when compared to baseline values.
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Table 2 summarizes the hormone levels at baseline and changes therein after 2 weeks and 6 
months. At baseline, patients with RA tended to have higher mean basal ACTH levels (p=0.09 at 
9:00 AM and p=0.10 at 4:00 PM) than healthy controls. Other basal hormone levels were not 
different between healthy controls and patients with RA. After 2 weeks of naproxen use, a significant 
decrease in urinary cortisol excretion (p=0.03) was observed. Other hormone levels were 
unchanged. After 6 months of additional DMARD treatment, urinary cortisol excretion had 
returned to its pre-treatm ent level. ACTH levels showed a significant decrease (p=0.005) when 
compared with baseline at 9:00 AM, but at 4:00 PM ACTH levels were unchanged compared with 
baseline (p>0.2). Figure 1 shows the cortisol levels in salivary samples. At baseline, no significant 
differences were found between healthy controls and RA patients. When salivary cortisol levels 
after 2 weeks and after 6 months were compared with baseline values, no significant changes were 
found in RA patients, neither at individual time points nor in AUC (p>0.2, data not shown).
HPA-axis activity: insulin to lerance tes ts
In response to insulin injection adequate hypoglycemia (glucose level < 2.0 mmol/l) occurred in 
all patients with a nadir at 30 minutes, with no significant difference between the groups.
Figure 2 shows the responses of ACTH to hypoglycaemia in the different groups and periods. 
There were no significant differences between the healthy controls and the patients with RA. 
Within the patients with RA, no significant changes occurred after 2 weeks and after 6 months of 
treatm ent when compared with baseline. The mean integrated ACTH levels during the ITT were 
not different between healthy controls and patients with RA and they did not change significantly 
from baseline after 2 weeks and after 6 months in patients with RA (p>0.2, data not shown). 
Figure 3 shows the mean integrated cortisol levels during the ITT in the healthy controls and in 
RA patients, before and after 2 weeks and 6 months of treatment. At baseline, the mean integrated 
level of cortisol tended to be lower in patients with RA than in healthy controls (p=0.07). In 
patients with RA, the mean integrated cortisol level was significantly lower after 2 weeks use of 
naproxen compared with baseline (p=0.015). After 6 months, it had returned to pre-treatment values. 
Figure 4 shows the levels of plasma cortisol during the ITT. At baseline no significant differences in 
cortisol levels at individual time points were found between patients with RA and healthy controls, 
and the mean (SD) maximal rise in plasma cortisol also did not differ between healthy controls and 
patients with RA: 0.31 (0.14) |imol/l and 0.31 (0.15) |imol/l respectively (p>0.2). In patients with 
RA treated for 2 weeks with naproxen plasma cortisol levels were significantly lower than baseline 
levels at 45 (p=0.02), 60 (p=0.03), 90 (p=0.03) and 120 (p=0.045) minutes after injection of insulin. 
After 6 months of treatment cortisol levels at individual time points and the maximal rise in cortisol 
during the ITT were not significantly different compared with baseline (p>0.20).
H PA -axis  a c tiv ity : basal values
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Cytokines
Table 3 shows the ex-vivo whole blood production of IL-1P, TN Fa and IL-6 after 24 hrs of incu­
bation with or w ithout LPS. Baseline values for IL-1P production were not significantly different 
between RA patients and healthy controls. After 2 weeks use of naproxen, the spontaneous pro­
duction of IL-1P did not change significantly compared with baseline. After 6 months of treat­
m ent however, the spontaneous production of IL-1P had decreased significantly (p=0.01 at 9:00 
AM and p=0.02 at 4:00 PM). This was also seen for levels during the ITT at all time points (data 
not shown). The LPS stimulated ex-vivo production of IL-1P decreased significantly after 2 weeks 
use of naproxen compared with baseline, both at 9:00 AM (p=0.03) and at 4:00 PM (p=0.01). This 
decrease was not seen however in the values during ITT. After 6 months of treatment, the LPS 
stimulated production of IL-1P was not significantly different from baseline anymore.
At baseline, both spontaneous and LPS-stimulated production of TNFa, did not significantly 
differ between RA patients and healthy controls. Levels of spontaneous TN Fa production were, 
for a great part, below detection level, and no significant changes were found after 2 weeks and 
after 6 months. Compared to baseline the LPS stimulated production of TN Fa had decreased 
after 2 weeks at 4:00 PM only, (p=0.02), but not after 6 months. This decrease was not found in 
levels during ITT (data not shown).
At baseline, the spontaneous production of IL-6 was significantly higher in RA patients than in 
healthy controls: mean values of 28 versus 8 ng/ml at 9:00 AM and 17 versus 8 ng/ml at 4:00 PM 
(p=0.004 and p=0.04 respectively). This was also found in levels during the ITT at all timepoints 
(data not shown). LPS-stimulated production of IL-6 did not significantly differ between RA 
patients and HC. No significant changes occurred in either stimulated or unstimulated IL-6 levels 
after 2 weeks and 6 months of treatment.
w Discussion
The main finding of our study is the decreased responsiveness of the HPA-axis in patients with 
RA after 2 weeks of treatm ent with naproxen, which results in a decreased 24 hrs urinary cortisol 
excretion and decreased plasma cortisol levels during ITTs compared with pre-treatm ent values. 
After 6 months, in which naproxen was continued and sulphasalazine or methotrexate were 
added to the treatm ent, these cortisol levels returned to pre-treatm ent values. This observation 
suggests the existence of adaptive mechanisms, the nature of which remains to  be elucidated. 
The significant decrease in plasma cortisol levels during the ITT between the assessments at base­
line and after 2 weeks of treatment with naproxen, was not found in plasma samples that were 
collected for basal values on a day separate from the day of the ITT. Possibly, this is due to the less
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standardized conditions under which these samples were collected. During the ITT, the first blood 
samplings were done 30 minutes after insertion of an intravenous catheter during which period 
all subjects were at rest in a supine position. The decrease in basal plasma ACTH level at 9:00 AM 
after 6 months of treatment compared with baseline was not confirmed under the more stan­
dardized conditions of the ITT, and we therefore consider it a spurious result.
Our findings cannot be explained by competition between naproxen and cortisol in binding to 
CBG or by a change in CBG levels, because the ratio between free and total cortisol as well as CBG 
levels remained unchanged after treatment with naproxen. Adaptation of patients to the test 
situation and improvement of disease activity are also unlikely to explain our results, especially 
because cortisol levels returned to pre-treatm ent levels after 6 months.
The most likely explanation for our observations is that naproxen has transient effects on the 
activity of the HPA-axis in patients with active RA. Naproxen and other NSAIDs inhibit the 
enzyme cyclooxygenase and thereby decrease prostaglandin synthesis. Prostaglandins are known 
to be involved in the regulation of ACTH and cortisol secretion [1,2]. Studies of the effects of 
cyclooxygenase inhibitors on ACTH and cortisol levels in healthy humans have yielded conflicting 
results. NSAIDs had no effects on basal ACTH and cortisol levels [16,17]. An iv infusion of sodium 
salicylate increased ACTH and cortisol responses to hypoglycaemia [18]. In contrast, 4 days use 
of acetylsalicylic acid decreased ACTH and cortisol responses [19]. Treatment with indomethacin 
has resulted in increased ACTH and decreased cortisol responses [19] and in decreased ACTH 
and norm al cortisol responses to hypoglycaemia [17]. Three days of treatm ent with 
indomethacin did not influence ACTH and cortisol responses to corticotropin-releasing 
hormone (CRH) [20]. A single oral dose of acetylsalicylic acid reduced ACTH and cortisol 
responses to arginine vasopressin [21] and to exercise related stress [22], but increased ACTH 
responses to naloxone [16].
The effects of NSAIDs on ACTH and cortisol have not been studied extensively in patients with 
RA. As far as we know, this is the first study that shows an effect of NSAID treatm ent on hypo- 
glycaemia stimulated cortisol levels in patients w ith RA. Hall et al. did a cross-sectional study in 
which they compared 8 untreated RA patients with 7 NSAID treated RA patients and 13 healthy 
controls [4]. Unlike in our longitudinal study, they found lower plasma ACTH levels in NSAID 
treated RA patients than in untreated RA patients while plasma cortisol levels were not different 
between the 2 groups.
A possible reason for the transient decrease in plasma cortisol levels during ITT and 24 hrs urinary 
cortisol excretion might be a change in the production of pro-inflammatory cytokines. In our 
patients we observed a transient decrease in LPS stimulated production of IL-1P after 2 weeks 
treatm ent with naproxen. Because IL-1P stimulates the adrenal gland to produce cortisol [9], this 
may have contributed to the transient decrease in cortisol levels. This decrease however, was not
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seen during the more standardized conditions of the ITT. Furthermore, the spontaneous ex-vivo 
production of IL-1P had not changed significantly after 2 weeks treatm ent with naproxen, but 
had decreased after 6 months compared with baseline, in basal values as well as during the ITT. If 
anything, this should have reduced the activation of the HPA-axis and have resulted in a further 
decrease in cortisol levels. Whether these reduced levels of spontaneous ex-vivo production of IL-1P 
after 6 months represent decreased disease activity, or are a direct effect of medication (DMARD) 
remains to be elucidated, but it has been reported that DMARDs may influence cytokine profiles [23]. 
Furthermore, we observed an increased spontaneous ex-vivo production of IL-6 in RA patients 
compared with healthy controls, which did not significantly change after 2 weeks or 6 months. An 
increased IL-6 production would be expected to activate the HPA-axis. However, levels of cortisol 
during the ITT tended to be lower in our RA patients than in healthy controls before treatment. 
This finding is consistent with the hypothesis that cortisol levels are inappropriately low in 
patients with RA [1].
To our knowledge, this is the first longitudinal study of the effects of antirheumatic treatm ent on 
the activity of the HPA-axis in patients with RA. We conclude that treatm ent with naproxen 
results in a transient suppression of HPA-axis activity. The degree of suppression is mild and 
probably without direct clinical consequences. It is nevertheless noteworthy because it adds up to 
the relative suppression of the HPA-axis seen in untreated patients with RA.
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Disease activity: baseline values and changes from baseline after 2 weeks and 6 months of antirheumatic drug therapy
Baseline Change from baseline
(n=20) A fte r 2 weeks (n=20) A fte r 6 months (n=17)
mean SD mean SD P s mean SD P s
DAS (units) 4.3 0.7 -0.7 0.7 0.0003 -1.6 1.2 0.0002
ESR (mm/hr) 21.6 24.7 3.4 8.1 0.13 2.6 32.2 0.30
RAI (units) 16.7 7.8 -4.3 4.9 0.001 -10.1 6.5 0.0001
Number of swollen joints 11.4 6.3 -2.4 5.1 0.02 -4.6 8.1 0.04
VAS general well-being (mm) 52.3 1.9 -12.8 19.1 0.007 -25.1 25.9 0.002
* fo r  comparison w ith baseline
DAS Disease activity score
ESR Erythrocyte sedim entation rate
R A I Ritchie articular index
VAS Visual analogue scale
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T a b le  2 .  Basal plasma levels of adrenocorticotropic hormone (ACTH), total and free cortisol and cortisol binding globulin (CBG), 
and total 24  hrs urinary excretion of cortisol: baseline and changes from baseline after 2 weeks and 6 months of 
antirheumatic treatm ent
Baseline Change from baseline in rheumatoid a rth ritis
Healthy controls 
(n=20)
Rheumatoid a rth ritis  
(n=20)
A fte r 2 weeks 
(n=20)
A fte r 6 months 
(n=17)
mean SD mean SD P s mean SD p ** mean SD p **
9 :00  AM
ACTH (pmol/l) 3.7 2.2 5.5 3.5 0.09 -1.2 2.9 0.14 -1.8 2.3 0.005
to ta l cortisol (mmol/l) 0.44 0.11 0.45 0.12 > 0.2 -0.04 0.12 0.18 -0.01 0.15 > 0.2
free cortisol (nmol/l) 20.1 4.7 20.5 4.6 > 0.2 -1.7 9.3 > 0.2 -0 .3 # 8.6 > 0.2
CBG (mmol/l) 0.83 0.10 0.83 0.11 > 0.2 -0.02 0.10 > 0.2 nd
4 :0 0  PM
ACTH (pmol/l) 3.3 1.6 4.3 2.4 0.10 -0.2 1.9 > 0.2 -0.6 1.9 > 0.2
Total cortisol (mmol/l) 0.27 0.10 0.26 0.09 > 0.2 -0.01 0.11 > 0.2 0.04 0.12 > 0.2
Free cortisol (nmol/l) 12.3 4.3 12.3 4.4 > 0.2 -0.4 5.8 > 0.2 4.01 # 9.8 > 0.2
CBG (mmol/l) 0.83 0.15 0.84 0.17 > 0.2 -0.02 0.15 > 0.2 nd
Urinary cortisol nm ol/24 hrs 69.9 26.5 67.5 36.0 > 0.2 -20.4 37.1 0.03 3.5 26.9 > 0.2
+ fo r  the comparison between healthy controls and  rheum atoid arthritis patients  
fo r  the comparison w ith baseline in rheum atoid arthritis patients  
#  available fo r  only 10 patients a t 9:00 A M  and  9 patients a t  4:00 P M  
nd no t done
Spontaneous and LPS * stimulated ex-uiuo whole blood production of IL-1P (ng/ml), TNFa (ng/m l) and IL-6 (ng/ml): base­
line and changes from baseline after 2 weeks and 6 months of antirheumatic treatm ent
Baseline Change from baseline in rheumatoid a rth ritis
Healthy controls Rheumatoid a rth ritis  A fte r 2 weeks A fte r 6 months
(n=20) (n=20) (n=20) (n=17)
mean SD mean SD p * * mean SD p *** mean SD p ** *
9 :00  AM  
IL-1 p, LPS- 0.059 0.017 0.058 0.058 > 0.2 -0.001 0.022 > 0.2 -0.029 0.043 0.01
IL-1 p, LPS+ 5.740 2.764 6.697 3.626 > 0.2 -1.29 2.42 0.03 -0.57 3.25 > 0.2
TNFa, LPS- 0.343 0.350 0.254 0.068 > 0.2 0.009 0.084 >0.2 0.013 0.111 > 0.2
TNFa, LPS+ 4.934 1.419 4.507 1.972 > 0.2 -0.59 1.67 > 0.2 0.7 1.41 0.08
IL-B, LPS- 8 2 28 28 0.004 11 29 0.10 18 67 > 0.2
IL-6, LPS+ 13538 7253 12002 7281 > 0.2 -2621 5246 0.10 -868 4787 > 0.2
4 :0 0  PM
IL-1 p, LPS- 0.065 0.015 0.061 0.069 > 0.2 -0.004 0.021 > 0.2 -0.031 0.054 0.02
IL-1 p, LPS+ 6.066 3.345 6.862 4.015 > 0.2 -1.871 2.792 0.01 2.279 12.54 > 0.2
TNFa, LPS- 0.252 0.045 0.211 0.077 0.07 0.020 0.090 > 0.2 0.056 0.112 0.11
TN F a,LP S + 4.714 1.414 5.209 2.260 > 0.2 -0.994 1.725 0.02 -0.404 1.741 > 0.2
IL-B, LPS- 8 3 17 16 0.04 3 23 > 0.2 9 27 > 0.2
IL-6, LPS+ 8540 4931 9691 5242 > 0.2 -1681 3805 0.10 1759 6440 > 0.2
LPS: m easurem ent after 24 hrs incubation w ith  (+) or w ith o u t (-) lipopolysaccharide 
fo r  the comparison between healthy controls and  rheum atoid arthritis patients 
fo r  the comparison w ith baseline in rheum atoid arthritis patients.
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Figure 1.  Circadian levels o f  cortisol in salivary samples during 24 hours. HC = healthy controls (n=20), RA  
= rheumatoid arthrits (n=20). No significant differences were found when RA patients were compared with HC  
or when values after 2 weeks (n=20) or 6 months (n=17) o f antirheumatic treatment were compared with base­
line values in RA patients
Figure 2. Mean plasma levels ofAC TH  during insulin tolerance tests o f  healthy controls (HC, n=20) and RA  
patients at baseline (n=20), after 2 weeks (n=20) and after 6 months (n=17) o f antirheumatic treatment. Insulin 
was administered a t 9:00 AM. No significant differences were found between HC and RA patients, and within 
RA patients before and after treatment.
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Figure 3 . Mean (SD) integrated mean plasma cortisol during insulin tolerance tests (calculated as area under 
the curve for cortisol divided by 180 minutes) for healthy controls (HC, n=20), and RA patients a t baseline 
(n=20), after 2 weeks (n=20) and after 6 months (n=17) o f antirheumatic treatment.
F ig u re  4 . Mean plasma levels o f  cortisol during insulin tolerance tests o f healthy controls (HC, n=20) and RA  
patients a t baseline (n=20), after 2 weeks (n=20), and after 6 months (n=17) o f antirheumatic treatment. Insulin 
was administered a t 9:00 AM . After 2 weeks o f treatment, cortisol levels were significantly (p<0.05) lower than at 
baseline a t the time points indicated with an asterisk. No significant differences were found between HC and RA  
patients, and within RA patients after 6 months o f treatment.
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O bje c t iv e  To study the effect of the use of the non-steroidal anti-inflammatory drug (NSAID) 
naproxen on the activity of the HPA-axis in healthy volunteers.
M e t h o d s  We performed a double blind, randomized study in two groups of twenty healthy vol­
unteers. The activity of the HPA-axis was measured before and after the use of naproxen or place­
bo during a period of two weeks. Under basal circumstances plasma ACTH and cortisol, 24 hr 
urinary cortisol excretion, and circadian cortisol rhythm in salivary samples were determined. 
Plasma ACTH and cortisol were also measured during a bicycle ergometry test with submaximal 
physical exercise. Before these investigations a maximal exercise test was performed in order to 
determine the maximal capacity of each individual neccesary for calculating the submaximal load 
at 80% of their maximal reached power.
R e s u l t s  There were no significant differences between the groups in basal plasma ACTH and 
cortisol levels, 24 hr urinary cortisol excretion, and circadian cortisol rhythm measured in sali­
vary samples. The maximal reached power during the bicycle ergometry was similar in both 
groups and during submaximal exercise a significant rise in plasma ACTH and cortisol levels was 
seen in both groups. After the use of placebo or naproxen for two weeks, no significant change in 
any of these parameters occurred, and we found no significant differences in these parameters be­
tween the two groups.
C o n c l u s i o n  The use of naproxen does not influence the activity of the HPA-axis in healthy vol­
unteers under basal circumstances nor in response to physical stress.
w Introduction
The hypothalamic-pituitary-adrenal axis (HPA-axis) plays an important role in immune 
responses [1-3], and it has been suggested that a decreased response of the HPA-axis, resulting 
in insufficient cortisol secretion, is a pathogenetic factor in the development of auto-immune 
diseases, in particular rheumatoid arthritis (RA) [4-6]. The HPA-axis is a neuroendocrine path­
way that consists of the hypothalamus, the pituitary gland, and the adrenal glands. In the hypo­
thalamus, corticotrophin releasing hormone (CRH) is secreted, which stimulates the synthesis 
and secretion of adrenocoticotrophic hormone (ACTH) by the pituitary gland into the circula­
tion. ACTH induces the secretion of the glucocorticoid cortisol, which is produced by the adre­
nal glands. This glucocorticoid has strong anti-inflammatory properties and is vital in the 
organisms response to inflammatory challenge and to stress.
w Summary
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Low cortisol levels have been reported in patients with RA [7,8], but normal levels were also 
found [9,10]. As most of these studies concern patients using non-steroidal anti-inflammatory 
drugs (NSAIDs), the question arises whether NSAIDs are able to reduce the activity of the HPA- 
axis, which might explain the reported decreased activity of the axis in RA.
In animal studies NSAIDs have been shown to influence the interactions between the immune sys­
tem and the HPA-axis [11,12]. In humans only few studies have been performed studying the influ­
ence of NSAIDs on the HPA-axis, and most of them reported decreased activity of the HPA-axis after 
the use of NSAIDs [13-17], although unchanged [18] and increased [19] activity were also reported. 
NSAIDs inhibit the cyclooxygenase (COX) enzyme, the key enzyme for the conversion of arachi- 
donic acid to prostaglandin (PG) G2 and PGH2, which are subsequently converted to a variety of 
eicosanoids including a num ber of different PGs and tromboxane. Prostaglandins have proin- 
flammatory effects, but also play a role in many different physiological processes, including sen­
sation of pain, induction of fever, kidney function, wound healing, blood vessel tone, and blood 
clotting. Inhibition of PG production through inhibition of COX accounts for the antiinflamma­
tory and pain relieving effect of NSAIDs, but also for their side effects [20]. Two isoforms of COX 
have been identified; COX1 and COX2, and the latter has been found to be mostly involved in 
inflammation, although its role in norm al physiology still has to be defined [21]. Naproxen is a 
non-selective NSAID which inhibits both COX1 and COX2 and is frequently used in the treat­
m ent of RA.
Previously, we have found a reduction of plasma cortisol levels and total cortisol excretion in 24 
hours urine in patients with recent onset RA, after two weeks use of naproxen [22]. This decreased 
HPA-axis activity in RA patients could be caused by a direct or an indirect effect of naproxen on 
the HPA-axis. In animal studies PGs have been shown to be able to activate the HPA-axis [23-25], 
and so it is possible that inhibition of PG production by NSAIDs decreases the activity of the 
HPA-axis directly, which would also be found in healthy volunteers. In RA patients, the effect of 
naproxen could also be indirect by reducing inflammation and/or pain itself, thereby reducing 
stress, resulting in lower cortisol levels.
To test the hypothesis that naproxen has a direct effect on the activity of the HPA-axis, we perfor­
med a double blind, randomized study in 40 healthy volunteers. The activity of the HPA-axis was 
studied both under basal circumstances as well as after stimulation by a standardized form of 
stress, induced by physical exercise on a bicycle ergometer. The basal activity measurements and 
the exercise test were performed twice in each subject; before and after two weeks treatment with 
placebo or naproxen. In order to detect subtle differences, which might not be detected after max­
imal exercise, we studied the reactions of ACTH and cortisol to submaximal exercise at 80%. An 
interm ittent schedule of exercise at a load of 50%-80% was chosen, which can be easier sustained 
by untrained persons than a constant work load at 80%.
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w Methods
S u b je c t s  We performed a double blind, randomized study, which was approved by the hospi­
tal's ethical committee, and all participants voluntarily signed an informed consent form. Forty 
healthy volunteers, between 18 and 40 years old, with norm al physical examination and electro­
cardiogram, were randomized into two groups of each twenty participants. Well trained athletes 
were no t included in the study, as elevated basal cortisol levels and an increased cortisol response 
to stress have been described in these subjects [26,27]. The subjects did not use any medication 
or oral contraceptives.
M e d i c a t i o n  One group received naproxen 500 mg twice daily during a period of two weeks, 
and the other group received placebo during this period. Naproxen and placebo were given in a 
double blinded fashion in the form of capsules, with equal appearance and smell, manifactured 
by the pharmacy of the university hospital.
I n v e s t i g a t i o n s  After inclusion, a maximal exercise test was performed in order to determine 
the individual maximal power (Wmax), from which the required load for the submaximal exerci­
se test of each individual could be calculated. On a separate day, basal activity of the HPA-axis was 
determined as follows: blood was drawn at 9.00 am (fasting) and at 4.00 pm for determination of 
plasma cortisol and ACTH levels. Urine was collected for determination of total cortisol excretion 
in 24 hours, and on the same day salivary samples were collected every 4 hours for a period of 24 
hours starting at 8.00 am, for the determination of the circadian rhythm of cortisol. These sam­
ples were collected by means of an absorbent swab, which was taken in the m outh for 5 minutes. 
It was then placed in a tube and kept in the refrigerator, and the next day all samples of 24 hours 
were brought to the laboratory, where they were centrifuged and the saliva frozen, until they were 
analyzed. On the next day, a submaximal exercise test was performed as described below. 
Thereafter the subjects received naproxen or placebo during two weeks, and at the end of this 
period, measurements of basal activity and submaximal exercise testing were repeated.
La b o r a t o r y  m e a s u r e m e n t s  Blood was collected in pre-chilled K3-EDTA tubes and cen­
trifuged for 10 minutes at 1500xg (4 °C) within one hour. The plasma obtained was aliquoted in 
polystyrene tubes containing 250 KIU/ml plasma Trasylol®(aprotonine, Bayer, Leverkusen, 
Germany), frozen and stored at - 20 °C.
ACTH: ACTH in plasma was measured by an imm unoradiometric assay (IRMA) based on two 
polyclonal antibodies (EuroDiagnostics, Arnhem, The Netherlands). The catching antibody is 
directed against the C-terminal part of the ACTH molecule and coupled via a sheep anti-rabbit 
antibody to a polystyrene tube. The detecting antibody is directed against the N-terminal part of
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ACTH and radioiodinated. Standard curves were prepared by spiking ACTH-free plasma with 
ACTH1-39 (MRC 74/555). The assay was performed as follows. Two hundred microliters of sam­
ple or standard (0-220 pmol/l) were added to the coated tubes and subsequently iodinated ACTH 
antiserum (250,000 dpm/200|il) was added. The mixture was incubated for 24 hours at room 
temperature. The supernatant was decanted and the tubes washed two times with 0.9% NaCl. 
Radioactivity in the tubes was counted using an automatic gamma-counter (1470 WizardTM 
Wallac, Turku, Finland). The sensitivity of the assay was 0.5 pmol/l and the within- and between- 
assay coefficients of variation of the IRMA procedure were 4.4% and 7.2% respectively. All sam­
ples were measured in duplo. The IRMA specifically detects ACTH1-39. Cross-reactivity with 
ACTH1-24, CLIP and P-endorphin was < 0.1%. Normal range at 8.00 am: 1.3-9.2 pmol/l. 
Cortisol: Plasma cortisol levels were measured by radioimmunoassay using an antiserum raised 
in rabbit against a cortisol-21-hemisuccinate-bovine serum albumin conjugate. The following 
crossreactivities (expressed as % on mass basis) were obtained: desoxy-cortisol, 3.1%; cortison, 
0.5%; dexamethason, 0.2%; prednisolone, 7.1%. Standard and samples (50 |il) are diluted 1:100 
with ethanol/water (5/95, v/v) and corticosteroid binding globulin was denaturated by incubation 
at 70°C for one hour. Subsequently, tracer ([1,2,6,7- 3H]cortisol) and antibody were added and 
bound and free hormone were separated by dextran-coated charcoal after incubation for 18 hours 
at 4 °C. After centrifugation the supernatants were decanted and radioactivity was measured. The 
sensitivity of the assay was 0.02 |imol/l. The within- and between-assay coefficients of variation 
were 4.5% and 6.6% at 0.21 |im ol/l and 4.0% and 3.8% at 1.04 |im ol/l respectively. Normal range 
at 8.00 am: 0.19-0.55 |imol/l.
M a x i m a l e x e r Cis e  t e s t  The subject was seated on a bicycle ergometer (Excalibur, Lode, 
Groningen, the Netherlands), and electrodes were placed on the chest, in order to m onitor ECG. 
Heart rate during the test was measured by means of the polar vantage NV. A well-fitting m outh­
piece was taken in the m outh by the subject, in order to measure respiratory quotient (RQ), which 
was measured by an automatized gasanalysing system, the oxicon IV (Mijnhardt oxicon systems, 
Bunnik, the Netherlands). Work load was started at 20 W att/minute with an increase of 20 watts 
every minute until exhaustion. Two minutes after the end of exercise, a capillary blood sample was 
taken to determine capillary base excess (BE). The test was considered adequate if two of the fol­
lowing three criteria were met: Maximal heart rate (Hfmax) > 220 -  age ± 10, RQ > 1.0, and BE 
< -10.0 meq/l.
S u b m a x i m a l —e x e r c i s e  t e s t  The subject reported to the laboratory at 9.00 am after an 
overnight fast, and at 09.30 am a catheter was inserted in an antecubital vein and kept patent by 
saline solution. Electrodes were placed on the chest, in order to m onitor heart rate during the test.
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After a 30 minutes rest in a supine position, the subject was seated on a bicycle ergometer. At 10.00 
am exercise was started with power set at 50% of the subject’s Wmax. After 5 minutes, a 15 m in­
utes period followed in which power was intermittently set at 50% and 80% of Wmax, changing 
every 30 seconds. This was followed by a recovery period of 3 minutes at 30%, and then the sub­
ject rested in a supine position (see fig.1). Blood samples were drawn just before exercise and at 
20, 30, 40, and 60 minutes after start of exercise.
Statistical analysis. Results are expressed as the mean ± standard deviation (SD). Statistical com­
parisons within groups were made with paired t-tests or by Wilcoxon rank sum test if data were 
not normally distributed. Comparisons between groups were made by unpaired t-test or by the 
M ann-W hitney test if data were not normally distributed.
A significance level of p  < 0.05 was applied. The areas under the curve (AUCs) were calculated 
w ith the trapezoid m ethod from the individual hormone levels at the various time points, using 
the absolute horm onal values.
w Results
The demographic variables of the two study groups and the results o f their maximal exercise test 
are shown in table 1. There were no significant differences between the two groups. The placebo 
group consisted of 7 men and 13 women with age 36 ± 8  (mean ± SD) years. The naproxen group 
consisted of 8 men and 12 women with age 37 ± 5  years. Wmax was 243 ± 63 watt in the place­
bo group, and 250 ± 68 watt in the naproxen group, with maximal heart rate 187 ± 11 and 184 
± 8 bpm respectively.
B a s a l  v a l u e s  Basal values of plasma ACTH and cortisol did not differ significantly between 
the groups. After the use of placebo or naproxen, no significant change in basal values had 
occurred, and no significant differences were seen between both groups (table 2).
Total cortisol excretion in 24 hours urine before medication was 67.5 ± 28.2 nmol/24h (mean ± 
SD) in the placebo group, and 86.8 ± 60.8 nmol/24h in the naproxen group, which was not signi­
ficantly different. After the use of placebo or naproxen, these values were 79.5 ± 38.9 nmol/24h 
and 81.7 ± 35.6 nmol/24h respectively, w ith no significant difference between both groups, and 
no significant change in either of the groups after the use of placebo or medication (table 2). 
Circadian rhythm of cortisol in saliva showed a norm al cortisol rhythm in both groups with a 
peak at 8.00 am, and AUC's in both groups did not differ significantly. After the use of placebo or 
naproxen, no significant change was seen in either of the groups, and no significant differences 
occurred between both groups (fig. 2).
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S u b m a x i m a l  e x e r c i s e  t e s t :  All subjects completed the test. In response to this physical 
exercise a significant rise of ACTH was seen (p<0.0001 in both  groups) with the maximum of 
ACTH reached at 20 minutes (fig. 3A), and a significant rise of cortisol (p=0.020 in the placebo 
and p=0.047 in the naproxen group), with its peak at 30 minutes. (fig. 3B). No significant differ­
ences were seen in AUC of both ACTH and cortisol between the groups, nor were any significant 
changes seen in these AUCs after the use of placebo or naproxen in either of the groups.
w Discussion
In two groups of healthy, non-athletic subjects, levels of plasma ACTH and cortisol, 24 hr uri­
nary cortisol excretion, and circadian cortisol rhythm in salivary samples under basal circum­
stances, did not change after the use of placebo or naproxen. Plasma levels of ACTH and corti­
sol in response to physical exercise on a bicycle ergometer, which caused significant rises in 
ACTH and cortisol, did not change either after the use of placebo or naproxen. On the basis of 
these results we conclude that the use of the NSAID naproxen does not influence the activity of 
the HPA-axis in healthy volunteers.
Prostaglandins are known to be involved in the regulation of ACTH and cortisol secretion 
[28,29]. Reports in the literature about the effect of NSAIDs on the HPA-axis in healthy humans 
have been few and have yielded conficting results [13-19]. In these studies different methods of 
stimulating the HPA-axis were used (hypoglycaemia induced stress, stimulation with naloxone or 
arginine vasopressin (AVP) and water-immersion), and various NSAIDs were studied, which per­
haps accounts for the contradictory results. A study of indomethacin in five norm al males, had 
no effect on basal ACTH and cortisol levels, but decreased the ACTH response to hypoglycaemia 
induced stress [13]. Treatment with indomethacin and acetylsalicylic acid in a single dose did not 
alter ACTH and cortisol levels, but treatm ent with indomethacin for 4 days increased the 
response of ACTH to hypoglycaemia while decreasing cortisol response [14], and 4 days use of 
acetylsalicylic acid decreased ACTH response and delayed the cortisol response to hypoglycemia 
[14]. An iv infusion of sodium salicylate in six healthy men increased ACTH and cortisol respons­
es to hypoglycaemia [19].Three days of treatm ent with indomethacin or meclofenamate in 7 
healthy subjects did not influence ACTH and cortisol responses to corticotropin-releasing hor­
mone (CRH) [18]. A single oral dose of acetylsalicylic acid reduced ACTH and cortisol respons­
es to the pituitary corticotrophic stimulator, arginine vasopressin [16]. In a recent, placebo-con­
trolled study in 12 healthy volunteers, treatm ent with acetylsalicylic acid for three days, was found 
to inhibit ACTH and cortisol response to physical stress induced by treadmill exercise, in contrast 
to our study [17]. In this study subjects were all male atletes, who may respond differently than
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our untrained and moderately trained subjects. Patients with RA receiving daily NSAID therapy 
were found to have lower ACTH levels under basal circumstances than patients w ithout NSAID 
therapy, but no differences in cortisol levels were found [15]. Water immersion did not change the 
ACTH or cortisol levels in either of the groups.
The num ber of study subjects in our study was larger than in any of the abovementioned studies, 
and only a few of them were randomized placebo-controlled. Furthermore, study medication was 
given during 2 weeks, allowing also for possible slow changes of the HPA-axis resetting at a new 
threshold.
Our findings in healthy volunteers in the present study suggest that the lower cortisol levels which 
we found after the use of naproxen in RA patients, and the relatively low cortisol levels in RA 
patients reported by others in the literature, are not the result of a direct effect of NSAIDs on the 
activity of the HPA-axis. The possibility of an indirect effect of the use of NSAIDs through reduc­
tion of pain and/or inflammation, resulting in lower cortisol levels, remains. However, other fac­
tors may contribute to these low cortisol levels, which may be characteristic of the disease itself, 
or the result of adaptative mechanisms in respons to constant challenge of the HPA-axis by 
chronic inflammation and/or pain.
We conclude that the use of naproxen does not influence the activity of the HPA-axis in healthy 
volunteers. Further studies will be needed to investigate the effect of NSAIDs in chronic inflam­
m atory states and in chronic pain, in order to determine its effect on the HPA-axis in these cir­
cumstances, and increase our understanding of abnormalities of the HPA-axis in patients with 
chronic inflammatory diseases.
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Demographic variables of the study subjects and results of maximal 
exercise test
Placebo (n=20) Naproxen (n=20)
Age (years) 36 ± 8 37 ±  5
male:female 7 :1 3 8:12
W eight (kg) 7 3 .7  ±  15 .9 7 3 .2  ± 1 1 .2
HR0 (bpm) 85 ± 1 1 80  ±  11
HRmax (bpm) 187 ± 1 1 184 ± 8
RQ0 0.77  ±  0 .07 0 .7 5  ±  0.11
RQmax 1.21 ±  0 .1 3 1 .22  ±  0 .09
BEmax (mEq/l) -1 1 .0  ±  2.1 -1 0 .9  ±  2 .6
W m ax (W att) 243  ±  63 250  ±  68
Values are m ean  ±  SD. H R 0  = heart rate before exercise, H R m a x  = heart rate a t end o f  m a x im a l  
exercise, R Q 0  = respiratory q u o tien t before exercise, R Q m a x  = respiratory q u o tien t a t  end o f  m a x ­
im a l exercise, B E m a x  = base excess a t end  o f  m a x im a l exercise, W m a x  = m a x im a l reached w ork­
load.
Table 2. Basal values of plasma 
urine collection
Before
placebo
(n=20)
ACTH, plasma cortisol and cortisol in 24  hr
Before After After 
naproxen placebo naproxen 
(n=20) (n=20) (n=20)
ACTH (pmol/l)
9 :0 0  am 3.1 2 .3 2 .8  ± 1 .9 3 .0  ±  2 .0 3 .0  ± 1 .7
4 :0 0  pm 2.2  ± 1 .1 2 .5  ± 1 .5 2 .0  ± 1 .0 2 .3  ± 1 .3
Cortisol (mmol/l)
9 :0 0  am 0 .4 5  ±  0 .12 0 .4 0  ±  0 .0 9 0 .4 5  ±  0 .16 0 .3 9  ±  0.11
4 :0 0  pm 0 .2 5  ±  0 .09 0 .2 3  ±  0 .0 4 0 .2 3  ±  0 .08 0 .2 3  ±  0 .10
Cortisol urine (nmol/24 hr) 6 7 .5  ±  28 .2 86 .8  ±  6 0 .8 7 9 .5  ±  38 .9 81 .7  ±  35 .6
Values are m ean  ±  SD. Cortisol urine  = total cortisol excretion in  24 hours urine  collection.
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Figure. 1 .  Schedule o f submaximal exercise. ▲ = insertion o f venous canule. J  = time points o f  blood sam­
pling. A  = work load at 50% o f individual maximal workload, B = intermittent work load at 50-80%, C = work­
load at 30%.
Time
Figure. 2 - Circadian cortisol rhythm measured in saliva samples o f two groups o f healthy volunteers, befoi 
and after two weeks treatment with placebo or naproxen.
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Figure. 3A .  Plasma ACTH levels o f two groups o f healthy volunteers during submaximal exercise test, before 
and after two weeks treatment with placebo or naproxen.
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Figure. 3B . Plasma cortisol levels o f  two groups o f healthy volunteers during submaximal exercise test, before 
and after two weeks treatment with placebo or naproxen.
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Hypothalam ic-pituitary-adrenal Axis A c tiv ity  and Prolactin  Secretion in Patients w ith  Rheumatoid A r th r itr is
Anti-TNF-treatment does not affect 
hypothalamic-pituitary-adrenal axis 
activity in patients with rheumatoid 
arthritis
Eijsbouts AMM, den Broeder AA, Laan RFJM, Sweep CGJ, Sander O, Rau R, van de 
Putte LBA, van den Hoogen FHJ. Anti-TNF-treatment does not affect hypothalamic- 
pituitary-adrenal axis activity in patients with rheumatoid arthritis. Submitted for 
publication.
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w Abstract
O b je c t i v e  Treatment with TNF-neutralizing agents yields rapid improvement of disease activ­
ity in patients with RA, and it has been suggested that this may be a cortisol-mediated effect. In 
this study we examined the effect of anti-TNF treatment on the activity of the HPA-axis in these 
patients.
M e t h o d s  Eighteen patients with active RA were studied before and after an i.v. injection with 
a TN Fa neutralizing agent (n=13) or placebo (n=5).
Before the first injection with anti-TNF, and on the day after injection, plasma ACTH, plasma 
cortisol and ESR were determined. Before and after injection 24 hr urinary cortisol excretion was 
measured, circadian cortisol rhythm was measured in salivary samples, and a composite disease 
activity score (DAS) was determined.
R e s u l t s  Disease activity as measured by DAS significantly improved in the group of patients 
treated with anti-TNF (DAS before injection 5.09 ± 1.18 and after injection 4.48 ± 1.21, p  = 
0.0007), but not in the placebo group. No changes were observed in the anti-TNF treatment 
group in plasma ACTH and plasma cortisol levels before and after injection, neither were there 
significant changes in 24 hrs urinary cortisol excretion or in the circadian cortisol rhythm.
C o n c l u s i o n  The rapid clinical improvement in response to treatment with TNF neutralizing 
agents is not due to changes in activity of the HPA-axis.
w Introduction
Rheumatoid arthritis (RA) is an auto-immune disease characterized by chronic inflammation, 
predominantly affecting the joints. Although its etiology still remains to be elucidated, the patho­
physiological mechanisms probably consist of a combination of genetical and environmental fac­
tors. Activation of the immune system, involving Th1 lymphocytes and several monocyte derived 
cytokines, has been shown to play an im portant role in RA. Bidirectional interactions between the 
imm une system and the hypothalamic-pituitary-adrenal axis (HPA-axis) have been identified 
[1,2]. In animal studies it has been shown that the proinflammatory cytokines interleukin-1P 
( IL-1P), interleukin-6 (IL-6) and tumor necrosis factor a  (TNFa), are able to increase the activity 
of the HPA-axis [3,4]. Conversely, cortisol influences cytokine production and inhibits the pro­
duction of several cytokines, including TNFa.
TN Fa is a proinflammatory cytokine, and in the joints of RA patients high levels of this cytokine 
have been detected, suggesting a crucial role for TN Fa in the inflammatory proces in RA.
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Inhibition of TN Fa has clearly been shown to reduce disease activity in RA, and recent develop­
m ent of anti-TNF treatm ent has been a major break-through in the treatm ent of RA [5-8]. This 
treatm ent causes a rapid objective and subjective clinical improvement, which already occurs on 
the first day after injection. The only other treatment of RA by which such a rapid improvement 
of disease activity can be achieved is by treatm ent with corticosteroids. Considering the close 
interaction between the HPA-axis and cytokines, the question arose, whether the rapid effect of 
anti-TNF treatm ent could be mediated through the HPA-axis. Relatively low plasma levels of cor­
tisol have been reported in patients with RA, especially when taking into account their level of 
active inflammation, suggesting a decreased activity of the HPA-axis in RA [9-12]. If TN Fa is in 
some way involved in maintaining these reduced plasma cortisol levels, anti-TNF treatment 
might restore these levels, resulting in clinical improvement.
However, in animal studies i.v. administration of TN Fa has been shown to activate the HPA-axis 
resulting in increased glucocorticoid blood levels [3,4]. Blockade of TNF could therefore not be 
expected to increase cortisol levels and the rapid improvement in response to this treatm ent must 
be due to other factors than increased plasma cortisol levels.
The aim of our study was to examine whether anti-TNF treatm ent affects the activity of the HPA- 
axis in patients with RA.
w Patients and Methods
P a t i e n t s  Eighteen patients with RA, participating in two different studies with a TNF-neutral- 
izing agent, were studied. The protocols were approved by the hospital’s ethical committee, and 
written consent was obtained from all patients.
All patients fulfilled the American College of Rheumatology criteria for RA, and had active 
disease, as defined by a Disease Activity Score (DAS) > 3.2 [13]. The use of a stable low dose of 
prednisone with a maximum of 2 mg daily was permitted, which was the case in two patients. 
Patients were excluded if they had used oral corticosteroids in a dose above 2 mg daily in the pre­
vious year, or if they had received an intramuscular injection with corticosteroids in the previous 
3 months. Patients using oral contraceptives or other drugs that are known to influence the HPA-axis 
were also excluded. The use of non-steroidal antiinflammatory drugs (NSAIDs) was allowed.
S t u d y  d e s i g n  a n d  m e a s u r e m e n t s  Two groups of patients, participating in two different 
studies with anti-TNF treatment, were studied before and on the day after they received their first 
injection with the TNF-neutralizing agent. Five patients participated in an open study with 
TNFR55-IgG1, Ro 45-2081 (F. Hoffmann-La Roche, Basel, Switzerland), and received an intra­
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venous injection with 20 mg Ro 45-2081 before 12:00 a.m. Thirteen patients participated in a 
placebo-controlled, double blinded study with the human anti-TNF antibody adalimumab 
(Knoll AG, Ludwigshafen, Germany). Eight of them received an injection with adalimumab in a 
dose of 1.0 mg/kg (n=4), 3.0 mg/kg (n=3) or 5.0 mg/kg (n=1), which was administered before 
12:00 a.m. by a subcutaneous injection. Five patients received an injection with placebo.
In the week before the injection, blood was drawn at 9:00 a.m. for the determination of plasma 
ACTH, plasma cortisol and ESR, and a joint examination was performed in order to determine 
the DAS. Blood for measurement of ACTH was immediately placed on ice and transported to the 
laboratory. Urine was collected for the determination of 24 hours cortisol excretion. Salivary 
samples were collected every 4 hours during 24 hrs for the determination of the circadian corti­
sol rhythm, starting at 8:00 a.m. On the day after the injection, all of these measurements were 
repeated.
L a b o r a t o r y  a s s a y s  Plasma cortisol levels were measured by radioimmunoassay (RIA) using 
an antiserum raised in rabbit against a cortisol-21-hemisuccinate-bovine serum albumin conju­
gate [14]. The sensitivity of the assay was 0.02 |imol/l. The within- and between-assay coefficients 
of variation were 6.9% and 7.3% at 0.208 |im ol/l and 4.2% and 5.6% at 1.03 |imol/l. Plasma 
ACTH was measured by an imm unoradiometric assay (IRMA) based on two polyclonal antibod­
ies (EuroDiagnostics, Arnhem, The Netherlands). Salivary cortisol as well as 24-hour urinary cor­
tisol (i.e. extractable by organic solvents) were measured by RIA after previous extraction and 
paper chromatography [15].
S t a t i s t i c a l—a n a l y s i s  Results are expressed as mean ± standard deviation (SD). Statistical 
comparisons within the groups compairing values before and after treatment were made with 
paired Student's t-test, using a significance level of p < 0.05. The area under the curve (AUC) was 
calculated for the cortisol measurements in salivary samples during 24 hours.
w Results
The characteristics of the two treatment groups are shown in table 1. Thirteen patients were treated 
with a TNF-neutralizing agent and 5 with placebo. Two patients in the treatment group were using
2 mg of prednisone daily, the others did not use corticosteroids. All patients had active 
disease, with a DAS of 5.09 ± 1.18 (mean ± SD) in the treatment group and 4.87 ± 0.74 in the place­
bo group. ESR was 34 ± 24 m m /hr in the treatment group and 31 ± 13 m m /hr in the placebo group. 
In the treatm ent group, a significant improvement of disease activity was seen on the day after the
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injection with the anti-TNF agent, as shown by a significant decline of the disease activity score 
which was 5.09 ± 1.18 before and 4.48 ± 1.21 after injection (p = 0.0007) (table 2). In the placebo 
group these figures were 4.87 ± 0.74 and 4.80 ± 0.57 respectively, showing no significant improve­
ment. No change was seen in ESR in both groups.
Baseline values of plasma ACTH, plasma cortisol and cortisol in 24 hours urine collection, were 
all in the norm al range, and cortisol in salivary samples revealed a norm al circadian rhythm with 
peak values at 8:00 am. (figure 1). We did not find a significant change in any of these parameters 
before and one day after the anti-TNF treatment. Area under the curve calculated from the 
salivary cortisol rhythm also showed no significant difference before and after treatment. In the 
patients who received an injection with placebo, no significant changes in these parameters before 
and after injection were observed either.
w Discussion
At baseline patients with active RA had plasma levels of ACTH and cortisol that were in the nor­
mal range. As mentioned earlier, decreased levels of cortisol have been reported in RA, but also 
norm al levels have been found in several studies [16,17]. These norm al levels however, are con­
sidered inappropriately low for the degree of inflammation [11,18]. Seven of the 18 patients were 
men, which is due to the fact that patients using oral contraceptives were excluded, leaving 
relatively more men than women to be selected for this study.
A significant improvement of disease activity was seen in the treatm ent group on the day after the 
injection with the TNF-neutralizing agent, and no improvement in the placebo group. Despite 
this significant improvement in disease activity, no change was seen in plasma ACTH or cortisol 
blood levels or salivary cortisol concentrations after injection. As interactions between the HPA-axis 
and the immune system are complex, and probably involve several cytokines, which have been 
shown to stimulate the activity of the HPA-axis, blockade of one of them, TNFa, may be com­
pensated by others, like IL-1P and IL-6, leaving HPA-axis activity unchanged.
O ur findings show that the rapid and significant clinical improvement, as observed on the first 
day after anti-TNF treatm ent by a significant improvement in DAS, is not mediated through a 
change in activity of the HPA-axis in patients with RA. The improvement is probably due to inhi­
bition of local action of TNF in the joints, where the highest TN Fa levels are found. However, 
besides a clear decrease of pain and stiffness of the joints, patients also experience a general feeling 
of wellbeing and decrease of tiredness, that can not be explained by a local effect in the joints 
alone. This general improvement suggests that a systemic effect in response to anti-TNF treat­
m ent takes place as well.
103
A
nti-T
N
F
-treatm
ent 
does 
not 
affect 
hypothalam
ic-pituitary-adrenal axis 
activity 
in 
patients 
with 
rheum
atoid 
a
rth
ritis
C
ha
pt
er
 
7
Patients who are treated with corticosteroids experience a similar effect, and one could speculate, 
knowing that corticosteroids inhibit cytokines, including TNFa, that inhibition of cytokines 
might play a role in the subjective improvement induced by corticosteroid treatment. However, 
corticosteroids have a wide range of action, and this might only be one aspect of the mechanism 
by which corticosteroids exert their effect.
In conclusion our study shows that TN Fa blockade does not affect the activity of the HPA-axis 
in patients with RA, and that the rapid clinical and subjective improvement observed in response 
to anti-TNF treatm ent is not a cortisol-mediated effect.
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Baseline patient characteristics.
TNFa-blockade Placebo
(n=13) (n=5)
Age (yrs) 54  ±  14 55 ±  14
male/female 7 /6 0 /5
rheumatoid fac to r positive 11 5
disease duration (yrs) 11 ± 5 19 ± 1 5
DAS 5 .0 9  ± 1 .1 8 4 .8 7  ±  0 .7 4
ESR 34 ±  24 31 ±  13
NSAIDs 12 5
use of prednisone 2 mg daily 2
A ll values are expressed as m ean  ±  SD  or num b er o f  p a tien ts
T ab le  2 . Clinical and HPA-axis variables before and after treatment.
TNFa-blockade (n=13) Placebo (n=5) 
Before After Before After
clinical DAS 5 .0 9  ±  1 .18 4 .4 8  ± 1 .2 1  * 4 .8 7  ±  0 .74 4 .8 0  ±  0 .57
ESR (mm/hr) 34 ±  24 33 ±  24 31 ±  13 31 ± 1 3
serum ACTH (pmol/l) 3 .9  ±  2.7 4.1 ±  3 .0 2 .6  ±  0 .8 2 .4  ± 1 .1
cortisol (mmol/l) 0 .47  ±  0 .19 0 .4 5  ±  0 .1 5 0 .4 5  ±  0 .29 0.51 ±  0 .24
urine cortisol (nm ol/24 hr) 9 4 .3  ± 1 1 0 .6 8 2 .3  ±  6 1 .8 7 1 .5  ±  17 .4 only 3 values
saliva cortisol 8 :0 0  (nmol/l) 11.1 ±  7 .2 11 .8  ± 7 .4 6 .6  ±  3 .6 5 .8  ±  4.1
A ll values are expressed as m ean  ±  SD  
* P  = 0.0007 com pared to before trea tm en t
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Figure 1. Circadian cortisol levels measured in saliva (nm ol/l) before and after trea tm en t w ith  
a n ti-T N F  (n=13); mean values ± SD.
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Prolactin is one of the hormones that may play a role in regulating immune function. It is mainly 
produced in the anterior pituitary gland and consists of a single peptide chain of 198 amino acids, 
w ith a molecular weight of 23,500 Da. Under normal circumstances, secretion of prolactin is 
restrained by the hypothalamus, where the most im portant prolactin inhibiting factor (PIF), 
dopamine, is produced in the arcuate and paraventricular nuclei. Dopamine travels down to the 
median eminence, where it is released into the portal circulation and reaches the anterior p itu­
itary where it inhibits prolactin secretion. With hypothalamic destruction or pituitary stalk sec­
tion, prolactin secretion increases, and serum concentrations rise [1]. Besides dopamine there are 
other PIFs including opiates. Prolactin secretion is stimulated by thyrotropin releasing hormone 
(TRH), oxytocin, serotonin, and vasoactive intestinal peptide [2]. Cytokines probably also par­
ticipate in this regulation. In vitro studies have shown that IL-1, IL-2 and IL-6 are able to stimu­
late prolactin production, IFN-y can inhibit prolactin production, while TN Fa has been found to 
increase as well as to decrease secretion of prolactin [3]. The 24-hour pattern of prolactin release 
shows episodic changes with highest blood levels during the nocturnal sleep period and the low­
est during waking hours [4,5]. Prolactin levels are higher in women than in men, though there is 
considerable overlap in the ranges. Prolactin levels rise in response to stress.
Besides in the pituitary gland, prolactin mRNA and protein have been identified at other sites, 
where prolactin most likely mediates local effects. This extra-pituitary prolactin is produced by 
human chorion, endometrium, the central nervous system, and also by cells of the immune sys­
tem, T and B lymphocytes [1].
The best known effect of prolactin is its ability to stimulate lactation. Moreover it has been 
discovered that prolactin plays a role in numerous other functions, including gestation, growth 
and development, immunoregulation, hematopoiesis and antitum or defense. Receptors for pro­
lactin have been found in various tissues, including cells of the immune system, referring to its 
widespread actions [1].
The first indication of a role of the pituitary gland in the immune response was the discovery in 
1930 that after hypophysectomy the thymus glands of rats involuted. Later it was shown that 
imm une reactions to various antigenic stimuli were impaired in rats after hypophysectomy [6], 
and that adjuvant arthritis in rats did not occur after hypophysectomy. A role of prolactin in the 
imm une response was disclosed by the finding that treatm ent with prolactin restored the immu- 
nocompetence of hypophysectomized rats and made them susceptible to the development of 
adjuvant arthritis. When norm al rats were treated with the dopamine-agonist bromocriptine, 
leading to a decrease in prolactin secretion, the development of adjuvant arthritis was inhibited, 
suggesting that normal levels of prolactin are required to develop this disease [7].
In humans, raised levels of prolactin have been reported in rheumatoid arthritis (RA) [8,9] and 
other autoimmune rheumatic diseases [10-13], but norm al prolactin levels were also found
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[14-16]. Most of these studies were cross-sectional studies, w ith patients using non-steroidal anti­
inflammatory drugs (NSAIDs) or disease modifying antirheumatic drugs (DMARDs). The effect 
of these medications on prolactin levels has not been established, but there are studies reporting 
a change of prolactin levels by these drugs, which may have been of influence on the reported 
abnormalities [17-23].
Another observation which has raised interest in a role of prolactin in RA activity is the fact that 
pregnancy is known to influence the course of RA in women. A characteristic feature of RA is 
remission of the disease during gestation and exacerbation in the post partum  period. During 
pregnancy prolactin levels start to rise during the second trimester, preparing the breasts for lac­
tation, and reach their peak at the end of pregnancy, which has been related to the post partum  
exacerbation of RA. Furthermore, a higher incidence of RA development has been found in the 
post partum  period, particularly when the m other breast feeds [25,26]. Another indication of a 
role of prolactin in the post-partum  flare of RA comes from a study in mice, in which brom ocrip­
tine, a prolactin secretion inhibitor, administered shortly after parturition, led to a reduction of 
the post-partum  flare of arthritis [27]. However, during pregnancy and after delivery there are 
many horm onal changes also involving hormones of the HPA-axis, which makes it very difficult 
to clearly show a relation of RA activity with one of these.
If enhanced levels of prolactin are a proinflammatory factor in RA, reduction of prolactin levels 
might improve disease outcome in RA. Reducing norm al levels of prolactin could still be benefi­
cial in arthritis as it was shown in animal studies that normal levels were necessary to induce 
autoimmune arthritis [7]. There are indeed a num ber of studies, mostly case reports, reporting a 
beneficial effect of reduction of prolactin secretion by treatment with bromocriptine in Reiter's 
disease [28], psoriatic arthritis [29,30] and RA [31-33].
The aim of the following studies was first to examine whether untreated patients with RA have 
abnormal prolactin levels and whether prolactin levels are influenced by antirheumatic drug 
treatment. To achieve this we studied prolactin levels in patients with RA and compared them 
with levels in healthy controls, and compared levels in RA patients before therapy with levels after 
treatm ent with NSAIDs and DMARDs. We measured serum prolactin levels under basal circum­
stances and also performed insulin tolerance tests (ITT) to assess the prolactin response to hypo- 
glycaemia associated stress. Second, we examined whether reduction of prolactin levels could 
improve disease activity in patients w ith RA. For this purpose, we performed an open study with 
the dopamine-agonist quinagolide, in patients with active RA.
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w Abstract
O b je c t i v e  To compare basal and stimulated prolactin levels between patients with rheumatoid 
arthritis (RA) and healthy controls (HC) and to assess the effects of antirheumatic treatm ent on 
prolactin levels in patients with RA.
M e t h o d s  Serum prolactin levels were assessed under basal conditions and during an insulin 
tolerance test (ITT) in 20 patients with recently diagnosed active RA and 20 age and sex matched 
HC. The patients with recent onset RA were reassessed after 2 weeks treatment w ith naproxen and 
after 6 months of additional treatm ent with either sulphasalazine or methotrexate. Disease activ­
ity was assessed with the disease activity score (DAS).
R e s u l t s  Basal levels of prolactin were not significantly different between patients with RA and 
HC. Prolactin responses to hypoglycaemia were significantly lower in untreated patients with RA 
than in HC. The DAS scores correlated negatively with the area under the curve (AUC) for pro­
lactin levels during the ITT. Treatment with naproxen for 2 weeks did not influence either basal 
or stimulated prolactin levels. After 6 months of antirheumatic treatment prolactin responses to 
hypoglycaemia increased significantly to levels observed in HC. At the same time point DAS had 
improved considerably. This improvement correlated significantly with the increase in AUC of 
prolactin during the ITT (r=0.48; p=0.05).
C o n c l u s i o n  Patients with active RA have decreased prolactin responses to hypoglycaemia 
induced stress. These responses restore following treatm ent with antirheumatic drugs.
w Introduction
Prolactin is a hormone, produced by the anterior pituitary gland, which is well known by its abil­
ity to stimulate lactation, but it has also been shown to play a role in regulating immune function 
and has potent pro-inflammatory effects [1,2]. Secretion of prolactin is restrained by the hypo­
thalamus, where the most im portant prolactin inhibiting factor (PIF), dopamine, is produced. 
Other factors are also involved in prolactin secretion including proinflammatory cytokines. 
Depending on the animal species studied and the severity of inflammation, proinflammatory 
cytokines can either stimulate or depress pituitary prolactin release [3,4]. Prolactin levels are 
higher in women than in men, though there is considerable overlap in the ranges. Prolactin lev­
els rise in respons to all kinds of stress.
It has been suggested that excessive prolactin secretion may contribute to the pathogenesis of RA [5]. 
A characteristic feature of RA is remission of the disease during gestation and exacerbation in the
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post partum period. During pregnancy prolactin levels are low, but start to rise during the second 
trimester, preparing the breasts for lactation, and reach their peak at the end of pregnancy, which has 
been related to the post partum exacerbation of RA. Furthermore, a higher incidence of RA devel­
opment has been found in the post partum period, particularly when the mother breast feeds [6,7]. 
Previous studies of prolactin levels in RA patients have shown contradictory results. Prolactin levels 
have been either increased [5,8-10], decreased [11-14] or unchanged [15-20]. Several explana­
tions may be offered to explain the different results in the literature.
Firstly, it may be that NSAIDs influence prolactin levels. In healthy subjects, treatm ent with 
NSAIDs can result in increased [21,22], decreased [23,24] or unchanged prolactin levels [25-26]. 
However, the effects of NSAIDs on prolactin levels have not been studied in patients with RA and 
in most previous studies on prolactin levels in patients with RA, patients have been examined 
while using NSAIDs.
Secondly, treatment with glucocorticoids may influence prolactin levels. This is suggested by the 
results of a study by Mateo et al. who found high serum prolactin levels in 91 men with RA. A 
large num ber of their patients (n=74) used glucocorticoids and they found that higher cumulative 
glucocorticoid doses were significantly associated with higher prolactin levels [10]. Furthermore, 
in a study in 50 healthy volunteers, Dinan et al. showed that prolactin responses to buspirone were 
correlated with baseline cortisol levels [27]. To exclude a possible influence of glucocorticoids on 
prolactin levels in our study, all patients who used glucocorticoids were excluded.
Thirdly, DMARDs may influence prolactin levels. To our knowledge, the effects of DMARDs on 
prolactin levels have not been studied.
The aim of this study was to compare prolactin levels between patients with RA and healthy 
controls, and investigate whether prolactin levels change after antirheumatic drug treatment. The 
patients were studied before and after the use of the NSAID naproxen, and after additional use of 
a DMARD. We studied basal serum prolactin levels and also performed insulin tolerance tests, a 
standardized form of stress, to assess the prolactin respons to hypoglycaemia induced stress.
w Subjects and Methods  
Subjects
We included 20 patients with recent onset (< 1 year) RA who had active disease, and 20 age and sex 
matched healthy controls. All subjects were aged between 18 and 65 years. All patients fulfilled the 
revised criteria for RA of the American College of Rheumatology [28], and were consecutive patients 
with newly diagnosed RA attending the outpatient clinic, who were willing to participate in the 
study. We included only IgM rheumatoid factor positive patients, in order to avoid inclusion of other
117
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forms of arthritis than rheumatoid arthritis. Active disease was defined by a disease activity score 
(DAS) > 3.5 [29]. Patients had not been treated with a disease modifying antirheumatic drug 
(DMARD) or with oral, intramuscular or intra-articular glucocorticoids. Treatment with nonsteroi­
dal anti-inflammatory drugs (NSAIDs) was discontinued in all patients one week prior to the study. 
The patients with RA were studied at baseline, after 2 weeks and after 6 months. At baseline they 
were without treatment as described above. Thereafter, all patients started treatment with naproxen 
500 mg twice a day and were studied again after 2 weeks. A DMARD was then added to the ther­
apeutic regimen by the rheumatologist in charge of the patient, if indicated. The initial DMARD 
was sulphasalazine which could be switched to methotrexate if necessary. After 6 months of therapy 
the final assessments were done.
Subjects could not be included if they had any condition or medication that is known to influ­
ence blood prolactin levels. Subjects using oral contraceptives were also excluded. Other exclusion 
criteria were anemia (Hb < 6.5 mmol/l), renal or hepatic disorders, and contra-indications for 
undergoing the stress of an insulin tolerance test, such as cardiovascular disorders, hypertension 
and epilepsy. All participants voluntarily signed an informed consent form. The study protocol 
was approved by the hospital's ethical committee.
Methods  
Disease activity
In patients with RA disease activity was assessed with a composite disease activity score (DAS), 
which includes the erythrocyte sedimentation rate (ESR), the Ritchie articular index, the number 
of swollen joints and a visual analogue scale for general well-being [29].
Prolactin levels
Serum prolactin levels were measured under basal conditions and, on separate days, during an 
insulin tolerance test (ITT). Blood was collected at 9:00 AM and 4:00 PM for the determination 
of basal prolactin levels. On the day of the ITT, subjects were fasting and placed in a supine posi­
tion. At 8:30 AM a catheter was inserted in an antecubital vene and kept patent by saline solution. 
After a 30 minute rest, insulin (Actrapid®, Novo-Nordisk, Bagsvaerd, Denmark) was adminis­
tered as a bolus injection at a dose of 0.1 units/kg body weight. Blood samples for measurement 
of glucose and prolactin levels were collected at 0, 20, 30, 45, 60, 90, 120 and 180 minutes after 
injection. During the test, heart rate and bloodpressure were measured using an automatic blood- 
pressure recorder. The test was considered adequate if a glucose level < 2.0 mmol/l was reached. 
If not, the test was repeated with a 50% higher dose of insulin. This occurred in one patient, but 
this patient reached a glucose level < 2.0 mmol/l when the test was repeated.
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All blood samples for measurement of prolactin levels were collected in dry tubes. Blood was cen­
trifuged at 2000 g for 10 minutes and serum was stored at -20 °C until analysis. Serum prolactin 
levels were measured using the Spectria competitive solid-phase RIA from Farmos Diagnostica 
(Turku, Finland) as described earlier [30]. The sensitivity of the assay was 30 mIU/l. The within- and 
between-assay coefficients of variation were 5.8% and 10% at 430 mIU/l and 4.9% and 8.5% at 1200 
mIU/l respectively (Normal range: 100-700 mIU/l).
Statistical analysis
Responses of prolactin to hypoglycemia were integrated over time as area under the response 
curve (AUC) from 0 to 180 minutes. The calculated AUCs are divided by 180 minutes to obtain 
an integrated level of prolactin during the ITT.
The prim ary outcome measure was the integrated serum prolactin level during the ITT. 
Secondary outcomes included unstimulated (basal) serum prolactin levels and levels of prolactin 
at individual time points during the ITT.
Comparisons between healthy controls and patients with RA were made with the unpaired t-test or 
with the Mann-Whitney test if data were not normally ditributed. In patients with RA, the assess­
ments after 2 weeks and after 6 months of treatment were compared with baseline with paired t- 
tests, or with the Wilcoxon signed rank test if data were not normally distributed. All P-values are 
based on 2 tailed tests and considered significant at the 0.05 level.
Spearman correlation coefficients were calculated between baseline DAS and the AUC for prolactin 
and between the change in DAS after 6 months and the change in AUC for prolactin after 6 months.
w Results
The 20 patients with active RA and the 20 healthy controls were matched for age and sex, and 
both groups included 3 men and 17 women. The healthy controls and the patients with RA had 
a mean (SD) age of 47.5 (9.8) years and 49.0 (12.0) years respectively. All 20 patients with RA were 
studied again after 2 weeks treatm ent with naproxen. Subsequently, 1 patient was treated with sys­
temic corticosteroids and 2 patients received no DMARD therapy. These 3 patients did not par­
ticipate in the assessments after 6 months.
Of the 20 woman in the healthy control group, 11 were pre-menopausal and of the 20 women in 
the RA group, 10 were premenopausal.
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Disease activity
Table 1 shows the baseline disease activity and the changes from baseline after 2 weeks and after 
6 months of treatm ent in the patients with recent onset RA. After 2 weeks use of naproxen the 
DAS decreased significantly with a mean value of 0.7 (p=0.0003). The individual components of 
the DAS also showed significant decreases with the exception of the ESR, which remained 
unchanged. After 6 months of additional treatm ent with either sulphasalazine or methotrexate, 
the DAS showed further improvement (mean decrease 1.6 units, p=0.0002 versus baseline). The 
ESR however, again remained unchanged when compared to baseline values.
Prolactin levels
Table 2 summarizes the prolactin levels at baseline and the changes therein after 2 weeks and 6 
months of antirheumatic treatment. At baseline the unstimulated prolactin levels were not dif­
ferent between the RA patients and the healthy controls.
There were no significant differences between the groups in the hypoglycemia nadir that was 
reached during the ITT. The serum prolactin levels during the ITT however, were significantly 
lower in RA patients than in healthy controls between 30 and 90 minutes after the bolus injection 
w ith insulin (figure 1). This resulted also in a significantly lower AUC for prolactin during the ITT 
in RA patients. After 2 weeks treatm ent with naproxen, no significant changes occurred in either 
basal or stimulated serum prolactin levels. After 6 months of antirheumatic drug treatm ent serum 
prolactin levels during the ITT were significantly higher than at baseline between 60 and 120 m in­
utes after the bolus injection with insulin. The AUC for prolactin was also significantly higher at 
6 months compared to baseline.
At baseline, the DAS correlated negatively with the AUC for prolactin (r = -0.58; p=0.008) in 
patient with RA. After 6 months of treatment, the improvement in DAS correlated with the 
change in AUC for prolactin (r=0.48; p=0.05).
w Discussion
In our study, untreated newly diagnosed patients with active RA have basal serum prolactin levels 
that are not different from healthy controls, but their prolactin responses to the stress induced by 
hypoglycaemia are decreased compared with healthy controls. Ideally, we should have measured 
the pre-menopausal women at the same phase of the menstrual cycle at each tim e-point of the 
study, but for practical reasons, this was not possible. Because of the large num ber of patients and 
the similar num ber of pre-menopausal and post-menopausal subjects in each group, we expected 
that this would not influence our results. The fact that we did not find any difference in basal pro­
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lactin levels between the groups, in our view confirms that assumption.
Previous studies of prolactin levels in RA patients have shown contradictory results. As discussed 
before, several explanations may be offered to account for the different results in the literature. 
The possibility that NSAIDs influence prolactin secretion, to us now seems unlikely, as our lon­
gitudinal results indicate that 2 weeks of treatm ent with the NSAID naproxen has no effect on 
either basal or stimulated prolactin levels. However, we are aware that this does not exclude a 
possible effect of other NSAIDs. The possibility of an influence of glucocorticoids on prolactin 
levels was excluded in this study as patients using glucocorticoids were excluded. The effects of 
DMARDs on prolactin levels have not been studied before. In our study prolactin responses to 
hypoglycaemia induced stress increase significantly after 6 months of treatm ent with either sul- 
phasalazine or methotrexate to levels comparable with the healthy controls. We hypothesize that 
this increase in prolactin response after 6 months is related to the considerable decrease in disease 
activity observed at that time point. The significant negative correlation between disease activity 
and prolactin levels that we found at baseline and the significant positive correlation between the 
improvement of the DAS and the increase in prolactin levels after 6 months of treatment, support 
this view. Gobjornssen et al. [14], in a study in 18 patients with active untreated RA, found a 
decreased prolactin response to MRH (multiple releasing hormone) test, but a normalisation of 
the prolactin response after treatm ent with corticosteroid therapy, which supports an impaired 
prolactin response due to inflammatory stimuli, consistent with our hypothesis. The exact mech­
anism by which the prolactin response to stress is decreased in active RA, remains unclear. One 
could speculate, that elevated levels of pro-inflammatory cytokines like IL-6 and IL-1P, which are 
found during active disease in RA, may have an inhibitory effect on prolactin secretion. This is 
supported by a study in rats, that showed that interleukin-ip was able to inhibit prolactin release 
[32]. However, in the litterature, inhibitory as well as stimulatory effects of cytokines on prolactin 
release have been described, and future research will be needed to clarify this issue.
Finally, another possible explanation for the differences in the literature could be the use of dif­
ferent prolactin stimulation tests. Chikanza et al. studied prolactin responses after major surgery, 
a non-standardized stimulus for prolactin release [5]. The increased prolactin responses they 
found could not be reproduced in a similar study [19]. Other investigators have employed 
thyrotropin releasing hormone (TRH) tests [8,9,18,20]. Templ et al.[18] and Gutiérrez et al.[20] 
found normal prolactin responses to TRH, while Jorgensen et al. found increased responses [8,9]. 
ITTs have not been used before to assess prolactin responses in RA patients. Normal or even 
increased prolactin responses to TRH may suggest that the decreased prolactin responses to hypo- 
glycaemia that we observed in untreated patients with RA, may be due to hypothalamic rather 
than pituitary defects in RA patients. This hypothesis should be studied in more detail in future 
investigations.
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To our knowledge, this is the first longitudinal study of prolactin levels in patients with newly 
diagnosed RA. We conclude that prolactin responses to hypoglycaemia are decreased in patients 
w ith active RA. The disturbance may be a consequence of active disease because prolactin 
responses increase towards norm al values when disease activity is reduced after 6 months of 
antirheumatic treatment.
Our data contradict the hypothesis that increased prolactin levels play a role in the pathogenesis 
of RA. Instead, we found decreased prolactin responses to stress in active RA, which may be con­
sidered as part of the norm al anti-inflammatory defense mechanism.
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Table 1 Disease activity: baseline values and changes from baseline after 2 weeks and 6 months of antirheumatic drug therapy
Baseline
(n=20)
Change from baseline
A fte r 2 weeks 
(n=20)
A fte r 6 months 
(n=17)
mean SD mean SD P s mean SD P s
DAS (units) 4.3 0.7 -0.7 0.7 0.0003 -1.6 1.2 0.0002
ESR (mm/hr) 21.6 24.7 3.4 8.1 0.13 2.6 32.2 0.30
RAI (units) 16.7 7.8 -4.3 4.9 0.001 -10.1 6.5 0.0001
Number swollen joints 11.4 6.3 -2.4 5.1 0.02 -4.6 8.1 0.04
VAS general well-being (mm) 52.3 1.9 -12.8 19.1 0.007 -25.1 25.9 0.002
* fo r  comparison w ith  baseline
DAS Diseuse activity score
ESR Erythrocyte sédim entation rate
R A I Ritchie articalar index
VAS Visual analogue scale ( 0 - 1 0 0  m m )
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Chapter 9
T a b le  2 . Basal serum levels of prolactin and integrated AUC of serum prolactin levels during ITT in healthy controls, and in
patients with recent onset RA: baseline and changes from baseline after 2 weeks and 6 months of antirheumatic treat­
ment.
Baseline Change from baseline
Healthy controls 
(n=20)
Rheumatoid a rth ritis  
(n=20)
A fte r 2 weeks 
(n=20)
A fte r 6 months 
(n=17)
mean SD mean SD P s mean SD P ** mean SD P **
Basal prolactin levels (mlU/L) 
9 :0 0  AM 317 169 276 159 >0.2 11 76 > 0 .2 35 120 > 0 .2
4 .0 0  PM 235 129 246 148 >0.2 -12 90 > 0 .2 -33 104 > 0 .2
Prolactin during ITT (m lll/L ): 
A UC/180 minutes " " " 552 287 409 313 0.03 -6 221 > 0 .2 190 413 0.04
+ fo r  the comparison between healthy controls and rheum atoid arthritis patients 
fo r  the comparison w ith baseline in rheum atoid arthritis patients 
AUC: area under the curve
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Fig ure  1 .  Serum prolactin levels during IT T  o f healthy controls, and o f patients with RA a t baseline, after 2 
weeks o f treatment with naproxen, and after 6 months o f additional treatment with a DMARD. * = Significant 
difference between HC and RA patients at baseline: p  < 0.05.
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Prolactin is one of the hormones that play a role in regulating immune function [1]. In humans, 
raised levels of prolactin have been reported in rheumatoid arthritis (RA) [2] and other autoim­
mune rheumatic diseases, although norm al levels were also found [3-5]. Some studies, mostly 
case reports, report beneficial effect of treatm ent with bromocriptine in Reiter's disease [6], 
psoriatic arthritis [7] and RA [8,9]. Our aim was to examine whether a reduction of circulating 
PRL levels may be an effective treatm ent in RA. We used the dopamine-agonist quinagolide 
because it is generally better tolerated than bromocriptine.
Patients were included if they had established RA, with disease activity score (DAS) [10] equal to 
or above 3.5, and had previously been treated with sulfasalazine and methotrexate. The use of 
NSAIDs and prednisone (up to 10 mg daily) in a stable dose during the trial was allowed. The 
patients were treated with quinagolide (Norprolac, Novartis) starting with 25 |igram daily which 
was gradually increased in four weeks to 150 |igram daily. Follow-up consisted of 2-weekly visits 
during the first 4 weeks and after that every 4 weeks for a total of 24 weeks. During each visit effi­
cacy of treatm ent was evaluated by the following: assessment of disease activity by means of the 
DAS, Ritchie articular index (RAI), total number of swollen joints of a 44 joints count (TSW44), 
a visual analogue scale (VAS) for general health, pain and assessment of disease activity by physician. 
A health assessment questionnaire (HAQ) was used to measure functional capacity.
Serum prolactin levels were measured using the Spectria competitive solid-phase RIA from 
Farmos Diagnostica (Turku, Finland) as described earlier [11]. The sensitivity of the assay was 20 
mIU/l. (Normal range: 100-700 mIU/l).
Sample size was determined by applying Gehan's rule [12]. According to this method, a prelimi­
nary sample of n1 patients is treated. If at least one response is observed in this sample, an addi­
tional n2 patients are treated. Sample size n1 is determined by the specified significance level for 
the hypothesis test and n2 represents the num ber of additional patients needed to estimate the 
response rate with required precision, as defined by the standard error. In this trial the primary 
efficacy variable was the response rate which should be 30% or more, and a rejection error of 0.05 
was accepted. To obtain this, a first sample (n1) of 9 patients was needed. If no responders were 
found in the first sample the hypothesis of a response rate of 30% or more could be rejected (with 
a=0.05) and the therapy considered to be ineffective. If there were 1 or more responders a second 
sample of 11-16 patients, depending on the number of responders, should be treated, in order to 
estimate the response rate with a standard error of 10 %. The EULAR criteria for good response
[13] were used to define a responder. Results are expressed as the mean ± standard deviation 
(SD). Statistical comparisons were made with Wilcoxon signed-rank test for paired samples using 
a significance level of p  < 0.05.
Nine patients were included in the study. Their demographic variables are given in table 1. All 
used NSAIDs and five used prednisone 10 mg daily. Eight patients completed the trial. One
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patient stopped treatment after 2 weeks because of exacerbation of disease requiring prescription of 
corticosteroids. Prior to treatment all patients had normal serum prolactin levels (mean 186 ± 104 
mIU/l), decreasing to below detection level (20 mIU/l) within 4 weeks after beginning of treatment. 
According to EULAR criteria there were no good responders to the treatment. Thus, applying 
Gehan's rule, treatment of a second group of patients was not required and we can conclude that 
treatm ent with quinagolide as a single drug is ineffective in RA. No significant changes in 
individual parameters were observed as shown in table 2, although a tendency of gradual im pro­
vement was seen in RAI, VAS for general health and VAS for assessment of disease activity by 
physician. There were two patients who fullfilled the EULAR criteria for moderate response; this 
mainly depended on improvement of subjective parameters, but not on improvement of biological 
variables like ESR and CRP.
No serious side effects occurred. Seven patients experienced mild dizziness or nausea in the 
beginning of treatment but this did not last longer than 2 weeks, except in 2 patients in whom 
reduction of medication was neccesary because of persisting nausea.
There are several possibilities to be considered which may explain our results: maybe prolactin 
does not play a role in RA after all, which is supported by the fact that none of the patients in this 
study had elevated prolactin levels before treatment. However, reducing normal levels of prolactin 
could still be beneficial in arthritis as it was shown in animal studies that norm al levels were 
necessary to induce autoimmune arthritis. Maybe prolactin is im portant in RA but lowering 
prolactin levels in already established RA is insufficient to improve disease activity. The few studies 
available reporting about treatm ent of RA with bromocriptine [8,9,14,15] are contradictory and 
there is no larger study available. It may also be possible that bromocriptine is effective in arthritis 
through another mechanism than through lowering prolactin levels and influences the immune 
response in a different way, which quinagolide does not.
From the present results we conclude that lowering prolactin levels with quinagolide as a single 
drug is not suitable as treatm ent of RA. Since it has minimal side effects, it may still be considered 
in combination with other DMARDs. This report emphasizes the necessity of further establishing 
the role of prolactin in the pathogenesis of RA.
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Tabel 1 .  D e m o g ra p h ic  f e a t u r e s  of the  p a t ie n ts
n=9
Age [years] 61 [41 -73 ]
Males : females 4 : 5
reumatoid fac to r positive 7
disease duration [years] 9 .7 [3 .8 -21 .0 ]
DAS 5 .8 5  (0 .93)
NSAIDs 9
prednisone 5
Values are Mean [range] or Mean (SD) or 
tis. DAS = disease activity score. NSAIDs =
number of patients or drugs. RA = rheumatoid arthri- 
nonsteroidal antiinflammatory drugs.
Ta b le 2 .  Values of disease parameters before and after therapy
baseline 24 weeks p-value
RAI 29  (11) 22 (11) 0 .0 8
VAS GH 71 (15) 47 (21) 0 .07
VAS phys 73  (13) 54 (17) 0 .07
VAS pain 68  (17) 52 (18) 0.21
ESR 27 (21) 28 (19) 0.61
CRP 58 (61) 42  (44) 0.61
TSW 44 23  (10) 24 (9) 0 .7 5
HAQ 1.78  (0.34) 1.61 (0 .52) 0 .1 6
DAS 5 .8 5  (0.93) 5 .3 2  (0 .85) 0 .2 6
Values are Mean (SD). RAI = Ritchie articular index. VAS GH, VAS phys and VAS pain = a 100­
mm visual analogue scale for general health, assessment of overall disease activity by physician and 
pain experienced by the patient respectively. ESR = erythrocyte sedimentation rate, CRP = C-reac­
tive protein, TSW44 = total number of swollen joints of a 44 joints count, HAQ = health assess­
ment questionnaire, DAS = disease activity score.
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Rheumatoid arthritis (RA) is a chronic auto-immune disease, characterised by a symmetric, 
chronic polyarthritis. Despite increased knowledge about the inflammatory process, the etiology 
of RA is still unknown. Neuroendocrine abnormalities may play a role in the pathogenesis of RA. 
The hypothalamic-pituitary-adrenal axis plays an important role in regulating and controling 
immune responses, and indications for dysfunction of this axis in chronic arthritis have been 
found in research in animals and in humans. For example, the susceptibility of Lewis rats for 
streptococcal cell wall arthritis depends on a hypothalamic abnormality that is associated with 
a deficient cortisol response. In patients with RA, Chikanza et al. found decreased cortisol 
responses to stress associated with major surgery [Arthritis Rheum 1992;35:1281-8]. In the same 
patients, they also found increased prolactin secretion [Br J Rheumatol 1993;32:445-8]. 
Evidence for a role of this hormone in the immune response was found in studies in which it was 
shown that treatment with prolactin restored the immunocompetence of hypophysectomized 
rats and made them susceptible to the development of adjuvant arthritis. In RA, a characteristic 
feature is exacerbation of the disease in the post partum period, particularly when the mother 
breast feeds, which has been related to the high levels of prolactin in that period.
Since the discovery of cytokines, insight into the bilateral communication between the endocrine 
and the immune system has grown, and it has been discovered that the HPA-axis can be activat­
ed by cytokines, in particular interleukin (IL)-ip, IL-6 and tum or necrosis factor (TNF)-a.
In this thesis several studies are described that evaluate the role of the HPA-axis and prolactin in 
RA. Furthermore, in some of the studies, the possible significance of the cytokines IL-ip, TNFa 
and IL-6 was examined.
w Summary
In chapter 1 a general introduction to the thesis is given.
We re-examined cortisol responses to stress associated with major surgery in a study that for the 
greater part was identical to the study reported by Chikanza et al. The results are described in 
chapter 2  of this thesis. We studied 9 patients with RA and 10 patients with osteoarthritis (OA) 
before and after knee or hip replacement. Plasma ACTH and cortisol levels and serum prolactin 
levels were determined immediately before surgery and on the following 4 days. We found that 
cortisol levels before surgery were not significantly different between RA and OA patients and 
were within the normal range. After surgery no significant changes of cortisol levels occurred. 
ACTH before surgery was in the norm al range and showed a comparable decrease the day after 
surgery in both groups and returned to baseline values in the following days. Prolactin before sur-
gery was in the normal range in both groups and did not differ between the groups. After surgery 
no change in prolactin levels was observed. So, in contrast to the study by Chikanza et al. we 
found no differences between RA and OA patients in cortisol, ACTH and prolactin levels before 
and after major surgery.
A review of the possible role of the hypothalamic-pituitary-adrenal (HPA) axis in RA is present­
ed in chapter 3 of this thesis.
We studied HPA-axis activity in a large group of patients with RA. The results are described in 
chapter 4  of this thesis. Three groups of patients with RA participated in this study: recent onset 
active RA (n=20), longstanding active RA (n=20) and longstanding RA in remission (n=10). The 
results were compared with those obtained in 20 healthy controls. The activity of the HPA-axis 
was assessed under basal conditions and in response to hypoglycaemia-induced stress (insulin 
tolerance test, ITT). In addition, the patients with recent onset RA underwent a corticotropin 
releasing hormone (CRH) test and a dexamethasone suppression test. Plasma levels of interleukin 
(IL)-ip, tum or necrosis factor-a (TNFa) and IL-6 were also measured. We did not find any dif­
ferences in basal plasma, salivary and urinary cortisol levels, plasma cortisol binding globulin lev­
els and plasma adrenocorticotropic hormone (ACTH) levels between patients with RA and 
healthy controls. During the ITT, cortisol levels were consistently lower in RA patients than in 
healthy controls. Compared with the healthy controls the area under the cortisol curve was lower 
in patients with recent onset RA (p=0.07), in patients with longstanding active RA (p=0.01), in 
patients with longstanding RA in remisson (p=0.01) and in the combined RA groups (p=0.005). 
The maximal rise in cortisol during the ITT however, was not different between RA patients and 
healthy controls. ACTH levels during the ITT were not different between patients with RA and 
healthy controls. ACTH and cortisol responses to CRH were assessed only in patients with recent 
onset RA and were found to be within norm al limits. Basal plasma IL-6 levels were significantly 
higher in patients with active RA than in the other groups. Plasma levels of IL-ip and TN Fa did 
not differ between the groups. We conclude that, under the standardized conditions of the ITT, 
patients with RA have decreased plasma cortisol levels compared to healthy controls. This occurs 
both in patients with RA in remission and in patients with active RA, despite elevated levels of IL- 
6. We hypothesize that the defect is located at the adrenal level and that it may be of pathogenet­
ic significance for the development of chronic arthritis.
The effects of antirheumatic treatment on HPA-axis activity have been examined separately, and the 
results of these studies are described in chapter 5 of this thesis. Twenty patients with recent onset 
active RA were studied before antirheumatic treatment, after 2 weeks of naproxen (500 mg bid)
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treatm ent and after 6 months of additional treatm ent with sulphasalazine or methotrexate. 
Twenty age- and sex-matched healthy controls were studied once. The activity of the HPA-axis 
was assessed both under basal conditions and after insulin-induced hypoglycaemia. The primary 
outcome measure was the mean integrated plasma cortisol level during the ITT. Secondary out­
comes included unstimulated plasma, salivary and urinary cortisol, plasma ACTH and cytokine 
levels, plasma levels of ACTH and cortisol at individual time points during the ITT, the maximal 
rise of plasma ACTH and cortisol in response to hypoglycaemia, and the mean integrated plasma 
ACTH level during the ITT. Before treatment, patients with RA tended to have higher basal ACTH 
levels than healthy controls (p=0.10). Basal plasma, salivary and urinary cortisol levels and plas­
ma cortisol binding globulin levels were not different between patients with RA and healthy con­
trols. The ACTH response to hypoglycaemia was not different between patients with RA and 
healthy controls. The mean integrated cortisol level however tended to be lower in RA-patients 
(p=0.07). After 2 weeks of treatm ent with naproxen, basal plasma and salivary cortisol levels and 
plasma cortisol binding globulin levels were unchanged, whereas urinary cortisol excretion 
decreased significantly in comparison to the pre-treatment period (p=0.03). The rise in plasma 
ACTH levels in response to hypoglycaemia was unchanged, but the mean integrated plasma cor­
tisol level during the ITT was significantly lower than in the pre-treatment period (p=0.015). 
After 6 months of additional treatment with either sulphasalazine or methotrexate these changes 
were reversed. Our results suggest that non-steroidal anti-inflammatory drugs suppress the HPA- 
axis at the adrenal level in the first weeks of treatment. After 6 months this suppressive effect is 
no longer present, suggesting the existence of adaptive mechanisms of the HPA-axis.
The effects of treatm ent with naproxen on the activity of the HPA-axis were also studied in 
healthy volunteers. The results are described in chapter 6 of this thesis. We performed a double 
blind, randomized study in two groups of 20 healthy volunteers. The activity of the HPA-axis was 
measured before and after the subjects used naproxen or placebo during a period of two weeks. 
Plasma ACTH and cortisol were measured under basal conditions and during a bicycle ergome- 
try test with submaximal physical exercise. Preceeding these measurements, a maximal exercise 
test was performed in order to determine the maximal capacity of each individual necessary for 
calculating the submaximal load at 80% of their maximal reached power. There were no signifi­
cant differences between the groups in basal plasma ACTH and cortisol levels, 24 hrs urinary cor­
tisol excretion and circadian cortisol rhythm measured in salivary samples. The maximal reached 
power during the bicycle ergometry test was similar in both groups and during submaximal exer­
cise a significant rise in plasma ACTH and cortisol levels was seen in both  groups. After the use 
of placebo or naproxen for two weeks, no significant change in any of these parameters occurred, 
and we found no significant differences in these parameters between the two groups. We there­
fore conclude that naproxen does not influence the activity of the HPA-axis in healthy volunteers 
under basal conditions nor in response to physical stress.
Recently tum or necrosis factor-a (TNFa) blocking agents have been introduced in the treatment 
of RA. Because TN Fa is a potent stimulator of the HPA-axis we studied the effects of TN Fa 
blocking agents on basal cortisol and ACTH levels. The results are described in chapter 7  of this 
thesis. Eighteen patients with active RA were studied before and after an intra-venous injection 
with a TN Fa neutralizing agent (n=13) or placebo (n=5). Before the first injection with anti- 
TN Fa or placebo, and on the day after the injection, plasma ACTH, plasma cortisol and ESR were 
determined. Before and on the first day after the injection, 24 hrs urinary cortisol excretion was 
measured, circadian cortisol rhythm was evaluated using cortisol determinations in salivary sam­
ples, and a composite disease activity score (DAS) was determined. The DAS significantly 
improved in the group of patients treated with anti-TN Fa (mean decrease of DAS ± SD: 0.64 ±
0.46, P=0.0007), but not in the placebo group (0.09 ± 0.35). In the treatm ent group, no changes 
were observed in plasma ACTH and plasma cortisol when comparing hormone levels before and 
after injection. Neither were there significant changes in 24 hrs urinary cortisol excretion or in the 
circadian cortisol rhythm. We conclude that the rapid clinical improvement after treatm ent with 
TN Fa neutralizing agents is not associated with changes in activity of the HPA-axis.
The second part of this thesis involves the possible role of prolactin in RA. In chapter 8 , the liter­
ature regarding the significance of prolactin in RA is reviewed.
In chapter 9 , the results are described of a study in 20 patients with RA. Serum prolactin levels 
were assessed under basal conditions and after hypoglycaemia-induced stress in 20 untreated 
patients with recently diagnosed RA. They were reassessed after 2 weeks treatm ent w ith naprox­
en and 6 months further treatment with either sulphasalazine or methotrexate. Disease activity 
was also assessed. Patients were compared to age- and sex-matched healthy controls. Basal levels 
of prolactin were not different between patients w ith RA and healthy controls. Prolactin respons­
es to hypoglycaemia were lower in untreated patients with RA than in healthy controls. Treatment 
with naproxen for 2 weeks did not influence basal or stimulated prolactin levels. After 6 months 
of antirheumatic treatm ent prolactin responses to hypoglycaemia increased significantly to levels 
observed in healthy controls. At the same time point disease activity had improved considerably. 
We conclude that patients with active untreated RA have decreased prolactin responses to hypo- 
glycaemia and that these responses are restored following treatm ent with antirheumatic drugs.
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If prolactin plays a role in the pathogenesis of RA, therapies aimed at reduction of prolactin lev­
els could contribute to control of disease activity. We therefore performed an open study of the 
antirheumatic effects of quinagolide, a dopamine-agonist. The results are described in chapter 10 
of this thesis. Nine patients with active RA were treated with quinagolide for 24 weeks. Five of 
them used prednisone in a stable dose and all used NSAIDs. Eight patients completed the study. 
One patient stopped treatm ent after 2 weeks because of exacerbation of disease requiring addi­
tional treatm ent with corticosteroids. Prolactin levels decreased to below the detection level w ith­
in 4 weeks after start of treatm ent in all patients. A composite disease activity score (DAS) did not 
improve significantly, and there were no good responders to the treatm ent according to EULAR 
response criteria. For individual variables no significant changes were observed either, although a 
tendency towards improvement was seen in Ritchie articular index, visual analogue scale (VAS) 
for general health and VAS for assessment of disease activity by physician. No improvement was 
seen in ESR, CRP, swollen joint count and health assessment questionnaire. We conclude that 
treatm ent with quinagolide as a single drug is not effective in RA.
w General discussion
In recent years convincing evidence has accumulated to suggest that a bilateral communication 
exists between the endocrine and the immune system. Research in animals and in humans sug­
gested that neuro-endocrine disturbances - in particular a decreased HPA-axis response and 
excessive prolactin secretion - could play a pathogenetic role in RA. If these hormonal abnor­
malities play a role in the development of RA, this could have therapeutic consequences.
In this thesis we have studied whether these horm onal abnormalities indeed exist in patients with 
RA, and if so whether they play a role in the pathogenesis of RA, or are merely the result of hav­
ing a chronic inflammatory disease, or the result of the use of antiinflammatory drugs. In our 
view, these issues had not been addressed appropriately in the literature.
The HPA-axis in RA
We did not find decreased cortisol levels in patients with RA before and after major surgery in 
comparison with osteoarthritis patients, as was described by others. However, one can still argue 
that normal cortisol levels in active RA are inappropriately low for the degree of inflammation. 
This issue cannot be solved by the results of the studies described in this thesis. In order to answer 
this question studies of cortisol levels in patients with other chronic inflammatory diseases should 
be performed. Chikanza et al. studied 10 patients with chronic osteomyelitis (OM) and found ele­
vated cortisol levels in these patients before and after major surgery, compared with patiens with
RA and OA. However, the RA and OA patients used NSAIDs, where the OM patients did not, 
which means that the difference might also be attributed to the NSAID use. Furthermore, in 
chronic osteomyelitis the nature of inflammation, caused by bacteriae, is different from that of an 
auto-immune disease and might have a different effect on cytokine release and activation of the 
HPA-axis. A study in patients with another chronic inflammatory disease without infection, like 
M.Crohn or ulcerative colitis, proved to be almost impossible, because in active disease all 
patients are treated with oral corticosteroids, or corticosteroid containing enemas, which also 
have systemic effects. Withholding their anti-inflammatory treatm ent augments their risk of seri­
ous complications, so for ethical reasons we could not performing such a study.
In a large study with 3 groups of RA patients (recent onset active disease n=20, longstanding 
active disease n=20, and longstanding disease in remission n=10) who were not using antiin­
flammatory medication, we did not find decreased activity of the HPA-axis under basal circum­
stances. The RA patients had values of ACTH and cortisol comparable to healthy volunteers. 
However, in response to insulin-induced hypoglycaemia (ITT), a standardized form of stress, 
lower plasma cortisol levels were consistently found in all 3 groups of RA patients when compared 
to healthy controls, both before and after hypoglycaemia. The maximal rise in cortisol after 
insulin administration was not different between the groups and the cortisol response curves of 
RA patients were similar in shape compared with the healthy controls. Therefore, patients with 
RA reacted to hypoglycaemia w ith a rapid and adequate increase in cortisol levels. However, due 
to lower basal levels they attained lower peak levels. In our opinion the cortisol levels before hypo- 
glycaemia reflect basal horm onal activity better than the other basal assessments, as the blood 
samplings were done after 30 minutes rest in a supine position after insertion of an intravenous 
catheter. ACTH levels before and during the ITT were not significantly different compared to 
healthy controls. After stimulation with CRH all 20 patients with recent onset active RA showed 
an increase of ACTH levels followed by an increase in cortisol levels in the norm al range of our 
laboratory. The differences in total plasma cortisol levels between RA patients and healthy con­
trols can not be attributed to differences in cortisol binding globulin (CBG) levels because the 
mean CBG levels were similar between RA patients and controls.
We observed increased plasma levels of IL-6 in patients with active RA and norm al levels in 
patients with longstanding RA in remission. Decreased plasma cortisol levels were found during 
the ITT both in RA in remission and in active RA. Apparently, elevated plasma IL-6 levels could 
not fully stimulate the HPA-axis in patients with active RA. Whether this contributes to the devel­
opment of chronic arthritis (since glucocorticoids inhibit inflammatory processes) remains to be 
elucidated.
Our findings indicate a reduced HPA-axis responsiveness in untreated patients with RA when 
compared to healthy controls. The norm al ACTH levels that we found do not support the hypoth­
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esis in the literature that hypothalamic function in RA is significantly defective, and we conclude 
that the defect is most likely located at the adrenal level. Reduced HPA-axis responsiveness may 
contribute to the pathogenesis of the disease, but may also be the result of adaptive mechanisms 
to a chronic inflammatory state. Further research is needed to elucidate the HPA-axis responsiv- 
ity in other chronic inflammatory diseases.
The ef fec t  of an t i i n f l am m ato ry  medicat ion on the HPA-axis
After 2 weeks treatm ent with naproxen, of patients with recent onset RA, basal ACTH levels and 
ACTH levels during the ITT were unchanged, but urinary cortisol excretion decreased signifi­
cantly in comparison to the pre-treatm ent period, and the mean integrated plasma cortisol level 
during the ITT was significantly lower than in the pre-treatm ent period. The maximal rise in cor­
tisol after hypoglycaemia tended to be decreased in comparison with the pre-treatm ent period 
and plasma cortisol levels were significantly lower after, but not before hypoglycaemia. After 6 
months of additional treatm ent with either sulphasalazine or methotrexate these changes were 
reversed. Our results suggest that non-steroidal anti-inflammatory drugs suppress the HPA-axis 
at the adrenal level in the first weeks of treatment. After 6 months this suppressive effect is no 
longer present, suggesting the existence of adaptive mechanisms.
In healthy volunteers, 2 weeks of treatm ent with naproxen did not influence the activity of the 
HPA-axis. This suggests that the lower cortisol levels which we found after the use of naproxen in 
RA patients, are not the result of a direct effect of NSAIDs on the activity of the HPA-axis. An 
indirect effect of the use of NSAIDs on the HPA-axis through reduction of inflammation and/or 
pain, resulting in lower cortisol levels, remains a possibility.
Prolact in
We have measured prolactin levels in 9 patients with RA in the major surgery study, in 20 patients 
with recent onset RA, 20 with longstanding active RA, and 10 with longstanding RA in remission, 
and in 9 with active disease in the quinagolide study. In total 68 patients with RA were studied, 
and in none of the study groups we found elevated prolactin levels. We therefore conclude that 
there is no excessive prolactin secretion in RA.
In view of the proinflammatory properties of prolactin and its role in the immune response, one 
could still argue that suppression of norm al prolactin secretion might improve disease activity in 
RA. However, treatm ent with quinagolide in 9 patients w ith RA, despite decreasing prolactin lev­
els below the detection levels, did not improve disease activity. We conclude that therapy aimed 
at reducing prolactin secretion is not effective in RA.
In patients with untreated newly diagnosed RA, we found basal serum prolactin levels that did 
not differ from healthy controls but significantly lower AUCs of prolactin levels in response to the
stress induced by hypoglycaemia (ITT). This reduced prolactin response to stress was unchanged 
after 2 weeks of treatm ent with naproxen, but restored following treatm ent with antirheumatic 
drugs. A significant negative correlation between disease activity and AUC of prolactin levels dur­
ing the ITT was found at baseline as well as a significant positive correlation between the 
improvement of the DAS and the increase in AUC of prolactin levels after 6 months of treatment. 
This indicates that the prolactin response to stress may be related to disease activity. However, 
other possible explanations like an effect of antirheumatic drugs, can not be excluded, and future 
research will be needed to address this issue.
w Conclusions
1. Patients with RA have norm al basal activity of the HPA-axis, comparable to healthy volun­
teers. However, normal basal cortisol levels in active RA may in fact be abnormal, i.e. inap­
propriate levels for the degree of inflammation.
2. In response to hypoglycaemia-induced stress, untreated RA patients have norm al ACTH, 
but reduced cortisol plasma levels, despite increased levels of IL-6, compatible with a defect 
most likely located at the adrenal level. Whether this contributes to the development of 
chronic arthritis, remains to be elucidated.
3. After 2 weeks of treatm ent w ith naproxen, HPA-axis activity at the adrenal level is decreased 
in patients with untreated recent onset RA. After 6 months this suppressive effect is no 
longer present, suggesting the existence of adaptive mechanisms.
4. After 2 weeks of treatm ent with naproxen, no change in HPA-axis activity appears in healthy 
volunteers, indicating that naproxen does not influence the HPA-axis directly.
5. Patients with RA do not have an excessive secretion of prolactin.
6. Suppression of prolactin secretion does not improve disease activity in patients w ith RA.
w Future research
Although this thesis answers some of the questions addressed, many issues related to the subject 
remain unanswered and new questions have arisen. For better interpretation of studies of the 
HPA-axis in RA patients, studies addressing the reactions o f the HPA-axis and cytokines in other 
chronic inflammatory diseases are needed, although difficult to perform. The effect of 
antirheumatic treatment, including anti-TNF treatment, on the HPA-axis should be studied 
more extensively, and for longer periods, and different NSAIDs should be studied.
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Although we found no excessive prolactin secretion in RA, and no improvement of disease activ­
ity after suppression of prolactin secretion, this hormone remains an interesting peptide playing 
a still incompletely understood role in the imm une response. The reduced prolactin response to 
hypoglycaemia-induced stress that we found in patients with active RA is an interesting finding 
and not described before in the literature. Future research will be needed to explain the signifi­
cance of this finding, to determinine whether it is specific for RA, or whether it also occurs in 
other inflammatory diseases, and whether anti-rheumatic treatment influences this response.
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Reumatoide artritis (RA) is een auto-immuunziekte, gekenmerkt door een symmetrische, chro­
nische polyartritis. Ondanks toegenomen kennis over het ontstekingsproces, is de etiologie van 
RA nog niet opgehelderd. Neuro-endocriene stoornissen spelen mogelijk een rol bij de pathoge­
nese van RA.
De hypothalamus-hypofyse-bijnier as (HPA-as) speelt een belangrijke rol bij de regulatie en con­
trole van immunologische reacties en er zijn aanwijzingen gevonden voor dysfunctie van de HPA- 
as in chronische artritis bij proefdieronderzoek en bij studies in mensen. Een voorbeeld hiervan 
is de bevinding, dat de gevoeligheid van Lewis ratten voor het ontwikkelen van een experimente­
le vorm van artitis (streprococcal cell wall arthritis) afhankelijk is van een afWijking in de hypo­
thalamus die geassociëerd is met een deficiënte cortisol response. Chikanza et al., vonden bij pati­
ënten met RA een verminderde reactie van cortisol op stress na een grote chirurgische ingreep. 
[Artritis Rheum 1992;35:1281-8]. Bij dezelfde patiënten vonden zij een verhoogde prolactine 
secretie [Br J Rheumatol 1993;32:445-8].
Een rol van dit horm oon in de im m uun respons werd aangetoond door studies, waarin werd 
geconstateerd dat door behandeling m et prolactine de verminderde immunocompetentie van 
ratten ten gevolge van hypofysectomie herstelde, waardoor ze vatbaar werden voor het ontwikke­
len van een experimentele vorm van artritis (adjuvant arthritis). Kenmerkend voor RA is exacer- 
batie van de ziekte in de post partum  periode, met name als borstvoeding wordt gegeven, hetgeen 
wel wordt toegeschreven aan de hoge prolactine spiegels in die periode.
Sinds de ontdekking van cytokinen, is het inzicht in de bilaterale communicatie tussen het endo­
criene en immuunsysteem gegroeid en men heeft ontdekt, dat de HPA-as geactiveerd kan worden 
door cytokinen, met name interleukine (IL)-1 P, IL-6 en tum or necrosis factor (TNF)a.
In dit proefschrift worden een aantal onderzoeken beschreven die de rol van de HPA-as en van 
prolactine evalueren in RA. In enkele van deze studies wordt ook de mogelijke betekenis van de 
cytokinen IL-1P, IL-6 en TN Fa bestudeerd.
In hoofdstuk  1 wordt een algemene inleiding op het proefschrift gegeven.
De cortisol respons op stress veroorzaakt door een grote chirurgische ingreep werd bestudeerd in 
een onderzoek dat grotendeels identiek was aan de studie door Chikanza et al. De resultaten hier­
van worden beschreven in hoofdstuk 2. Er werden 9 patiënten met RA en 10 patiënten m et atrose 
(OA) bestudeerd, vóór en na plaatsing van een totale knie- of heupprothese. Plasma ACTH en 
cortisol spiegels en serum prolactine spiegels werden bepaald direct vóór operatie en op de vier 
daaropvolgende dagen. Er werd geen significant verschil gevonden in cortisol spiegels tussen RA
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w Samenvatting
en OA patiënten en de gevonden waarden bevonden zich in de normale range. Na chirurgie wer­
den geen significante veranderingen in cortisol spiegels gevonden. ACTH spiegels bevonden zich 
vóór chirurgie binnen de normale range en vertoonden in beide groepen een vergelijkbare daling 
op de eerste dag na chirurgie, met een geleidelijke terugkeer naar de uitgangswaarde in de dagen 
daarna. Prolactine spiegels vóór chirurgie bevonden zich in beide groepen in de normale range en 
vertoonden geen significant verschil tussen de groepen. Na chirurgie werden geen veranderingen 
in prolactinespiegels gevonden. In tegenstelling tot Chikanza et al., vonden we dus geen verschil­
len tussen RA en OA patiënten in ACTH-, cortisol- en prolactine spiegels vóór en na een grote 
chirurgische ingreep.
In hoofdstuk 3 wordt een overzicht gegeven van de literatuur betreffende de mogelijke rol van de 
HPA-as bij RA.
In een grote groep patiënten met RA bestudeerden we de activiteit van de HPA-as. De resultaten 
worden beschreven in hoofdstuk 4 van dit proefschrift. Drie groepen patiënten met RA namen deel 
aan het onderzoek: recente, actieve RA (n=20), langbestaande actieve RA (n=20) en langbestaan- 
de RA in remissie (n=10). De resultaten werden vergeleken met die van 20 gezonde vrijwilligers. 
De activiteit van de HPA-as werd gemeten onder basale omstandigheden en in reactie op hypogly- 
cemie-geïnduceerde stress (insuline tolerantie test, ITT). Tevens werden de plasma spiegels van de 
cytokinen IL-1P, IL-6 en TN Fa gemeten. De patienten met recente RA ondergingen bovendien een 
corticotrophin releasing hormone (CRH) test en een dexamethason suppressie test.
We vonden geen verschillen in basale waarden van cortisol in plasma, speeksel en urine, spiegels 
van cortisol binding globuline en plasma ACTH tussen patiënten met RA en OA. Tijdens de ITT, 
hadden de RA patiënten consistent lagere cortisol spiegels dan de gezonden. In vergelijking met 
de gezonde vrijwilligers was de aerea under de curve voor cortisol lager bij patiënten met RA. De 
maximale cortisolstijging tijdens de ITT was echter niet significant verschillend tussen deze groe­
pen. ACTH en cortisol reacties op CRH werden alleen gemeten in de patiënten met recente RA 
en vertoonden normale waarden. De basale plasma IL-6 spiegels waren hoger in actieve RA dan 
in gezonden. De plasma spiegels van IL-1P en TN Fa vertoonden geen verschillen tussen de groe­
pen. We concluderen dat, onder de standaard condities van de ITT, patiënten met RA lagere cort­
isol spiegels hebben dan gezonden. Dit treedt zowel op bij actieve RA als bij RA in remissie, 
ondanks verhoogde spiegels van IL-6. Dit zou kunnen wijzen op een defect gelocaliseerd op bij­
nier niveau, hetgeen van betekenis zou kunnen zijn bij de pathogenese van RA.
De effecten van antireumatische therapie werden apart bestudeerd en de resultaten hiervan wor­
den beschreven in hoofdstuk 5. Twintig patiënten m et recente, actieve RA werden bestudeerd vóór
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behandeling, na 2 weken behandeling met naproxen (2 dd 500 mg.) en na 6 maanden aanvullen­
de behandeling met sulphasalazine of metotrexaat. Twintig gezonde vrijwilligers werden 1 maal 
gemeten. De activiteit van de HPA-as werd bepaald onder basale omstandigheden en in reactie op 
hypoglycemie-geïnduceerde stress. De primaire uitkomstmaat was de gemiddelde geïntegreerde 
cortisol spiegel tijdens de ITT. Secundaire uitkomstmaten waren basale waarden van plasma, 
speeksel en urine cortisol, plasma ACTH en cytokine spiegels, plasma spiegels van ACTH en cor­
tisol op individuele tijdstippen tijdens de ITT, de maximale stijging van ACTH en cortisol tijdens 
de ITT en de gemiddelde geïntegreerde ACTH-spiegel tijdens de ITT.
Vóór behandeling was er een trend naar hogere basale ACTH waarden in RA dan in gezonden. Er 
was geen verschil in basale spiegels van cortisol in plasma, speeksel en urine en cortisol binding 
globuline tussen RA en gezonden. Ook werd er geen verschil gevonden in de ACTH reactie tijdens 
de ITT tussen de groepen. Er werd wel een iets lagere gemiddelde geïntegreerde cortisol waarde 
gevonden in RA dan in gezonden (p=0.07). Na twee weken behandeling met naproxen, waren de 
basale waarden van plasma cortisol, speeksel cortisol en plasma cortisol binding globuline onver­
anderd, maar was er een significante daling van cortisol in 24 uurs urine vergeleken met de 
waarde vóór naproxen (p=0,03). De ACTH reactie op hypoglycemie was niet verschillend tussen 
RA en gezonden, maar de gemiddelde geïntegreerde cortisol spiegel tijdens ITT was significant 
lager dan vóór naproxen (p=0,015). Na 6 maanden aanvullende behandeling met sulfasalazine of 
metotrexaat werden deze veranderingen niet meer gezien en waren de waarden vergelijkbaar met 
de waarden vóór behandeling. Deze resultaten suggereren dat behandeling met NSAIDs de HPA- 
as activiteit onderdrukt op bijnier niveau in de eerste weken van behandeling. Na 6 maanden is 
dit effect verdwenen, hetgeen suggestief is voor adaptatiemechanismen van de HPA-as.
De effecten van behandeling met naproxen op de activiteit van de HPA-as werden vervolgens 
bestudeerd in gezonde vrijwilligers. De resultaten hiervan worden beschreven in hoofdstuk 6. Het 
betrof een dubbelblind, gerandomiseerd onderzoek bij 2 groepen gezonde vrijwilligers. De acti­
viteit van de HPA-as werd bepaald vóór en na het gebruik van naproxen of een placebo geduren­
de 2 weken. Plasma ACTH en cortisol spiegels werden bepaald onder basale omstandigheden en 
gedurende een fiets ergometrie test met submaximale inspanning. Voorafgaand aan deze m etin­
gen, werd een maximale inspanningstest uitgevoerd om de maximale capaciteit van ieder indivi­
du te bepalen, waaruit de submaximale belasting van 80% van het bereikte maximum van de 
betreffende persoon kon worden berekend. Er waren geen significante verschillen tussen de groe­
pen in basale plasma ACTH en cortisol spiegels, 24 uurs urine cortisol excretie en circadiaan cor­
tisol ritme gemeten in speekselmonsters. De maximale inspanning die werd bereikt tijdens de 
ergometrietest was gelijk in beide groepen en in beide groepen werd een significante stijging 
gezien van plasma ACTH en cortisol spiegels tijdens de submaximale inspanningstest. Na het
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gebruik van naproxen of placebo gedurende 2 weken traden er geen significante veranderingen 
op in de genoemde parameters en we vonden geen significante verschillen tussen de beide groe­
pen in deze parameters. We concluderen hieruit dat naproxen geen invloed heeft op de activiteit 
van de HPA-as in gezonde vrijwilligers onder basale omstandigheden en in reactie op fysieke 
inspanning.
In de afgelopen jaren zijn tum or necrosis factor-a (TNFa) blokkerende middelen geïntroduceerd 
als behandeling van RA. Aangezien TN Fa een krachtige stimulator is van de HPA-as bestudeer­
den we de effecten van TN Fa blokkerende middelen op basale ACTH en cortisol spiegels. De 
resultaten worden beschreven in hoofdstuk 7. 18 patiënten werden bestudeerd vóór en na een 
intraveneuze injectie met een TN Fa blokkerend middel (n=13) of placebo (n=5). Vóór de injec­
tie en op de eerste dag erna, werden plasma ACTH, plasma cortisol en BSE bepaald. Tevens werd 
op deze dagen de cortisol excretie in 24 uurs urine bepaald, het circadiaan cortisol ritme in speek­
sel monsters gemeten en werd een samengestelde ziekteactiviteitsscore (DAS) bepaald. De DAS 
verbeterde significant in de groep patiënten met anti-TN Fa (gemiddelde daling DAS ± SD: 0,64 
± 0,46, P=0,0007), maar niet in de placebo groep (0,09 ± 0,35). In de anti-TNF groep werden geen 
veranderingen gevonden tussen plasma ACTH en plasma cortisol spiegels vóór en na injectie. 
Ook waren er geen veranderingen in de cortisol excretie in 24 uurs urine of het circadiaan cort­
isol ritme in speeksel monsters. We concluderen dat de snelle klinische verbetering die word 
gezien na behandeling met TN Fa blokkerende middelen niet berust op een veranderde activiteit 
van de HPA-as.
Het tweede deel van dit proefschrift is gericht op de mogelijke rol van prolactine bij RA. In hoofd­
stu k  8  wordt de literatuur betreffende prolactine bij RA besproken.
In hoofdstuk 9  worden de resultaten beschreven van een studie bij 20 patiënten m et RA. Serum 
prolactine spiegels werden bepaald onder basale omstandigheden en in reactie op hypoglycemie 
geïnduceerde stress in 20 onbehandelde patiënten met recente, actieve RA. Deze patiënten wer­
den opnieuw geëvalueerd na 2 weken behandeling m et naproxen and na 6 maanden aanvullende 
behandeling met sulphasalazine of methotrexaat. Tevens werd de ziekteactiviteit bepaald. De 
patienten werden vergeleken met voor leeftijd en geslacht gematchte gezonde vrijwilligers. De 
serum prolactine spiegels onder basale omstandigheden waren niet significant verschillend tus­
sen patiënten m et RA en gezonde vrijwilligers. De prolactine respons op hypoglycemie was signi­
ficant lager in onbehandelde patiënten met RA dan in gezonde vrijwilligers. Behandeling met 
naproxen gedurende 2 weken had geen invloed op de basale prolactine spiegels of de prolactin 
spiegels na stress. Na 6 maanden behandeling met antireumatica was er een significante stijging
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van de prolactine respons op hypoglycemie geïnduceerde stress to t waarden vergelijkbaar met die 
van de gezonde controles. Tevens was er in dezelfde periode een significante verbetering van de 
ziekteactiviteit. We concluderen dat patiënten met actieve onbehandelde RA een verminderde 
prolactine respons hebben op hypoglycaemie en dat deze verminderde respons herstelt na behan­
deling met antireumatische therapie.
Indien prolactine een rol speelt bij de pathogenese van RA, zou therapie gericht op reductie van 
prolactine spiegels kunnen bijdragen aan het verminderen van ziekteactiviteit. Met deze achter­
grond verrichten we een studie naar het antireumatisch effect van quinagolide, een dopamine­
agonist, die de prolactine secretie onderdrukt. De resultaten hiervan worden beschreven in hoofd­
s tu k  10. Negen patiënten met actieve RA werden behandeld met quinagolide gedurende 24 
wekens. Vijf van hen werden daarnaast behandeld met prednison in een stabiele dosis en allen 
werden tevens behandeld met een NSAID. Acht patiënten volbrachten de studie. Eén patiënt 
moest deelname staken na 2 weken wegens exacerbatie van de ziekte waarvoor aanvullende 
behandeling met corticosteroïden noodzakelijk was. De prolactine spiegels daalden tot onder de 
detectiegrens binnen 4 weken na start van de behandeling in alle patiënten. Een samengestelde 
maat voor ziekteactiviteit (DAS) verbeterde niet significant en er waren geen goede responders op 
de therapie volgens de EULAR respons criteria. Ook de individuele variabelen lieten geen signifi­
cante veranderingen zien, behoudens een tendens tot verbetering in de Ritchie articular index, 
visual analogue scale (VAS) for general health and VAS for assessment of disease activity by 
physician. Er werd geen verbetering gevonden in BSE, CRP, aantal gezwollen gewrichten en health 
assessment questionnaire (HAQ). We concluderen dat behandeling met quinagolide als m ono­
therapie niet effectief is in RA.
w Algemene discussie
In de afgelopen jaren zijn er steeds meer overtuigende bewijzen geleverd dat er een bilaterale 
communicatie bestaat tussen het endocriene systeem en het immuun systeem. Bij dierexperi­
mentele studies en bij humaan onderzoek zijn er aanwijzingen gevonden voor neuro-endocrie- 
ne stoornissen -  met name een verlaagde HPA-as activiteit en excessieve prolactine secretie -  die 
een pathogenetische rol zouden kunnen spelen bij RA. Als deze hormonale stoornissen inder­
daad een rol spelen bij het ontstaan van RA, kan dit therapeutische consequenties hebben.
Doel van dit proefschrift was te onderzoeken of deze hormonale stoornissen aanwezig zijn in 
patiënten met RA, of deze stoornissen een rol spelen in de pathogenese van RA, of dat ze het
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gevolg zijn van het hebben van een chronisch inflammatoire ziekte of het resultaat van het 
gebruik van antiinflammatoire medicamenten. Wij waren van mening dat deze onderwerpen nog 
onvoldoende waren uitgezocht in de literatuur.
De HPA-as in RA
In tegenstelling tot anderen, vonden wij geen daling van cortisol spiegels in patiënten met RA 
vóór en na een grote chirurgische ingreep, vergeleken met artose patiënten. Toch zou je kunnen 
stellen dat normale cortisol spiegels bij actieve RA te laag zijn voor de mate van ontsteking. Of dit 
laatste het geval is kan niet worden beantwoord door de gegevens van oze studies. Om dit goed te 
kunnen beoordelen zou een studie van cortisol spiegels nodig zijn in patiënten met andere chro­
nische inflammatoire ziekten. Chikanza et al. bestudeerden 10 patiënten met chronische osteom­
yelitis (OM) en vonden verhoogde cortisol spiegels bij patiënten met OM vóór en na een grote 
chirurgische ingreep vergeleken met RA en OA. De patiënten met RA and OA gebruikten echter 
NSAIDs, terwijl de OM patiënts dit niet gebruikten, zodat de gevonden verschillen ook toege­
schreven zouden kunnen worden aan NSAID gebruik. Verder is de aard van de inflammatie in 
chronische osteomyelitis, veroorzaakt door bacteriën, verschillend van die bij een auto-immuun 
ziekte, hetgeen een ander effect zou kunnen geven op cytokine release en activatie van de HPA- 
as. Een studie bij patiënten m et andere chronisch inflammatoire aandoeningen zonder infectie, 
zoals M.Crohn of colitis ulcerosa, bleek vrijwel onmogelijk, omdat bij actieve ziekte alle patiën­
ten worden behandeld met orale corticosteroïden, of corticosteroïd bevattende klysmata, waarvan 
bekend is dat ze ook een systemisch effect hebben. Het staken van de antiinflammatoire therapie 
bij deze aandoeningen vergroot het risico op ernstige complicaties, zodat we op ethische gronden 
een dergelijke studie niet konden uitvoeren.
In een grote studie met 3 groepen RA patiënten (recente, actieve RA n=20, langbestaande, actie­
ve RA n=20, en langbestaande RA, in remission n=10) zonder antiinflammatoire medicatie, von­
den we geen verlaagde activiteit van de HPA-as onder basale omstandigheden. De ACTH- en cort­
isol spiegels van de RA patiënten waren vergelijkbaar m et die van de gezonde vrijwilligers. In res­
pons op hypoglycemie-geïnduceerde stress tijdens de insuline tolerantie test (ITT), een gestan­
daardiseerde vorm van stress, werden echter wel lagere plasma cortisol spiegels gevonden in alle 
3 de groepen met RA patiënten vergeleken met gezonden, zowel vóór als na hypoglycemie. De 
maximale cortisolstijging na toediening van insuline was niet significant verschillend tussen de 
groepen en de response curves van cortisol van de RA patiënten vertoonden eenzelfde verloop als 
die van de gezonde vrijwilligers. De RA patiënten reageerden op hypoglycemie met een snelle en 
adequate cortisolstijging, maar behaalden een lagere piekwaarde door lagere uitgangswaarde van 
cortisol bij aanvang van de test. Wij veronderstellen, dat de cortisol spiegels bij aanvang van de
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test een beter weergave is van de basale hormonale activiteit dan die bij de basale metingen, aan­
gezien bij de ITT de bloedafname geschiedde na 30 m inuten rust in liggende houding, na inbren­
gen van een intraveneuze catheter. ACTH spiegels zowel vóór als tijdens de ITT waren niet signi­
ficant verschillend van die van de gezonde vrijwilligers. Na stimulatie met CRH vertoonden alle 
20 patiënten met recente, actieve RA een stijging van ACTH spiegels, gevolgd door een stijging 
van cortisol spiegels in de normale range van ons laboratorium. Het verschil in totaal plasma cort­
isol spiegels tussen RA patiënten en gezonde controles kan niet worden verklaard door verschil­
len in cortisol binding globulin (CBG) spiegels aangezien deze niet verschilden tussen de groepen. 
We vonden verhoogde plasma spiegels van IL-6 in patiënten met actieve RA and normale spiegels 
in langbestaande RA in remissie. Verlaagde plasma cortisol spiegels werden gevonden gedurende 
de ITT zowel bij actieve RA als bij RA in remissie. Kennelijk leidden de verhoogde plasma IL-6 
waarden in patiënten met actieve RA spiegels niet tot stimulatie van de HPA-as. Of dit bijdraagt 
aan de ontwikkeling van chronische artritis (aangezien glucocorticoïden een antiinflammatoir 
effect hebben) zal nog moeten blijken.
Onze bevindingen wijzen op een verminderde HPA-as reactie in onbehandelde patiënten met RA 
vergeleken met gezonden. De normale ACTH spiegels die we vonden zijn niet in overeenstem­
ming met de hypothese in the literatuur dat er een belangrijk defect is op hypothalaam niveau in 
RA, maar we concluderen dat een defect waarschijnlijk is gelokaliseerd op het niveau van de bij­
nier. Verminderde HPA-as activiteit zou een rol kunnen spelen bij de pathogenese van de ziekte, 
maar kan ook het resultaat zijn van adaptie aan een chronisch inflammatoire toestand. Verder 
onderzoek is noodzakelijk om de activiteit van de HPA-as in andere chronische inflammatoire 
aandoeningen te bepalen.
Het  e f fect  van an t i in f l ammato i re  medicat ie op de HPA-as
Na 2 weken behandeling met naproxen, waren bij patiënten met recente RA, de basale ACTH spie­
gels en ACTH spiegels tijdens de ITT onveranderd, maar de cortisol excretie in 24 uurs urine was 
significant gedaald in vergelijking met de periode vóór behandeling. Ook was de gemiddelde 
geïntegreerde plasma cortisol spiegel gedurende de ITT significant lager dan vóór behandeling. 
De maximale stijging van cortisol na hypoglycemie vertoonde een tendens tot daling in vergelij­
king met vóór behandeling en de plasma cortisol spiegels waren significant lager na, maar niet 
vóór hypoglycemie. Na 6 maanden van aanvullende behandeling m et sulphasalazine of meto- 
trexaat werden deze veranderingen niet meer gezien. Onze resultaten suggereren dat NSAIDs de 
HPA-as onderdrukken op bijnier niveau in de eerste weken van behandeling. Na 6 maanden is dit 
suppressieve effect niet meer aanwezig, hetgeen de mogelijkheid van adaptatieve mechanismen 
doet vermoeden.
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Bij gezonde vrijwilligers werd geen invloed op de HPA-as gevonden van behandeling met 
naproxen gedurende 2 weken. Dit suggereert dat de lage cortisol waarden die we vonden na het 
gebruik van 2 weken naproxen in RA patiënten, niet het gevolg zijn van een direct effect van 
NSAIDs op de activiteit van de HPA-as. Een indirect effect van het gebruik van NSAIDs op de 
HPA-as middels reductie van inflammatie en/of pijn, resulterend in lagere cortisol spiegels, is wel 
mogelijk.
Prolact ine
We hebben prolactine spiegels gemeten in 9 patiënten m et RA in de studie met chirurgische pati­
ënten, in 20 patiënten m et recente, actieve RA, 20 m et langbestaande actieve RA en 10 met lang- 
bestaande RA in remissie, en in 9 patiënten met actieve RA in de quinagolide studie. In totaal wer­
den dus 68 patiënten met RA bestudeerd en in geen van deze studiegroepen vonden we verhoog­
de prolactine spiegels. We concluderen dan ook dat er geen sprake is van een excessieve prolacti- 
ne secretie in RA.
Gezien de pro-inflammatoire eigenschappen van prolactine en de rol die het speelt in de im m uun 
respons, zou het toch mogelijk kunnen zijn dat onderdrukking van de normale prolactine secre­
tie ziekteactiviteit in RA zou kunnen verbeteren. Behandeling met quinagolide van 9 patiënten 
met RA gaf echter geen verbetering van de ziekteactiviteit, ondanks daling van prolactine spiegels 
tot onder de detectie grens. We concluderen dat therapie gericht op verlaging van prolactine 
secretie niet effectief is in RA.
In patiënten met recente, onbehandelde RA vonden we basale serum prolactine spiegels die over­
eenkwamen met die van gezonden, maar significant lagere AUCs van prolactine spiegels in res­
pons op stress geïnduceerd door hypoglycemie (ITT). Deze verlaagde prolactine respons op stress 
was onveranderd na 2 weken behandeling met naproxen, maar normaliseerde na 6 maanden 
behandeling met antireumatica. Een significante negatieve correlatie tussen DAS en AUC van 
prolactine spiegels gedurende de ITT werd gevonden op baseline evenals een significante positie­
ve correlatie tussen de verbetering van de DAS en de stijging van de AUC van de prolactine spie­
gels na 6 maanden behandeling. Dit suggereert dat de prolactine respons op stress gerelateerd zou 
kunnen zijn aan ziekteactiviteit. Andere mogelijke verklaringen kunnen echter niet worden uit­
gesloten en verder onderzoek zal nodig zijn om dit te verhelderen.
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1. Patiënten met RA hebben een normale basale activiteit van de HPA-as, vergelijkbaar met 
gezonde vrijwilligers. Normale basale cortisol spiegels in actieve RA zouden echter in feite 
abnormaal kunnen zijn, dat wil zeggen te laag voor de mate van ontsteking.
2. In respons op hypoglycemie-geïnduceerde stress, hebben onbehandelde RA patiënten nor­
male ACTH, maar verlaagde cortisol plasma spiegels, ondanks verhoogde spiegels van IL-6, 
hetgeen kan passen bij een defect op bijnier niveau. Of dit een bijdrage levert aan de 
ontwikkeling van chronische artritis, blijft nog onopgehelderd.
3. Na 2 weken behandeling m et naproxen, is de activiteit van de HPA-as verminderd op bijnier 
niveau bij patiënten met onbehandelde recente RA. Na 6 maanden is dit effect verdwenen, 
hetgeen suggestief is voor adaptatie mechanismen.
4. Bij gezonde vrijwilligers wordt na 2 weken behandeling met naproxen geen verandering in 
HPA-as activiteit waargenomen, hetgeen erop wijst dat naproxen geen direct effect heeft op 
de HPA-as.
5. Patiënten met RA hebben geen verhoogde prolactine secretie.
6. Onderdrukking van de prolactine secretie leidt niet tot verbetering van de ziekteactiviteit bij 
patiënten met RA.
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t Toekomstig onderzoek
Hoewel in dit proefschrift een aantal van de gestelde vragen worden beantwoord, blijven ande­
ren nog onbeantwoord en zijn nieuwe vragen gerezen. Om onderzoeksresultaten van studies 
naar de HPA-as bij RA patiënten beter te kunnen interpreteren, zijn studies noodzakelijk naar 
de reacties van de HPA-as en cytokinen bij patiënten met andere chronische inflammatoire ziek­
ten, hoewel moeilijk uitvoerbaar. Het effect van antireumatische therapie, waaronder anti-TNF 
behandeling, op de activiteit van de HPA-as moet verder worden bestudeerd en gedurende lan­
gere periodes, waarbij verschillende NSAIDs zouden moeten worden bestudeerd.
Hoewel we geen verhoogde prolactine secretie vonden bij patiënten met RA en geen verbetering van 
ziekteactiviteit na onderdrukken van de prolactine secretie, blijft dit hormoon een interessant peptide 
met een nog onvoldoende opgehelderde rol bij de immuun respons. De verminderde prolactine reactie 
op hypoglycemie-geïnduceerde stress die we vonden bij patiënten met actieve RA is een interessante 
bevinding die niet eerder werd beschreven in de literatuur. Toekomstig onderzoek zal de betekenis van 
deze bevinding moeten uitwijzen en bepalen of deze specifiek is voor RA, of dat het ook voorkomt bij 
andere chronisch inflammatoire aandoeningen en of antireumatische therapie hierop van invloed is.
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Een proefschrift schrijven doe je niet alleen. Bij het tot stand komen van dit boekje heb ik hulp 
gehad van velen, die ik bij deze gelegenheid heel hartelijk wil bedanken.
In de allereerste plaats wil ik alle patiënten en gezonde vrijwilligers danken voor de enorme trouw 
waarmee ze de vele afspraken nakwamen en de zorgvuldigheid waarmee ze alle speeksel en uri­
nemonsters hebben gespaard. Zelden was er een monster vergeten of incompleet, hetgeen de kwa­
liteit van het onderzoek ten goede kwam. De patiënten hebben me getoond hoe belangrijk ze het 
vinden dat er onderzoek gebeurt naar hun aandoening en dat ze daar veel voor over hebben.
Leo van de Putte, prom otor en opleider, bedankt voor de gelegenheid die je me gaf dit onderzoek 
uit te voeren en mijn opleiding tot reumatoloog op je afdeling te starten. Jij bent één van de eer­
ste opleiders die besef heeft van de noodzaak part-tim e opleiding toe te staan. Ad Hermus, pro­
m otor vanuit de endocrinologie. Jouw begeleiding was onontbeerlijk bij dit onderzoek, en ik heb 
veel gehad aan onze besprekingen van de resultaten, waarbij me duidelijk werd hoe weinig zeker­
heden er bestaan binnen de endocrinologie. Je was een zeer precies kriticus en zette de puntjes op 
de i. Fred Sweep, zo mogelijk nog kritischer, jij zette zelfs de puntjes op de i die ik was vergeten in 
de referenties. Ik vond het altijd plezierig bij je langs te komen en je maakte altijd even tijd voor 
me, waarvoor mijn dank. Beste Frank. Co-promotor, coach, collega en vriend. Niemand is zo goed 
in pep-talk als jij. Als ik bij je langs was geweest zag ik mijn boekje al voor me. Bedankt voor je 
enthousiasme en de vrijheid die je me gaf bij het uitvoeren van het onderzoek en het schrijven 
van dit proefschrift.
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hebben bewerkt. Ik voelde me altijd heel welkom op het lab en heb m et jou, Gerard, ook meer­
dere discussies gevoerd waarbij je altijd enorm veel interesse toonde voor mijn onderzoek.
Erik Brummelkamp, bedankt voor je onmisbare hulp bij het verwerken van het grote aantal getal­
len en de uitvoering van de noodzakelijke berekeningen. Ik moest even wennen aan je stoïcijnse 
manier van doen, maar ik begreep al snel dat je het niet persoonlijk bedoelde als je weer eens 
intypte: del Agnes of move Agnes. Computertaal blijft voor mij een wezensvreemd gebeuren, 
maar gelukkig is het voor jou een piece of cake.
Eugenie Olde Riekerink, verpleegkundige van de afdeling klinische fysiologie, bedankt voor je 
hulp bij de vele ITTs die we uitvoerden en vooral de warme sfeer waardoor de proefpersonen zich 
op hun gemak voelden.
De medewerkers van post geel wil ik bedanken voor de gezellige sfeer en het feit, dat ze altijd wel 
weer een kamertje voor me wisten te vinden en mijn proefpersonen de weg wezen. Alfons den
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Broeder bedank ik voor zijn aandeel in het onderzoek bij de patiënten die hij behandelde met 
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eigen keuzes te mogen maken waarbij ze ondersteunend aanwezig bleven. Ik ben dankbaar dat ze 
wel de geboorte van onze kinderen hebben mogen meemaken en van hun kleinkinderen hebben 
kunnen genieten.
Gelukkig bestaat er ook nog zoiets als schoonouders. Lucy en Rien, bedankt voor jullie belang­
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Om zonder zorgen te kunnen werken is een constante factor thuis noodzakelijk. Debby wil ik dan 
ook bedanken voor de zorg en liefde die ze onze kinderen de afgelopen jaren heeft gegeven en de 
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De schrijfster van dit proefschrift werd geboren op 6 februari 1961 te Gemert. In 1979 behaalde 
zij het diploma atheneum B aan het Dr. Knippenbergcollege te Helmond. Vervolgens startte zij 
met de studie geneeskunde aan de Katholieke Universiteit te Nijmegen. Het artsexamen werd 
behaald in 1987. Van 15 juni van dat jaar to t en m et 31 maart 1988 was zij werkzaam als agnio 
in het Mariaziekenhuis te Tilburg, op de afdeling cardiologie. Van 1 april 1988 to t en met 31 
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dr. A. van ‘t Laar, gevolgd door prof. dr. J.W.M. van der Meer). Op 1 januari 1995 volgde regis­
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Vervolgens werd zij aangesteld als onderzoeker op de afdeling reumatologie van het Universitair 
Medisch Centrum St Radboud te Nijmegen waar werd aangevangen met het onderzoek dat zou 
leiden to t dit proefschrift. Op 1 februari 1999 werd op deze afdeling begonnen met de opleiding 
to t reumatoloog (opleider prof. dr. L.B.A. van de Putte), welke zal worden afgerond op 1 augus­
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waarmee een uitbreiding van het onderzoek kon worden uitgevoerd.
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